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Abstract  
 
The mitochondrial pathway to apoptosis is tightly regulated through the protein-protein 
interactions of pro- and anti-apoptotic members of Bcl-2 family proteins. The balance of pro- 
and anti-apoptotic proteins is important in regulating proper cell survival. Overexpression of the 
anti-apoptotic members such as Mcl-1, Bcl-2 and Bcl-XL has been observed in cancer, 
contributing to chemoresistance and aberrant survival. Pro-apoptotic BH3-only proteins normally 
serve to suppress the anti-apoptotic members. Thus, small molecules mimicking the function of 
BH3-only proteins, known as BH3 mimetics, have been developed and exhibited anti-cancer 
activity. Such compounds are being advanced in clinical trials as promising anti-cancer 
therapeutics. Notably, ABT-737, a selective and potent Bcl-2/Bcl-XL inhibitor, has shown to be 
highly efficacious at inducing apoptosis in Bcl-2/Bcl-XL-dependent cancers, but it is not 
effective in cancer cells with high Mcl-1 levels. Therefore, Mcl-1 represents an attractive 
molecular target for the development of a new class of anti-cancer therapy that would be 
synergistic with ABT-737. 
High throughput screening (HTS) approaches were utilized and several small molecules 
capable of binding Mcl-1 and disrupting its interaction with BH3 peptides were identified. To 
improve the output and the quality of the HTS hits, as well as to incorporate structure-based 
knowledge, in silico target-based screening of identified hits was integrated and the most 
promising inhibitors were selected for further evaluation. In this work, two classes of novel 
small-molecule Mcl-1 inhibitors were developed based on two HTS leads, 59 bearing a 
hydroxynaphthalenylsulfonamide scaffold and 38 with a 1H-pyrazolo[3,4-b]pyridine scaffold.  
Employing structure-based design in conjunction with protein NMR spectroscopy, new 
analogs were designed, synthesized and SARs were established. Two potent inhibitors, analog 21 
(Ki = 0.180 µM) from 59 class and 8 (Ki = 2 µM) from 38 class, were developed exhibiting 9- and 
12-fold improvement over their respective HTS leads. Both analogs exhibited selective inhibition 
of Mcl-1 over other anti-apoptotic proteins. NMR studies mapped the binding sites of 21 and 8 to 
the BH3-binding groove of Mcl-1. Analog 21 was further characterized in cell-based assays and 
  xiii 
caused cell death in Mcl-1-dependant cancer cell lines through a Bak/Bax-dependent mechanism 
and activation of caspase-3. Additionally, another potent analog from 59 series, 10, was used as a 
chemical tool to validate Mcl-1 as a potential therapeutic target in pancreatic cancer.  The 
efficacy studies showed single-agent anti-tumor activity in a pancreatic cancer xenograft model, 
demonstrating for the first time the potential use of Mcl-1 inhibitors as a therapeutic strategy for 
the treatment of human pancreatic cancer. This work provides further understanding in the 
development of selective Mcl-1 inhibitors and lays a foundation for the design of more potent 
inhibitors which can advance the field of targeted therapies for Mcl-1-driven cancers.  
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Chapter 1  
Introduction  
 
“Nothing in life is to be feared, it is only to be understood.”   
Marie Curie (1867-1934) 
 
 
1.1 Hallmarks of cancer 
 
Cancer is a major health problem worldwide. While numerous challenges are still being 
faced to identify its origins and develop effective treatments, our understanding of cancer as a 
genetic disease over a century ago revolutionized the field of cancer research1. Cancer research 
has since turned into a logical science, where the complexities of the disease can be attributed to 
a number of underlying principles2. One set of these principles includes the molecular pathways 
that govern the transformation of normal cells to a neoplastic state2. Hanahan and Weinberg have 
enumerated the traits normal cells acquire during the multistage tumorigenesis process to a 
malignant phenotype2, 3. These traits or biological capabilities are termed “hallmarks of cancer” 
(Figure 1.1) and include 1) sustaining proliferative signaling 2) evading growth suppressors 3) 
resisting cell death 4) enabling replicative immortality 5) inducing angiogenesis and 6) activating 
invasion and metastasis. More recently and through further extensive mechanistic studies, it has 
been proposed that the core hallmarks of cancer cells are acquired through two enabling 
characteristics, namely genome instability and tumor-promoting inflammation3. The genome 
instability of cancer cells refers to the cancer cells evolving genomes being able to acquire 
mutations that facilitate tumorigenesis4, 5. The tumor-promoting inflammation characteristic of 
cancer cells mediated through the immune system also enhances tumorigenesis and progression 
by providing the tumor microenviroment with chemicals, such as reactive oxygen species, that 
are mutagenic to cancer cells and further facilitate their evolution toward malignancy6, 7. 
Furthermore, there are two emerging hallmarks of cancer that have been proposed, but not yet 
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proven to have generality among all cancers. These include reprogramming energy metabolism, 
which refers to an altered metabolism of neoplastic cells also known as “Warburg effect”8, 9, and 
evasion of immune destruction, which is an ability of cancer cells to avoid recognition and 
elimination by the immune system10, 11. Both emerging hallmarks warrant further studies as it is 
still unclear whether they can be classified as core hallmarks or if their occurrence is a 
consequence of the aforementioned six core hallmarks.  
 
 
Figure 1.1. Hallmarks of cancer including the enabling ones and therapeutic targeting of 
the hallmarks. 
Figure adapted from Hanahan, D.; Weinberg, R. A., Cell 2011, 144 (5), 646-74. 
 
As a result of our increased understanding of the underlying mechanisms of cancer, 
increasingly more rational mechanism-based targeted therapies have been developed. Indeed, 
there are targeted therapies interfering with each of the acquired capabilities and even enabling 
characteristics, and extensive research is being done to target emerging hallmarks3 (Figure 1.1). 
One of the therapeutic areas which has been an active area of research and the focus of this 
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dissertation is the development of molecular-targeted therapies against cancer cells resistance to 
apoptosis.    
1.2 Programed cell death or apoptosis 
 
Apoptosis is a genetically-regulated cell death program distinct from necrosis. The term 
apoptosis was first coined and described in 1972 by Kerr et al12. The morphological changes 
apoptotic cells undergo were described as cell shrinkage, chromatin condensation, and nuclear 
and cell fragmentation leading to the formation of apoptotic bodies which are eventually taken 
up by neighboring cells12. Apoptosis is essential for embryogenesis, tissue homeostasis and 
immunity13 and defects in the process can cause a myriad of diseases: insufficient cell death can 
lead to cancer and autoimmunity disorders whereas excessive cell death can result in 
neurodegenerative disorders14.  
Bcl-2 (B-cell lymphoma-2) was the first protein identified to be involved in the regulation of 
apoptosis. The Bcl-2 gene at the t(14;18) chromosome translocation breakpoint in B-cell 
follicular lymphomas was discovered in 198515-17. However, it was not until 1988, that Vaux et 
al. showed that expression of bcl-2 promoted the survival of haematopoietic cells for extended 
periods in the absence of growth factors and a combination of oncogene myc and bcl-2 produced 
tumors in immunocompromised mice18. This and other subsequent works19-21 showed that the 
mechanism regulating cell death differs from the one regulating cell survival and that 
overexpression of Bcl-2 inhibits cell death whose impairment is a critical step in tumor 
development. These key discoveries introduced a new paradigm in carcinogenesis that cancer 
can be driven by impairment in the process of apoptosis22 which led to intensive investigations 
into the regulatory mechanisms that control apoptosis.   
In mammals, the execution of apoptosis is governed by two distinct molecular programs that 
ultimately converge on the activation of caspases, which are intracellular cysteine proteases 
synthesized as inactive zymogens22. The two molecular pathways are the extrinsic pathway 
operating downstream of death receptors and the intrinsic pathway, which is regulated by the 
Bcl-2 family of proteins, and is activated by various stress signals23 (Figure 1.2). The extrinsic or 
death-receptor pathway is triggered when the so-called death receptors (members of the TNF) 
such as Fas or TNF receptor-1 (TNFR1) on the cell surface bind to cognate ligands of TNF 
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family (Figure 1.2). The death receptors, which contain an intracellular death domain, can then 
activate caspase-8 through adaptor proteins that include Fas-associated death domain (FADD)24.  
Caspase-8 activation can further cause activation of effector caspases such as caspase-3, -6 
or -7, without the involvement of the Bcl-2 family22. Instances of cross-talk between the intrinsic 
and extrinsic pathways have been observed in some cells such as hepatocytes in which caspase-8 
mediates cleavage and activation of the pro-apoptotic BH3-only protein Bid to its active 
truncated form (tBid)25 (Figure 1.2). tBid translocates to mitochondria and causes further caspase 
activation (caspase-9 and the effector caspases, caspase-3,-6,-7) through the intrinsic pathway22.   
Identification of cytochrome c as an apoptogenic factor released from mitochondria26 was a key 
discovery in highlighting the importance of this organelle in the intrinsic pathway of apoptosis23. 
The mitochondrial outer membrane permeabilization  (MOMP) is an irreversible process and is 
the “point of no return” in the intrinsic pathway, which results in the release of cytochrome c23, 
27. The Bcl-2 family of proteins govern mitochondrial integrity through regulation of MOMP and 
thereby are the arbiters of cell fate. 
 
                          
Figure 1.2. Simplified scheme of intrinsic and extrinsic pathways of apoptosis. 
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1.3 Bcl-2 family of proteins in apoptosis 
 
Over 25 Bcl-2 family members have been identified28, 29. These can be divided into two 
classes based on their functions: anti-apoptotic proteins which inhibit apoptosis and pro-
apoptotic proteins which promote apoptosis (Figure 1.3). These proteins share sequence 
homology within a conserved region known as Bcl-2 homology (BH) domains, which are α-
helical segments and determine structure and function23. Anti-apoptotic members include Bcl-2, 
Bcl-w, Bcl-XL, Bcl-b, Bfl-1/A1 and Mcl-1.  These share sequence homology within three to four 
BH domains and generally function to bind and inhibit the pro-apoptotic proteins (Figure 1.3A). 
The pro-apoptotic Bcl-2 proteins are divided into two subclasses. The first subclass is multi-
domain proteins which include Bak, Bax and Bok that share sequence homology within three to 
four BH domains just like anti-apoptotic proteins (Figure 1.3A). They are absolutely required for 
MOMP30, 31. The second subclass is the BH3-only proteins, including Bad, Bid, Bik, Bim, Noxa 
and Puma, which as the name suggests show sequence homology only within the α-helical BH3 
domain (Figure 1.3B). The BH3-only proteins are expressed in response to distinct cellular stress 
pathways. For example, stimuli such as DNA damage results in induction of Noxa and Puma by 
the tumor suppressor p5332-34. It is important to note that the BH3 region of pro-apoptotic 
proteins is responsible for engaging with anti-apoptotic proteins and induction of apoptosis35 
(Figure 1.3C). In addition to BH domains, several Bcl-2 family members possess a C-terminal 
transmembrane (TM) domain which anchors them to subcellular membranes, including the 
mitochondrial outer membrane, endoplasmic reticulum (ER) and nuclear membranes23. 
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Figure 1.3. The extended Bcl-2 family of proteins. This family comprises of pro-survival 
proteins (shown in green boxes) and pro-apoptotic proteins (shown in red boxes). (A) Family 
members sharing four Bcl-2 homology (BH) domains are the multi-domain proteins. A third pro-
apoptotic multi-domain protein, Bok, is not well characterized and not shown. (B) Family 
members displaying only the BH3 domain are the BH3-only proteins. BH3-only proteins are 
usually unstructured prior to binding pro-survival proteins. (C) crystal structure of Mcl-1 (green) 
bound to Bim BH3 peptide (white) (PDB 2PQK). Bim BH3 peptide inserts as an α-helix into the 
BH3-binding site (formed by BH1-BH3) of Mcl-1.  
 
It has been shown that the mode of interaction between anti- and pro-apoptotic proteins 
includes the binding of the hydrophobic face of the amphipathic α-helical BH3 domain from pro-
apoptotic proteins to the hydrophobic cleft formed on the surface of anti-apoptotic proteins 
through their BH1-3 domains36-41 (Figure 1.3C). However, the exact nature of protein-protein 
interactions among the Bcl-2 family proteins that leads to mitochondrial-mediated apoptosis 
remains controversial.  
Historically, two distinct models have been proposed for the protein interactions that 
regulate the process. Each model takes into account all three classes of the Bcl-2 family of 
proteins. In the indirect model (Figure 1.4A) of Bak and Bax activation, BH3-only proteins such 
as Noxa and Bad target anti-apoptotic members releasing the sequestered Bak and Bax42-45. 
These BH3-only proteins are also known as sensitizers. In the direct model (Figure 1.4B), the so-
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called activator BH3-only protein, such as Bim, Bid and Puma, can still block the anti-apoptotic 
members while directly activating the multi-domain pro-apoptotic proteins Bak and Bax46-52. 
 
      
Figure 1.4. Two models by which Bcl-2 family members regulate mitochondrial apoptosis. 
(A) The indirect model for Bak and Bax activation in which BH3-only proteins inhibit the anti-
apoptotic proteins leading to release and activation of Bak and Bax, which can oligomerize and 
cause MOMP. (B) The direct model for Bak and Bax activation in which BH3-only proteins 
directly activate Bak and Bax and inhibit the anti-apoptotic proteins to sequester activated forms 
of Bak and Bax, resulting in their activation and MOMP. 
 
In either case, it is the activation and oligomerization of Bak and Bax which trigger MOMP. 
Upon MOMP, apoptogenic factors such as cytochrome c and Apaf-1 are released from the 
intermitochondrial membrane to the cytosol27, 53 (Figure 1.2). Cytochrome c and Apaf-1 form a 
heptameric protein ring called an apoptosome which can bind pro-caspase-9 and activate it54, 55. 
Caspsase 9 then activates the effector caspase-3 which mediates cleavage of critical cellular 
proteins and execution of cell death56.   
Cancer cells shift the pro- and anti-apoptotic activities of Bcl-2 family members toward 
survival by genetic and epigenetic changes, altered signaling pathways and post-translational 
modifications57. For example, overexpression of anti-apoptotic Bcl-2, Bcl-XL and Mcl-1 has 
been observed in human haematopoietic cancers58, 59 and a number of solid tumors60. Therefore, 
therapeutic targeting of the Bcl-2 family proteins in cancer has been a priority. However to 
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develop effective therapeutics against this family, a structural understanding of the interactions 
between the family members are required.  
1.4  Structural analysis of Bcl-2 family interactions  
 
Structural studies of various BH3 domains bound to the BH3-binding site of anti-apoptotic 
proteins have identified several conserved interactions between the two interacting partners37, 38, 
41, 61-63. These include four hydrophobic (h1-h4) and a charged residues on the BH3 ligands that 
form hydrophobic interactions with hydrophobic pockets (p1-p4) and an electrostatic interaction 
with Arg of anti-apoptotic proteins, respectively (Figure 1.5A). Furthermore, studies using 
synthetic BH3-only peptides encompassing BH3 domains showed that these domains promote 
apoptosis42, 47, 49. However, distinct peptides have distinct selectivity profiles and effects42 
(Figure 1.5B). While Bad BH3 peptide is selective in binding to Bcl-2, Bcl-XL, Bcl-w and not 
Mcl-1, Noxa BH3 peptide selectivity binds only to Mcl-1 and Bfl-1/A1. On the other hand, Bid, 
Bim, and Puma BH3 peptides are promiscuous binders to all the anti-apoptotic proteins.  
 
                
Figure 1.5. Conserved interactions of BH3-only and pro-survival proteins. (A) Bim-BH3 
bound to Mcl-1 (PDB 2PQK). The residues shown are the four conserved hydrophobic residues 
(h1-h4) as well as the conserved aspartate of Bim-BH3 interacting with p1-p4 pockets and Arg 
of Mcl-1, respectively. (B) Sequences (mostly 26-mers) of BH3-only proteins used to determine 
their binding selectivity for anti-apoptotic proteins. The canonical four hydrophobic residues are 
indicated (h1–h4) in red while the conserved aspartate is shown in green.  
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The selectivity profile of the selective BH3-only peptides can be explained based on the  
differences in the nature of key residues within both the BH3 domain and the BH3-binding site. 
The Asp residue in the BH3 ligand that is involved in hydrogen bonding with Arg in the BH3- 
binding site seems to be more important in binding to Mcl-1 than Bcl-XL because Arg residue is 
less exposed in Bcl-XL 64. Furthermore, the first two hydrophobic pockets (p1 and p2) of Mcl-1 
are more constricted and less contiguous upon BH3 ligand binding than Bcl-XL because the third 
α-helix is well-formed and less flexible in Mcl-1 than Bcl-XL62, 65. Differences in the BH3 
domain of Mcl-1 also change the nature of the p4 pocket making it less well-defined and more 
solvent-exposed than Bcl-XL62, 65. On the other hand, the promiscuity profile observed for Bid, 
Bim and Puma BH3-only peptides stems from the similarities shared between the BH3-binding 
sites of anti-apoptotic proteins due to the sequence homology in their BH1-3 domains as well as 
the plasticity of both partners to mutually undergo a conformational change upon binding57.   
The detailed structural understanding of the interactions between the pro- and anti-apoptotic 
proteins paved the way for development of small molecules and peptides targeting the Bcl-2 
family protein-protein interactions (PPIs) for cancer therapy.  
1.5 Small molecules targeting Bcl-2 family PPIs 
 
PPIs are ubiquitous and important in biological processes such as programed cell death and 
present great opportunities for therapeutic intervention66. However, targeting PPIs by small 
molecules has been challenging for a number of reasons including large and extended PPI 
interfaces, lack of presence of defined pockets, and the hydrophobic nature of PPIs. A typical 
PPI interface encompasses 1500-3000 Å2, which is a large surface area to be covered by a small 
molecule (surface area covered by a small molecule is ~300-1000 Å2)67. Unlike enzymes, which 
have well-defined pockets that can be occupied by endogenous ligands, protein interfaces do not 
present deep and defined cavities for small molecules to bind. Additionally, due to the 
hydrophobic nature of protein interfaces, small molecules that tend to bind to these surfaces are 
large and hydrophobic with poor physicochemical properties68. These problems, however, have 
been addressed through the development of several successful PPI inhibitors.  
Alanine scanning and mutagenesis studies of PPIs later showed that there are residues on 
each of the interacting proteins that contribute significantly to the free energy of binding between 
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the two partners, which are termed “hot spots” 69-72. For a small molecule to achieve high affinity 
for the target and disrupt PPI, it must mimic the hot spots. Secondly, a variety of methods such 
as peptidomimetic approaches, virtual screening/structure-based design and screening of natural 
product or synthetic molecules libraries can be used in conjunction with biophysical methods 
such as nuclear magnetic resonance (NMR) spectroscopy, surface plasmon resonance (SPR), and 
x-ray crystallography to identify robust PPI small-molecule inhibitors66, 68, which then can be 
further modified through medicinal chemistry for improved physicochemical properties. 
Early attempts at the discovery of inhibitors of anti-apoptotic proteins included 
peptidomimetic73 and high throughput screening approaches74-76. The premise in developing 
inhibitors of anti-apoptotic proteins is to mimic the function of BH3-only proteins to lower the 
“threshold for apoptosis”, defined as the amount of stress imposed on a given cell population to 
trigger apoptosis. The initially identified small molecule BH3 mimetics are generally pan-
inhibitors of all anti-apoptotic proteins with poor affinity for their targets and non-specific 
mechanism of actions57, 64. However, despite poor affinities and exhibition of other mechanism 
of actions, obatoclax (GX15-070)77 and a gossypol derivative, TW-3778, have progressed 
towards clinical trials. Selective and potent stapled peptides targeting Mcl-179, 80 have been 
developed more recently. However, they have not moved forward beyond preclinical research 
and have only found use for screen assay development81. 
A major breakthrough by Fesik, Rosenberg and co-workers at Abbott Laboratories came in 
2005 with the development of ABT-73782 (Figure 1.6A) and then its orally bioavailable analog 
ABT-26383, also known as navitoclax. ABT-737 was shown to function like a Bad BH3-only 
protein as it binds and inhibits Bcl-2, Bcl-XL and Bcl-w but not Mcl-1 or Bfl-1/A1. The first x-
ray crystal structure of a non-peptidic ligand to an anti-apoptotic protein was between ABT-737 
and Bcl-XL84  (Figure 1.6B) which provided the binding mode of the compound and explained its 
selectivity profile. Chlorobiphenyl and nitrophenyl along with thiophenyl of ABT-737 occupies 
p2 and p4 of Bcl-XL, respectively, while the same moieties cannot be accommodated into a more 
constrained p2 and p4 of Mcl-185. Both ABT-737 and navitoclax required Bax/Bak for cell 
killing, thus confirming a mechanism-based effect and exhibited potent in vitro and in vivo 
antitumor activity82. The strategy used in the development of ABT-737 was a combination of 
NMR-based fragment screen86 and structure-based design. Navitoclax is currently in phase II 
clinical trial. However, due to lack of inhibition of Mcl-1, resistance to Mcl-1 can quickly 
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develop upon treatment with ABT-73787, 88 and recently the results from phase I study of 
navitocalx in chronic lymphocytic leukemia (CLL) showed that treatment was not effective when 
high expression levels of Mcl-1 were present89. Therefore, Mcl-1 has become an important 
resistance factor and a priority for therapeutic intervention.  
                      
Figure 1.6. Structural studies of ABT-737. (A) Structure of ABT-737. (B) Bcl-XL bound to 
ABT-737 (PDB 2YXJ). (C) Overlay of Bcl-XL–ABT-737 complex with Bcl-XL–Bim BH3 
complex (PDB 1PQ1). For clarity Bcl-XL from the BCL-XL–Bim BH3 structure is not displayed 
in the overlay.  
 
1.6 Targeting Mcl-1 with small molecules  
 
Mcl-1 is among the top ten pathologic factors in a variety of cancers60 and its overexpression 
in cancers has emerged as a resistance factor to anti-cancer chemotherapies90 including ABT-737 
as mentioned previously. Pharmacological77 or genetic downregulation91 of Mcl-1 has shown to 
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be sufficient to overcome Mcl-1-mediated resistance. Thus, Mcl-1 is an attractive therapeutic 
target for cancer therapy and has been the subject of intensive research over the past few years. 
However, development of Mcl-1 inhibitors has not been trivial due to the similarity of its BH3-
binding site to other anti-apoptotic members and it’s plasticity preventing its crystallization with 
small molecules, and despite successful attempts, nothing has entered into clinical trials.  
Among several reports over the past few years on the discovery of small molecule Mcl-1 
inhibitors81, 92-98, only four can be pointed out as robust inhibitors because they have been 
extensively characterized. UMI-7796 (Figure 1.7) with a Ki = 490 nM against Mcl-1 was 
developed in our lab. This compound selectively inhibits Mcl-1 over other anti-apoptotic 
members and is a more potent analog of a HTS lead 59 discussed in Chapter 2. UMI-77 inhibited 
cell growth and induced apoptosis in pancreatic cancer cells accompanied by cytochrome c 
release and caspase-3 activation. Furthermore, studies in in vivo pancreatic xenograft model 
showed that UMI-77 effectively inhibited tumor growth. MIM181 (Figure 1.7), identified from a 
HTS of a library of small molecules using a selective fluorescently-labeled Mcl-1 stapled 
peptide, binds Mcl-1 in low micromolar range. MIM1 showed to bind to Mcl-1 and release Bax, 
trigger the death of Mcl-1- dependent cells and synergize with ABT-737 to kill cells that express 
both Mcl-1 and Bcl-XL. Friberg et al. reported compound 53 (Figure 1.7) which was developed 
through a similar method of NMR-based fragment screen used to develop ABT-73797. 53 is a 
potent and selective inhibitor of Mcl-1 and led to the first crystal structure of Mcl-1 bound to a 
non-peptidic small molecule. The crystal structure of Mcl-1 bound to 53 was a significant 
accomplishment as flexibility of Mcl-1 has been a major hurdle for its crystallization and 
structure-based design of novel inhibitors. Finally, compound 11 (Figure 1.7), published recently 
by Takeda Pharmaceutical98, is a dual inhibitor of Mcl-1 and Bcl-XL and was discovered by a 
hybridization strategy linking a Mcl-1 small-molecule inhibitor similar in structure to compound 
53 to a portion of ABT-737 structure that binds the p4 of Bcl-XL. A crystal structure of an analog 
of 11 bound to Mcl-1 and Bcl-XL confirmed its mode of binding to these anti-apoptotic proteins. 
The activities of both compounds 53 and 11 have been limited to in vitro assays and their use in 
cells and animal models is yet to be studied. While the development of these four Mcl-1 
inhibitors clearly suggest that access to selective and potent small molecules against Mcl-1 is not 
out of reach, their low micromolar to high nanomolar affinities make them non-ideal for 
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extensive cell-based and in vivo efficacy studies and further optimization is needed to improve 
potency and selectivity of these compounds.   
 
Figure 1.7. Structures and binding affinities of UMI-77, MIM1, 53, and 11. 
 
It still is not clear whether targeting all anti-apoptotic family members or a subset of them is 
beneficial in cancer therapy. Additionally, it is still debated whether the activation model 
(indirect or direct) of Bak/Bax exists and if there is one which is dominant in some cancers 
versus others. Such questions can only be answered by having access to a wide variety of potent 
inhibitors with different selectivity profiles. These inhibitors can also serve as useful tools to 
better understand the biology and role of anti- and pro- apoptotic proteins in cancer and normal 
physiology.  
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Chapter 2  
3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective 
Mcl-1 inhibitors 
 
 
2.1 Introduction  
 
Evasion of apoptosis or programmed cell death, a key regulator of physiological growth 
control and regulation of tissue homeostasis, is a hallmark of cancer and a contributor to the 
emergence of resistance to current therapies1-3. The B-cell lumphoma-2 (Bcl-2) family of 
proteins regulate the intrinsic (mitochondrial) pathway of apoptosis through a network of 
protein-protein interactions between pro- and anti-apoptotic members4. The anti-apoptotic 
proteins contain a hydrophobic surface known as the BH3-binding site, which is comprised of 
four contiguous hydrophobic pockets (p1-p4), that can bind to the BH3-binding domain of pro-
apoptotic proteins preventing apoptosis from happening. 
Overexpression of Bcl-2 survival members is observed in different types of human tumor 
samples and cancer cell lines, and much effort has been focused on developing therapeutics 
against this family of proteins for the treatment of cancers5-7. Selective and potent small 
molecule inhibitors have been successfully developed against Bcl-28, Bcl-XL9 and Bcl-2/Bcl-
XL10-13 with Navitoclax (ABT-263) currently in phase I/II clinical trials. The efficacy of ABT-
263 as a single agent has been demonstrated in tumors with low levels of the pro-survival Mcl-1. 
Several studies14-18 have shown that resistance to ABT-263 and its analog ABT-737 is linked to 
high expression levels of Mcl-1 and in many instances this resistance can be overcome by 
treatment with agents that downregulate, destabilize, or inactivate Mcl-1. The biological 
significance of Mcl-1 protein expression in support of cell survival has been well documented in 
a number of cell systems, including human myeloblastic leukemia19, myeloma20-22, B-
lymphoma23, non-small cell lung24, melanoma25, pancreatic26, 27 and prostate28. Furthermore, 
Mcl-1 is overexpressed in many human tumor specimens26, 29-32 and metastatic tissue33. This 
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overexpression contributes to chemoresistance and disease relapse34-36. It has been shown that 
Mcl-1 down-regulation is important toward making multiple myeloma cells susceptible to BH3-
only proteins and therefore to mitochondrial disruption37, 38. Such down-regulation can increase 
the sensitivity to rituximab-mediated killing of chronic and acute lymphoid leukemia (CLL and 
ALL)39. Antisense strategies targeting Mcl-1 in vitro and in vivo have provided promising results 
in sensitizing human melanoma and pancreatic cancer40-42. These data suggest that therapies 
specifically targeting Mcl-1, either as a single agent or in combination, can be effective in the 
treatment of different human cancers.  
Recently, several groups including us have reported on small molecules43-50 and stapled 
peptides51, 52 as Mcl-1 inhibitors. Herein we disclose a novel series of small molecule Mcl-1 
inhibitors discovered through high throughput screening (HTS) followed by the utilization of 
structure-based design to develop structure-activity relationships (SAR) around lead compound 
59 (Figure 2.1A). Docking studies and two-dimensional 1H, 15N heteronuclear single quantum 
coherence spectroscopy (HSQC) NMR studies were employed to provide information about its 
binding mode which was used for the design and synthesis of additional analogs. A SAR was 
developed which resulted in the identification of several selective small-molecule Mcl-1 
inhibitors with improved binding. Selected analogs were then tested in a series of complementary 
biochemical, biophysical, functional and cellular assays to evaluate their potency, specificity and 
mechanism of action.  
2.2 Discovery of HTS lead compound 59 
 
HTS of a 53.3K small molecule library was performed using a fluorescence polarization 
(FP) binding assay based on the interaction between recombinant human Mcl-1 and fluorescently 
labeled Bid BH3 peptide (Flu-Bid). Compound 59 (also refered to as 1) (Figure 2.1A) was one of 
the validated hits and a resynthesized sample exhibited a Ki of 1.55 ± 0.18 µM against Mcl-1. To 
explore the binding mode of 59 with Mcl-1, in silico induced fit docking (IFD)53 studies were 
performed using the crystal structure of Mcl-1 in complex with mNOXA BH3 peptide (PDB ID: 
2NLA)54. The predicted binding model of 59 in the complex with Mcl-1 revealed that the 
thiophene and the naphthalene rings of 59 occupy two hydrophobic pockets, p2 and p3, of Mcl-1, 
mimicking two conserved hydrophobic residues in the BH3 binding motif represented by Leu 78 
and Ile 81, respectively, in mNoxaB (Figure 2.1B). The importance of the two conserved 
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hydrophobic residues, Leu and Ile, in the BH3 binding motif for the high affinity interaction and 
selective binding to Mcl-1 has been demonstrated with structural studies of Bims2A55, a highly 
selective peptide derived from Bim peptide, as well as from recently reported selective small 
molecule inhibitor in complex with Mcl-145. The carboxylic acid group of 59 forms a network of 
hydrogen bonds with Arg 263 and Asn 260 of Mcl-1, mimicking the conserved Asp in BH3 
peptides (Asp 83 in mNoxa). The predicted binding model also suggests that the phenolic group 
forms a hydrogen bond with His 224, which is one of the residues composing the p3 pocket of 
Mcl-1. A recent report56 on the conformational flexibility of Mcl-1 and its binding hotspots 
identified His 224 as an acidic hotspot in the p3 site of Mcl-1, supporting the predicted hydrogen 
bonding in this region of Mcl-1. 
To validate the computationally predicted binding site and confirm the binding of 59 to the 
BH3 groove of Mcl-1, HSQC NMR spectroscopy studies were performed. For this purpose the 
assignment of the backbone amides of apo human Mcl-1 was based on the work by Liu et al.57, 
and a series of 1H,15N-HSQC studies were carried out. The HSQC spectra were of good quality 
with well-dispersed peaks, and concentration-dependent shifts of residues were observed (Figure 
2.1C) indicating that 59 binds Mcl-1 specifically and causes dose-dependent perturbations of 
backbone amides. The chemical shift changes in the presence of a 2-fold excess of 59 were 
mapped and plotted against Mcl-1 residues (Figure 2.1D). Compound 59 caused moderate to 
significant chemical shift perturbations for residues of Met 231, Met 250, Leu 267, Phe 270, 
which constitute the p2 and p3 pockets and which are predicted to be occupied by the thiophene 
and naphthalene rings of 59, respectively. Moderate chemical shift perturbations of Arg 263 and 
His 224 were also observed, which are predicted to form hydrogen bonds with the thioacidic acid 
and phenolic moieties of 59, respectively. Additionally, the residues in the vicinity of the 
predicted binding pose (Leu 232, Val 243, Arg 248), and the ones located on an unstructured 
loop connecting α-helix 3 to α-helix 4 (Lys 234, Leu 235, Lys 238, Asn 239) were also 
perturbed. Overall analysis of the chemical shift changes of the compound 59 in complex with 
Mcl-1 showed that 59 affects the residues forming the BH3-binding groove, and provided 
conclusive evidence that 59 binds Mcl-1 protein at the same site that the conserved BH3 peptides 
interact with Mcl-1 protein. Therefore, based on our modeling and NMR results, the substituted-
N-(4-hydroxynaphthalen-1-yl)arylsulfonamide represents a promising class for further 
optimization. A structure-based design approach supported by NMR and docking studies was 
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undertaken and a focused library of analogs of 59 was designed and synthesized to improve the 
potency of this series and validate our binding model to Mcl-1.  
 
 
Figure 2.1. Docking and NMR studies of 59. (A) Structure of the HTS lead compound 59 or 1. 
(B) Putative binding mode of 59 to Mcl-1 (2NLA). Side chains residues of mNoxa peptide are 
shown in blue sticks. The surface of Mcl-1 protein is colored according to the chemical shift 
intensity. Significant shift (> 0.09 ppm) is represented with purple, moderate shift (≥ 0.03 ppm 
and ≤ 0.09 ppm) represented with pink. (C) Overlaid 15N-1H HSQC spectra of Mcl-1 (red), and 
in presence of 59 (Mcl-1:59 ratio of 1:2) (black), (Mcl-1:59 ratio of 1:1) (purple). Arrows show 
the direction of chemical shift changes upon binding of 59. (D) Plot of chemical shift changes of 
Mcl-1 amide upon addition of 59 (Mcl-1:59 ratio of 1:2) as a function of Mcl-1 residue numbers.  
 
2.3 Synthesis 
 
Except for analogs 4-8, 15, and 38 which were commercially available, all analogs were 
synthesized through a novel, modular route (Scheme 2.1), which differs from that recently 
reported by Ge et al.58 Our route allows for facile access to a variety of analogs with variations at 
R1, R2 and R3 and the linker region (X). It starts with the electrophilic aromatic substitution 
(SEAr) of 1-methoxy-4-nitronaphthalene with N-iodosuccinamide to provide aryl iodide (46)59. 
This was subjected to Pd-catalyzed C-S or C-C cross-coupling using conditions previously 
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reported60, 61, or developed in our lab based on recent literature62-64, to provide several desired 
intermediates (47). The nitro function was reduced with iron65 or via catalytic hydrogenation66 to 
provide the corresponding amines. Reaction of the amines with appropriate sulfonyl or acyl 
chlorides or 3-methyl-1-((4-phenylpiperazin-1-yl)sulfonyl)-1H-imidazol-3-ium67 provided the 
penultimate compounds (48), which were demethylated with BBr3 followed by purification by 
trituration or reverse-phase HPLC to afford the target compounds (1-3, 9-14, 16-23, 25-26, 28-
29, 31-37) of >95% purity (Tables 2.1-2.3). In the case of analogs with an ester side chain, the 
BBr3 step provided a convenient way to concomitantly hydrolyze the ester in a single pot. To 
preserve the methyl ester of analog 32 (Table 2.3), analog 40 (Table 2.4) was subjected to BBr3 
conditions followed by a quench with MeOH.  For the synthesis of 48o, intermediate 48k 
underwent Suzuki-Miyaura coupling68, 69 with phenyl boronic acid to provide the desired 
compound which was subjected to BBr3 to provide 17 (Table 2.1). Aminolysis of 40 with 
NH4OH70 provided carboxamide 41 (Table 2.4) which was subjected to BBr3 to give 33 (Table 
2.3). The terminal amide of 41 was converted by a known procedure71 to tetrazole 48bb, which 
after BBr3 demethylation provided 36  (Table 2.3). The thioacidic acid analogs with a methoxy at 
R3 (39, 42-43), (Table 2.4) were obtained via LiOH hydrolysis of esters 40, 48n, and 48o, 
respectively. Acetylation of 10 (Table 2.1) with acetyl chloride72 provided 45 (Table 2.4). 
It should be mentioned that the synthetic route (Scheme 2.1) that was developed for 
synthesis of 59 (1) and its analogs was amenable to scale-up. Analog 10 (also referred to as 
UMI-77) was synthesized in 1 g utilizing this scheme for later efficacy studies in a pancreatic 
xenograft model.  
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      Scheme 2.1. Synthetic route for 59 and analogsa. 
 
aReagents and conditions: (a) NIS, TFA, reflux, 24 h, 70%; (b) HS(CH2)nCOOCH3 (n=1, 2), 
Pd(OAc)2, Xantphos, Cs2CO3, LiI, ZnCl2, THF, 60 oC, overnight, 66%, or HS(CH2)3CH3, 
Pd2(dba)3, Dppf, Et3N, NMP, 80 oC, 2-3 h, 71%, or HCC(CH2)nOH (n=1, 2), Pd(PPh3)2Cl2, CuI, 
Et3N/THF (4:1), 60 oC, 2 h, 83-97%; (c) Fe, AcOH, 70 oC, 1 h, or Pd/C, H2 30 psi, EtOH/EtOAc 
(6:1), rt, overnight; (d) RSO2Cl, pyridine, CH2Cl2, rt, overnight, 33%-80% over two steps, or 
RCOCl, Et3N, CH2Cl2, rt, overnight, 49%-69% over two steps, or , 
CH3CN, 80 oC, 15 h, 25% over three steps; (e) BBr3, CH2Cl2, 0 oC to rt, 1 h, 8%-61% or BBr3, 
CH2Cl2, 0 oC to rt, 1 h, quench with MeOH at 0 oC, 13%; (g) phenyl boronic acid, Pd(PPh3)4, 
Na2CO3, THF/H2O, 60 oC, 2 h, 92%; (h)  NH4OH, rt, 1 h, 90%; (i) NaN3, SiCl4, CH3CN, 80 oC, 
15 h, 50%; (j) LiOH, THF, rt, 1 h, 59%-74%; (k) H3CCOCl, Et3N, 0 oC, rt, 30 min, 61%. 
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Analog 24 (Table 2.1) with a phenyl scaffold in place of naphthalene was synthesized 
starting from 2-iodoanisole (Scheme 2.2) which underwent SEAr with nitric acid and acetic acid 
as described previously73 to yield 49. Aryl iodide 49 was then subjected to C-S coupling reaction 
with methyl thioglycolate to introduce the methyl thioacetate in 50. The nitro group of 50 was 
reduced using iron and the free amine was subjected to sulfonamide coupling with 4-
bromobenzene sulfonyl chloride to provide 51. Subjection of 51 to boron tribromide conditions 
provided desired analog 24. 
 
Scheme 2.2. Synthesis of 24a. 
 
aReagents and conditions: (a) HNO3, AcOH, 0 oC to 50 oC, 1 h, 56%; (b) HSCH2COOCH3, 
Pd(OAc)2, Xantphos, Cs2CO3, LiI, ZnCl2, THF, 60 oC, 6 h, 63%; (c) Fe, AcOH, 70 oC, 1 h; (d) 4-
bromobenzene sulfonyl chloride, pyridine, CH2Cl2, rt, overnight, 41% over two steps; (e) BBr3, 
CH2Cl2, 0 oC to rt, 1 h, 29%. 
 
For the synthesis of analog 27 (Table 2.2), with a methylene linker in between the 
naphthalene scaffold and sulfonamide linker, Scheme 2.3 was utilized. 4-methoxy-1-
naphthaldehyde was first subjected to NIS to provide 52 via SEAr. Aldehyde 52 was treated with 
benzenesulfonamide in the presence of titanium chloride and triethylamine to form the 
corresponding sulfonimide intermediate which was reduced with sodium borohydride to 
sulfonaminde 53.74 Subjection of 53 to C-S coupling in presence of methyl thioglycoate provided 
54 which was treated with boron tribromide to yield the final analog 27.    
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Scheme 2.3. Synthesis of 27a. 
 
aReagents and conditions: (a) NIS, TFA, reflux, 8 h, 77%; (b) benzenesulfonamide, Et3N, TiCl4, 
CH2Cl2, 0 oC to rt, 3 h; (c) NaBH4, MeOH/CH2Cl2 (1:1), 0 oC to rt, 45 min, 60% over two steps; 
(d) HSCH2COOCH3, Pd(OAc)2, Xantphos, Cs2CO3, LiI, ZnCl2, THF, 60 oC, 10 h, 53%; (e) 
BBr3, CH2Cl2, 0 oC to rt, 1 h, 18%. 
 
Analog 30 missing the thioacetic acid side chain was synthesized starting from 1-
nitronaphthalene (Schemes 2.4) which was hydroxylated with cumene hydroperoxide in presence 
of a base via nucleaphilic aromatic substitution (SNAr).75 Protection of free hydroxyl via 
Williamson ether synthesis with benzyl bromide provided 55. Nitro of 55 was reduced with iron 
and the free amine was subjected to sulfonamide coupling with benzenesulfonyl chloride to 
provide sulfonamide 56. Removal of benzyl group was achieved via catalytic hydrogenation to 
provide the final analog 30. 
 
Scheme 2.4. Synthesis of 30a. 
 
 
aReagents and conditions: (a) cumene hydroperoxide, KOH, DMSO/H2O (3:1), 0 oC to rt, 2 h, 
67%; (b) benzyl bromide, NaH, DMF/THF (2:1), 0 oC to rt, 2-3 h, 64%; (c) Fe, AcOH, 70 oC, 1 
h; (d) benzenesulfonyl chloride, pyridine, CH2Cl2, rt, overnight, 55% over two steps; (e) Pd/C, 
H2 30 psi, MeOH, rt, overnight, 21%. 
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2.4 Structure-activity relationships 
 
Structure-based design of analogs based on 59 yielded a focused library of compounds 
leading to clear SAR for this series. The binding affinities of our Mcl-1 inhibitors were 
determined by using competitive FP- and surface plasmon resonance (SPR)-based binding 
assays, which test the ability of inhibitors to disrupt interaction between Mcl-1 and two different 
BH3 peptides, fluorescently-labeled Bid and biotin-labeled Bim, respectively. Concurrently, 
HSQC NMR experiments were performed to provide structural insights of protein-bound ligand 
and experimental validation for the modeling studies.  
The predicted binding model showed that the thiophene ring at R1 of 59 projects into the p2 
pocket (Figure 2.1B), which is the biggest and deepest pocket amongst the four hydrophobic 
pockets of Mcl-154. To investigate the importance of hydrophobic interaction at this site and 
increase the binding affinity of 59, a series of analogs with variation at R1 was synthesized and 
evaluated (Table 2.1). When R1 is changed to a methyl group in 2, the binding affinity is 
significantly reduced, which is supported by the lack of chemical shift perturbations of backbone 
residues in the Mcl-1 BH3-binding site after addition of 2 (Figure 2.2).  
 
                   Table 2.1. Binding affinities of sulfonamide analogs with variations at R1. 
 
Cpd R1 
FP 
 Ki ± SD (µM) 
SPR 
IC50 ± SD (µM) 
1(59) 
 
1.55 ± 0.18 7.12 ± 1.02 
2  74.92 ± 6.33 >100 
3 
 
3.56 ± 0.45 12.58 ± 3.60 
4 
 
3.13 ± 0.22 11.57 ± 7.86 
  30 
5 
 
1.55 ± 0.37 8.68 ± 1.63 
6 
 
1.06 ± 0.17 4.0 ± 1.7 
7 
 
0.81 ± 0.04 8.7 ± 0.95 
8 
 
4.23 ± 0.93 5.0 ± 1.1 
9 
 
0.82 ± 0.10 2.7 ± 0.6 
10 
 
0.49 ± 0.06 2.4 ± 0.17 
11 
 
9.31 ± 3.1 7.2 ± 2.8 
12 
 
2.35 ± 0.19 9.68 ± 0.88 
13 
 
4.42 ± 0.86 6.2 ± 1.2 
14 
 
1.54 ± 0.32 7.5 ± 3.0 
15 
 
0.73 ± 0.05 2.76 ± 1.72 
16 
 
0.37 ± 0.10 2.03 ± 1.1 
17 
 
0.38 ± 0.03 2.31 ± 0.76 
18 
 
2.03 ± 0.41 9.9 ± 3.5 
19 
 
0.17 ± 0.04 0.88 ± 0.15 
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20 
 
0.24 ± 0.06 0.92 ± 0.20 
21 
 
0.18 ± 0.05 1.45 ± 0.29 
22 
 
0.29 ± 0.04 0.9 ± 0.42 
23  2.22 ± 0.36 16.2 ± 5.8 
24 
 
283.36 ± 81.50 >100 
 
 
Figure 2.2. NMR studies of 2. Plot of chemical shift changes of Mcl-1 residues upon addition of 
2 (Mcl-1:2 ratio of 1 to 2). 
 
As was expected, isosteric replacement of the thiophene in 59 to a phenyl in 3 maintained 
binding affinity. To probe the hydrophobic interactions in the p2 pocket, analogs with alkyl and 
halogen substituents of various sizes at the para-position of the phenyl ring were prepared. From 
this set of compounds, a trend emerged showing improved binding with increasing size and 
hydrophobicity of substituents. Tert-butyl phenyl (7) exhibited 4-fold (Ki = 0.8 µM) and bromo 
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phenyl (10) 7-fold (Ki = 0.5 µM) improved binding over 3. Introduction of a more polar methoxy 
group in 11 was accommodated, but resulted in a 3-fold decreased binding compared to 3. 
Bromine substitution at the meta- and ortho- positions of the phenyl ring was also explored and 
the binding results (Ki = 2.4 µM and Ki = 4.4 µM, respectively) indicated that para-bromo 
substitution is best, exhibiting the highest binding affinity to Mcl-1 amongst these three isomers. 
To improve the quality and accuracy of ligand-induced Mcl-1 chemical shift perturbations, 
resonance assignments were also determined for 10 in complex with Mcl-1 using 13C,15N-Mcl-1 
in the presence of a 2-fold excess of 10. The HSQC spectrum of 10 showed a similar pattern of 
chemical shift perturbations as with 1, which we attribute to the structural similarity of the two 
analogs. Consistent with the 7-fold improved binding of 10 in comparison with 1, the chemical 
shift perturbations were larger for 10 (Figure 2.3A). In particular, significant perturbation of 
residues S247, R248, V253 on α-helix 4, which forms the upper rim of the p2 pocket, and 
residues V216, V220, Q221 located toward the C-terminus of α-helix 2, which are at the border 
between the p3 and p4 pockets, were observed for 10 suggesting that the Mcl-1 conformational 
flexibility accommodates larger R1 substituent into the p2 pocket. Chemical shift perturbation 
plots derived from 1H,15N-HSQC experiments of the other two bromophenyl isomers showed a 
similar perturbation pattern as 10 with chemical shift changes that correlate well with the binding 
data in which the strongest perturbation is observed for 10, followed by 12 and 13 (Figure 2.3A-
C).  
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Figure 2.3. NMR studies of 10, 12, 13. Plots of chemical shift changes of Mcl-1 residues upon 
addition of (A) 10 (Mcl-1:10 ratio of 1 to 2) (B) 12 (Mcl-1:12 ratio of 1 to 2) (C) 13 (Mcl-1:13 
ratio of 1 to 2). Significant shift (> 0.09 ppm) is represented with purple, moderate shift (≥ 0.03 
ppm and ≤ 0.09 ppm) represented with pink. 
 
To further extend into the p2 pocket and gain additional interactions, analogs with biphenyl 
substituents were synthesized because biphenyl is considered a privileged moiety in targeting 
protein-protein interactions76. Analogs 16 and 17, with para-, and meta-biphenyl substituents, 
showed a similar 9-fold improvement in binding compared to 3, while the ortho-biphenyl analog, 
18 showed only a 2-fold increase in binding. The predicted binding models of these compounds 
showed that the distal phenyl ring of 16 and 17 inserts deeper into the p2 pocket (Figures 2.4A 
and B, respectively). For 18, this phenyl ring is partially solvent exposed (Figure 2.4C) which 
might explain its lower affinity compared to 16 and 17. In agreement with their binding 
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affinities, chemical shift perturbation plots of 16 and 17 show stronger perturbation of residues 
involved in the binding site compared to 18 (Figure 2.4D-F).  
 
 
Figure 2.4 Docking and NMR studies of 16, 17, 18. Putative binding modes of (A) 16, (B) 17, 
(C) 18 to Mcl-1. Surface of Mcl-1 protein is colored according to the chemical shift intensity. 
Significant shift (> 0.09 ppm) is represented with purple, moderate shift (≥ 0.03 ppm and ≤ 0.09 
ppm) represented with pink. Plots of chemical shift changes of Mcl-1 amide upon addition of (D) 
16 (Mcl-1:16 ratio of 1:2) (E) 17 (Mcl-1:17 ratio of 1:2) (F) 18 (Mcl-1:18 ratio of 1:2) as a 
function of Mcl-1 residue numbers. 
 
Analysis of the HSQC spectra of analogs 16 to 18 resulted in an important finding that 
strongly supports their predicted binding mode. One long-standing question for us was the 
possibility of a flipped binding mode for this class of analogs where R1 would occupy the p4 
pocket instead of p2. The possibility of a flipped conformation has been previously documented 
for a different class of dual Mcl-1 and Bcl-XL inhibitors49. We resorted to differential chemical 
shift mapping77, 78 using the three biphenyl analogs differing only in the orientation of distal 
phenyl ring. The difference in the orientation of the phenyl ring would create a distinct chemical 
environment with the interacting residues facilitating binding site mapping. Careful analysis of 
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the HSQC spectra of these analogs reveals a different direction of the chemical shifts of the 
residues forming the p2 pocket (Phe 270, Met 250) or in its vicinity (Phe 228) as well as residues 
located on α-helix 4, (Val 249, Val 253) (Figures 2.5A-E). This finding provides conclusive 
evidence for biphenyl occupation of the p2 pocket and further supports a recently published 
report56 that identifies α-helix 4 as the flexible helix of Mcl-1.  
 
 
Figure 2.5. Mapping the binding site of R1 of analogs 16, 17, 18. Overlaid 15N-1H HSQC 
spectra of Mcl-1 (red), and in the presence of 16 (Mcl-1:16 ratio of 1:2) (purple), 17 (Mcl-1:17 
ratio of 1:2) (black), 18 (Mcl-1:18 ratio of 1:2) (green) for (A) Phe 228 (B) Phe 270 (C) Met 250 
(D) Val 249 and Val 253. Arrows show the direction of chemical shift changes upon binding of 
compounds. (E) Overlay of putative binding modes of 16 (purple), 17 (blue), 18 (green) to Mcl-1 
highlighting in red Val 249, Met 250, and Val 253 on helix 4, Phe 228 on helix 3 and Phe 270 on 
helix 5 of Mcl-1. 
 
Due to encouraging binding data with 16, analogs 19 and 20 with halogenated biphenyl 
rings at R1 were synthesized to further increase potency. Satisfyingly, 19 with para-
chlorobiphenyl showed a 21-fold improved binding compared to 3, becoming the most potent 
analog in our series with a Ki of 170 nM. The chemical shift perturbation plot of 19 (Figure 2.6) 
showed a similar pattern of perturbations to 16 suggesting a similar binding conformation but 
with a lower perturbation magnitude, likely due to the lower solubility of 19 in our NMR studies.  
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Figure 2.6. NMR studies of 19. Plot of chemical shift changes of Mcl-1 residues upon addition 
of 19 (Mcl-1:19 ratio of 1 to 2). Significant shift (> 0.09 ppm) is represented with purple, 
moderate shift (≥ 0.03 ppm and ≤ 0.09 ppm) represented with pink. 
 
To further improve the physicochemical properties of the biphenyl analogs, we synthesized 
and evaluated analogs 21 with para-phenoxyphenyl at R1 and its fluorine substituted congener, 
22. Analog 21 showed a Ki of 180 nM and a 2-fold gain in potency over 16. The chemical shift 
perturbation plot derived from HSQC further confirmed binding of 21 (Figure 2.7A-C). 
Computational docking of 21 predicted a π-π stacking of the distal phenyl of the para-
phenoxyphenyl moiety with the phenyl of Phe 270 of Mc-1 (Figure 2.7D), which could account 
for its improved affinity. To increase the aqueous solubility of this class of analogs a para-
phenylpiperazine group at R1 was introduced in 23 which led to a 6-fold decrease in binding in 
comparison with the biphenyl substituent in 16. This can be attributed to a relatively polar 
substitutent projecting into the hydrophobic p2 pocket and a less optimal conformational 
preference of phenylpiperazine versus biphenyl for the p2 pocket. 
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Figure 2.7. NMR and docking studies of 21. (A) Putative binding mode of 21. Surface of the 
Mcl-1 protein is colored according to the chemical shift intensity. Significant shift (> 0.09 ppm) 
is represented with purple, moderate shift (≥ 0.03 ppm and ≤ 0.09 ppm) represented with pink. 
(B) Plot of chemical shift changes of Mcl-1 amide upon addition of 21 (Mcl-1:21 ratio of 1:2) as 
a function of Mcl-1 residue numbers. (C) Overlaid 15N-1H HSQC spectra of Mcl-1 (red), and in 
presence of 21 (Mcl-1:21 ratio of 1:2) (black), (Mcl-1:21 ratio of 1:1) (purple). Arrows show the 
direction of chemical shift changes upon binding of 21. (D) Mcl-1 residues shown to be 
perturbed in HSQC NMR in the presence of 21 (Mcl-1:21 ratio of 1:2) (green). 
 
To briefly explore the importance of the naphthalene core to the binding potency, analog 24 
with a phenyl core was evaluated and showed a significant drop in potency (Ki = 283 µM) 
compared to to 10 supporting the importance of hydrophobic interaction at the p3 to the overall 
Mcl-1 binding.  
The next focus of our SAR studies was the sulfonamide linker for which modeling 
suggested lack of any specific interactions with Mcl-1. To investigate the importance of the 
sulfonamide linker several analogs were synthesized (Table 2.2). Replacement of the 
sulfonamide with a carboxamide in 25 led to a significant decrease in the binding affinity with Ki 
value of 40.8 ± 8.50 µM compared to 10, possibly due to an unfavorable orientation of R1 by the 
carboxamide linker. The decreased binding potency was confirmed by NMR studies (Figure 2.8).  
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                         Table 2.2. Binding affinities of analogs with linker (X) variations. 
 
Cpd X-R1 
FP 
Ki ± SD (µM) 
SPR 
IC50 ± SD (µM) 
25 
 
40.8 ± 8.50 45.1 ± 3.9 
26 
 
5.23 ± 0.36 9.6 ± 5.1 
27 
 
64.75 ± 12.61 30.2 ± 4.0 
28 
 
12.53 ± 1.24 18.3±6.6 
29 
 
59.4± 15.5 63.8 ± 10.8 
 
          
Figure 2.8. NMR studies of 25.  Plot of chemical shift changes of Mcl-1 residues upon addition 
of 25 (Mcl-1:25 ratio of 1 to 2). Significant shift (> 0.09 ppm) is represented with purple, 
moderate shift (≥ 0.03 ppm and ≤ 0.09 ppm) represented with pink. 
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To explore the impact of the flexibility of the linker, a methylene linker distal (26) or 
proximal (27) to the naphthalene core was inserted and both analogs showed decreased binding 
affinity to 9 and 3 respectively. As expected, the change of the sulfonamide linker in 26 to a 
carboxamide in 28 decreased the potency, but only by 2-fold, suggesting that the insertion of the 
methylene linker between the carboxamide and the pendant aryl ring provides a degree of 
freedom to better orient R1 into p2 pocket of Mcl-1.  
Modeling showed that the thioacetic acid moiety at R2 mimics the conserved Asp of BH3-
only peptides and that the carboxylate is involved in electrostatic interaction with Asn 260 and 
Arg 263 of Mcl-1. Therefore, to further explore this site, analogs with different substituents at R2 
were synthesized (Table 2.3). Removal of the acid side chain (30) or its replacement with 
thiobutyl (31) did not show binding up to 100 µM. Introducing a methyl ester (32), or a primary 
carboxamide (33) resulted in decreased binding by 10- and 3-fold, respectively, compared to 10, 
consistent with each of these functional groups forming a weaker interaction with Arg 263 
compared to the carboxylic acid moiety. When the carboxylic acid was changed to an alcohol 
and the sulfur to methylene (34) or ethylene (35), both analogs showed decreased binding 
compared to parent congener 10. As was expected, bioisosteric replacement of the carboxylic 
acid group with a tetrazole (36) maintained the binding affinity. Homologating the thioacetic 
acid in 37 had no detrimental effect on binding and showed a similar Ki of about 1 µM as with 
15, which might be explained with the flexibility of both the thiopropanoic acid moiety and Arg 
263 side chain. However, changing the point of fusion of the naphthalene ring in 37 substantially 
affected the binding, and 38 with 1-naphthyl substituent did not show binding up to 100 µM. Our 
docking studies suggest that this might be attributed to a clash with the residues in the p2 pocket 
of Mcl-1. 
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Table 2.3. Binding affinities of sulfonamide analogs with variations at R1 and R2. 
 
Cpd R1 R2 
FP 
Ki ± SD (µM) 
SPR 
IC50 ± SD (µM) 
30 
 
-H >27* >100 
31 
  
>27* >100 
32   
5.08 ± 1.35 14.9 ± 3.3 
33   
1.71 ± 0.35 3.9 ± 0.6 
34 
 
 3.79 ± 0.62 11.0 ± 0.53 
35 
  
2.18 ± 0.91 19.7 ± 4.7 
36  
 
1.01 ± 0.22 1.50 ± 0.30 
37 
  
1.13 ± 0.34 5.0 ± 1.9 
38 
 
 >27* 64.9 ± 17.2 
                              *Compounds were tested up to 100 µM. 
 
Modeling showed that the phenolic group of the core naphthalene scaffold forms a hydrogen 
bond with His 224 of Mcl-1, consistent with the reported acidic hotspot in the p3 site of Mcl-1 
close to His 22456. Several analogs were synthesized to probe the contribution of the phenolic 
group to binding to Mcl-1 (Table 2.4). When the hydroxyl group is changed to a methoxy in 
analog 39, the potency decreased by 170 fold (Ki = 86.98 ± 15.35 µM) compared to the phenolic 
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congener 10. The analog 40, where R2 is methyl thioacetate and R3 is methoxy, did not show 
binding up to 100 µM and the loss of the binding was confirmed with HSQC experiment as 
expected (Figure 2.9). Similar significant loss of binding is also apparent in compounds 41 to 44 
compared to their corresponding phenolic analogs clearly indicating the importance of the 
phenolic group to the overall binding to Mcl-1. Compound 45 where the hydroxyl group was 
acetylated exhibited a Ki of 33.97 ± 15.96 µM, which is 69-fold decrease in binding compared to 
10. However, 45 showed improved binding relative to 39, which might be attributed to the 
formation of a hydrogen bond between the carbonyl of the acetyl group and protonated His 224, 
supported by computational prediction. 
Table 2.4. Binding affinities of sulfonamide analogs with variations at R1, R2, R3. 
 
Cpd R1 R2 R3 FP
a 
Ki ± SD (µM) 
SPRa 
IC50 ± SD (µM) 
39   
-OCH3 86.98 ± 15.35 >100 
40   
-OCH3 >27* >100 
41   
-OCH3 >27* >100 
42   
-OCH3 20.00 ± 0.79 >100 
43 
 
 -OCH3 24.2± 1.9 58.4 ±9.5 
44 
  
-OCH3 >27* >100 
45    
33.97 ± 15.96 26.8 ± 7.1 
                       *Compounds were tested up to 100 µM. 
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Figure 2.9. NMR studies of 40. Plot of chemical shift changes of Mcl-1 residues upon addition 
of 40 (Mcl-1:40 ratio of 1 to 2). 
 
2.5 Selectivity studies 
 
We determined the selectivity of this class of compounds against four other Bcl-2 anti-
apoptotic proteins (Bcl-2, Bcl-xL, Bcl-w, Bfl-1/A1). The most potent analogs were tested in 
competitive FP-based assays that were optimized for each protein, and Ki values were calculated 
using equations developed previously79 (Table 2.5). In general, all the analogs inhibit Mcl-1 most 
potently with the following order of selectively: Bfl-1/A1 > Bcl-w > Bcl-2 > Bcl-xL. As the 
BH3-domain binding profile to Bfl-1/A1, as well as its BH3-binding groove, is most similar to 
that of Mcl-180, it is not surprising that the tested compounds showed less selective inhibition of 
A1. The most potent analogs in this series, 19 and 21, show a profile for selectively inhibiting 
Mcl-1 with 7- and 19-fold versus Bfl-1/A1, 8- and 9-fold versus Bcl-w, 36- and 42-fold versus 
Bcl-2, and 56- and 59-fold versus Bcl-xL respectively. 
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Table 2.5. Selectivity of selected analogs against Bcl-2 anti-apoptotic proteins. 
Cpd Mcl-1 Ki ± SD (µM) 
A1/Bfl-1 
Ki ± SD (µM) 
Bcl-2 
Ki ± SD (µM) 
Bcl-w 
Ki ± SD (µM) 
Bcl-XL 
Ki ± SD (µM) 
1 1.55 ± 0.18 6.14 ± 1.0 54.65 ± 9.56 37.53 ± 7.96 99.0 ± 22.63 
10 0.49 ± 0.06 5.33 ± 1.0 23.83 ± 1.81 8.19 ± 1.91 32.99 ± 4.33 
16 0.37 ± 0.1 2.34 ± 0.37 8.82 ± 0.65 1.92 ± 0.37 8.05 ± 0.5 
17 0.38 ± 0.03 3.18 ± 0.41 7.85 ± 0.65 2.19 ± 0.45 15.14 ± 1.11 
18 2.03 ± 0.41 17.26 ± 0.56 23.84 ± 3.16 4.41 ± 0.39 48.15 ± 3.28 
19 0.17 ± 0.04 1.11 ± 0.19 6.11 ± 0.65 1.36 ± 0.51 9.59 ± 1.28 
21 0.18 ± 0.05 3.36 ± 0.56 7.56 ± 1.08 1.58 ± 0.35 10.58 ± 1.53 
 
2.6 Biological characterization of Mcl-1 inhibitors 
 
To verify the specific binding of novel inhibitors to Mcl-1, we employed a pull-down assay 
using biotin-labeled Noxa (BL-Noxa) and whole cell lysate from the human breast cancer cell 
line, 2LMP. As shown in Figure 2.10, Mcl-1 was pulled down by BL-Noxa, and as was expected 
the Bim BH3 peptide disrupted the interaction between BL-Noxa and the Mcl-1 protein. Pre-
incubation with several Mcl-1 inhibitors, 10, 19 and 21, completely blocked the binding of BL-
Noxa to Mcl-1, similar to Bim peptide, demonstrating that these inhibitors can recognize and 
specifically bind to the BH3-binding groove of endogenous Mcl-1.  
 
 
Figure 2.10. Interaction of Mcl-1 inhibitors with endogenous Mcl-1 protein and Noxa. 
Biotin-labeled Noxa (BL-Noxa, 0.1 µM) was incubated with whole cell lysates of 2LMP cells 
Mcl-1
BL-Noxa (0.1 µM) - - +     +    +     +     +
Bim (1 µM) - - - +     - - -
Comp. [100 µM]      - - - - 10   19   21  
Input (1%)               +
Pull-­‐down
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with or without tested Mcl-1 inhibitors and Bim BH3 peptide as a positive control, followed by 
incubation with precleared streptavidin agarose beads. Eluted beads were subjected to Western 
blot analysis with anti-Mcl-1 antibody.  
 
It is well established that Bax and Bak are required for the initiation of intrinsic, 
mitochondrial, apoptotic cell death, and they are maintained in an inactive state through 
interaction with the anti-apoptotic proteins14, 81. Therefore, cells subjected to inhibitors of anti-
apoptotic proteins are expected to undergo cell death in a Bax/Bak-dependent manner82. To 
determine the contribution of Bak and Bax in the cell death induced by our Mcl-1 inhibitors, we 
employed murine embryonic fibroblasts (MEFs) wild type (wt) and deficient in both Bax and 
Bak (double knock out - DKO). Exposure of the wt MEFs to 21 resulted in a concentration-
dependent cell death (assessed by PI staining), while Bax/Bak deletion significantly rescued cells 
from 21-induced cell death (Figure 2.11). Although 21 induced cell death also in DKO MEFs 
(23% positive PI at 16 µM), it is clear that 21 is more potent in wt MEFs (61% positive PI at 16 
µM), indicating that Bax and/or Bak are involved in cell death induction. Taken together, our 
data suggest that 21 induces cell death in a Bax/Bak-dependent manner due to its Mcl-1 
inhibitory function. 
 
 
Figure 2.11. Cell death induced by 21 is Bax/Bak-dependent. MEFs deficient in Bax and Bak 
(gray bars) along with their wild-type counterpart (black bars) were exposed for 15 hours to 
different concentrations of 21 and the cell viability was assessed with PI staining. Error bars 
represent the mean±SEM. The significance was calculated using unpaired t test and the number 
of data is shown for each tested concentration with corresponding significance: (**) p<0.01 and 
(***) p<0.001. 
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To further confirm the specificity of our novel Mcl-1 inhibitors and to determine whether 
different pro-survival Bcl-2 proteins could suppress the apoptotic activities of novel Mcl-1 
inhibitors, we used reported cell lines developed by retroviral transduction of lymphoma cells 
isolated from Eµ-myc transgenic mice which differ only in their expression of pro-survival Bcl-2 
family proteins83. Lymphoma cells overexpressing Mcl-1 and Bcl-2 were treated with varying 
concentrations of tested compounds for 15-18 hours, and then cell viability was determined by 
flow cytometry using fluorescent reactive dye (LIVE/DEAD Fixable Violet Stain Kit). ABT-263 
(navitoclax), a selective inhibitor of Bcl-2, Bcl-XL and Bcl-w, was used as a positive control. As 
predicted, lymphoma cells overexpressing Mcl-1 were sensitive to 19 and 21 as assessed by an 
increased percentage of cell death in a concentration-dependent manner. In contrast, cells 
overexpressing Bcl-2 were resistant to both Mcl-1 inhibitors (Figure 2.12). Importantly, 40 did 
not show any activity against both cell lines overexpressing Mcl-1 or Bcl-2, consistent with our 
binding studies which showed that 40 does not bind to Mcl-1.  In contrast, lymphoma cells 
overexpressing Bcl-2 were sensitive to cell death induced by ABT-263, while cells 
overexpressing Mcl-1 were resistant, as expected. Collectively, these results, demonstrate that 19 
and 21 specifically bind and inhibit Mcl-1 and have no effect on Bcl-2, which is consistent with 
our biochemical data for their selectivity profile.  
 
Figure 2.12. Sensitivity of Eµ-myc lymphoma cells overexpressing Mcl-1 and Bcl-2 anti-
apoptotic proteins to inhibitor-induced cell death. Eµ-myc/Mcl-1 and Eµ-myc/Bcl-2 
lymphomas were treated for 15-18 hours with increasing concentrations of 19, 21, 40 and ABT-
263. Dead cells were assessed by LIVE/DEAD Fixable Dead Cell Stain Kit (ViVID). The data 
shown represents means ± SEM from at least 3 experiments and the significance (*) is p<0.05. 
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We next evaluated our most potent compounds for their ability to inhibit cell growth in the 
leukemia cell lines HL-60, MV4,11 and K-562 (Figure 2.13). It has been shown that AML-
derived cell lines, HL-60 and MV4,11, are sensitive to inhibition of the anti-apoptotic protein 
Mcl-1, while CML-derived K-562 cell line is less sensitive to Mcl-1 inhibition84. Tested 
compounds from our series showed inhibition of the cell growth in a dose-dependent manner 
with similar potencies, IC50 values ranging from 4.24 µM to 7.56 µM against the HL-60 and 
MV4,11 cell lines (Figure 2.13A). Interestingly, these compounds showed decreased ability to 
inhibit the cell growth of K-562 with IC50 values of 12.5 µM to 29.9 µM. Compound 40, which 
does not bind to Mcl-1, did not show inhibition up to 50 µM. Compound 21 was evaluated for its 
ability to induce apoptosis in the HL-60 cell line using Annexin-V and propidium iodide (PI) 
double staining by flow cytometry (Figure 2.13B). 21 effectively induced apoptosis in a dose-
dependent manner. Treatment of the HL-60 cells by 2.5, 5.0 and 10 µM of 21 for 24 hours results 
in 28.9%, 37.8% and 78.4% of apoptotic cells (early + late), as compared to 7.6% of apoptotic 
cells in the DMSO control. Compound 40 at 40 µM has no effect on apoptosis induction just like 
untreated control, which is consistent with its lack of binding and inhibition of cell growth. We 
further tested compounds 19 and 21 in HL-60 cell line for their ability to induce caspase-3 
activity, one of the important biochemical markers of apoptosis (Figure 2.13C). Both compounds 
induce activation of caspase-3 activity in a dose-dependent manner with 21 effectively inducing 
activation over a 24 h period starting at 2.5 µM. Importantly, these results correlate with the 
ability of 21 to induce apoposis and inhibit HL-60 cell growth. 
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Figure 2.13. Cell-death and apoptosis induction by Mcl-1 inhibitors in human leukemic cell 
lines. (A) Inhibition of cell growth by designed Mcl-1 inhibitors in the HL-60, MV4,11 and K-
562 leukemia cell lines. Cells were treated for 3 days and cell growth was determined using 
CellTiter-Glo Luminescent Cell Viability Assay. (B) Analysis of apoptosis induced by 21 in the 
HL-60 leukemia cell line. Cells were treated with 21 and 40 for 15 h using indicated 
concentrations and apoptosis was analyzed with Annexin-V and propidium Iodide (PI) double 
staining by flow cytometry. Early apoptotic cells were defined as Annexin-V positive/PI-
negative, and late apoptotic cells as Annexin-V/PI-double positive. (C) Induction of caspase-3 by 
19 and 21 in the HL-60 cell line. Cells were treated for 20 h, and caspase-3 was detected with 
fluorometric-based assay. Results shown are the mean and SEM from at least 3 separate 
experiments. 
 
2.7 Efficacy studies of compound 10 (UMI-77) in pancreatic xenograft model 
 
In addition to the in vitro cell-based studies performed with the most potent inhibitors of 59 
in leukemia model cells, we have recently reported43 on the use of analog 10 (UMI-77) (Ki = 
0.50 µM), synthesized in 1 g scale using Scheme 2.1, in pancreatic cancer (PC) cells and 
xenograft mice model. Mcl-1 overexpression in PC cells is associated with resistance of cancer 
cells to chemotherapy and radiation making Mcl-1 an attractive molecular target for treatment of 
PC. It was shown that 10 inhibits PC cell growth and induces apoptosis in PC cells, but most 
importantly when 10 was administered at its maximum tolerated dose (MTD) of 60 mg/kg 
(Figure 2.14 A) to BxPC-3 xenograft model daily for 5 consecutive days a week for two weeks, 
it resulted in statistically significant tumor growth inhibition by 65% and 56% in comparison 
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with the controls in day 19 (p < 0.0001) and day 22 (p < 0.003) respectively (Figure 2.14 B). 
These data indicate that analog 10 exhibits single-agent antitumor activity in BxPC-3 xenograft 
model and highlights the potential of Mcl-1 inhibitors as novel antitumor agents in treatment of 
PC.  
 
 
Figure 2.14. In vivo characterization of 10 (UMI-77). (A) Evaluation of the effect of 
compound UMI-77 on weight loss of SCID mice. UMI-77 was administrated two cycles i.v. for 
5 days per week in two tested concentrations 60 and 80 mg/kg. (B) In vivo efficacy of UMI-77 in 
BxPC-3 xenograft animal model. BxPC-3 xenografts were inoculated subcutaneously in SCID 
mice. Once transplanted, fragments developed into palpable tumors, about 60 mg, groups of 4 
animals with bi-lateral tumors were removed randomly and assigned to two treatment groups. 
Mice were administered UMI-77 i.v 60 mg/kg for 5 consecutive days a week for two weeks. [■] 
vehicle treated group and [▼] UMI-77 treated groups. ** indicates p < 0.0001, while * is p < 
0.003 when compared to treatments with vehicle. 
 
2.8 Conclusions 
 
Applying HTS approach, we have identified a novel class of small molecules as selective 
Mcl-1 inhibitors. Employing structure-based design supported by NMR studies, we synthesized a 
focused library of analogs and established a SAR for binding to Mcl-1. Careful HSQC analysis 
of analogs 16 to 18 provided strong evidence for the predicted binding model of these 
compounds and further confirmation that R1 substituent of this class of inhibitors binds to one 
well-defined binding pocket of Mcl-1, known as p2 pocket. Analogs 19 and 21 with Ki values of 
170 nM and 180 nM, respectively, were developed as the most potent compounds in this series 
with an overall 9-fold increase in binding compared to 1. Binding studies showed that 19 and 21 
maintained the selectivity profile of 1. Using wild type and Bax/Bak double knockout MEFs 
cells, the contribution of these two multi-domain pro-apoptotic proteins in 21 induction of cell 
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death was determined and demonstrated that 21 primarily cause cell death in wild type MEFs in 
a Bax/Bak-dependent manner. Furthermore, 19 and 21 led to sensitization of Eµ-myc 
lymphomas overexpressing Mcl-1, but did not show effect on cells overexpressing Bcl-2 anti-
apoptotic protein, confirming their selective targeting of Mcl-1. Most potent Mcl-1 inhibitors 
inhibited the cell growth of AML-derived cell lines, HL-60 and MV4,11. Compounds 19 and 21 
induced activation of caspase-3 in HL-60 cell line, and 21 effectively induced apoptosis starting 
at 2.5 µM. Finally, efficacy studies in a PC xenograft model with analog 10 demonstrated that 
this analog exhibited robust antitumor activity. These promising findings, for the first time, 
provide a proof of principle for the therapeutic potential of selective Mcl-1 inhibitors for the 
treatment of PC. 
2.9 Experimental  
Chemistry  
 
All anhydrous reactions were run under an atmosphere of dry nitrogen. Reagents were used as 
supplied without further purification. Reactions were monitored by TLC using precoated silica 
gel 60 F254 plates. Silica gel chromatography was performed with silica gel (220–240 mesh) 
obtained from Silicycle. Purities of final compounds were assessed by analytical HPLC 
performed on a Shimadzu system with a Restek Ultra C18 (4.6 x 150 mm, 5µm particle size) 
column or an Agilent 1100 series with an Agilent Zorbax Eclipse Plus−C18 column and a 
gradient of acetonitrile with 0.1 vol% TFA (10-90%) in water with 0.1 vol% TFA. Semi-
preparative HPLC was performed on a Shimadzu system with a Restek Ultra C18 (21.2 x 150 
mm, 5µm particle size) column.  All NMR spectra were obtained in DMSO-d6 or CDCl3 and 
results were recorded at 400 MHz on a Varian 400 instrument or at 500 MHz on a Varian 500 
instrument. Mass spectrometry analysis was performed using a Waters LCT time-of-flight mass 
spectrometry instrument utilizing electrospray ionization operating in positive-ion (ESI+) or 
negative-ion (ESI-) modes where indicated. High-resolution mass spectrometry (HRMS) analysis 
was performed on an Agilent Q-TOF system. Analogs 4-8, 15, and 38 were purchased from 
commercial vendors. 
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2-Iodo-1-methoxy-4-nitronaphthalene (46). Synthesized using reported procedure with 
modification.59  A mixture of 1-methoxy-4-nitronaphthalene (2.1 g, 10.4 mmol), N-
iodosuccinimide (2.7 g, 12 mmol) in TFA (40 mL) was heated to reflux and stirred for 20 h 
under nitrogen. The reaction mixture was diluted with EtOAc (40 mL), washed with saturated 
aqueous Na2S2O3 solution (30 mL), saturated aqueous NaHCO3 (30 mL x 2), and brine (30 mL). 
The organic layer was dried (MgSO4), filtered and silica was added to filtrate and the solvent 
was removed under reduced pressure. The adsorbed crude residue was purified by flash column 
chromatography (100% hexane) on silica gel to give 46 (2.4 g, 70%) as a light yellow solid. 
Note: Rf of starting material and product are very close and a good separation is achieved with a 
relatively long silica gel column and 100% hexane gradient. >95% pure product is needed for pd-
catalyzed coupling step. 1H NMR (400 MHz, CDCl3) δ 8.59 (s, 1H), 8.58 (s, 1H), 8.21 (d, J = 
8.42 Hz, 1H), 7.74 (t, J = 7.53 Hz, 1H), 7.65 (t, J = 7.53 Hz, 1H), 4.03 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 161.69, 142.85, 134.07, 129.99, 128.55, 128.08, 126.55, 123.92, 123.02, 83.35, 
62.20; ESI MS: m/z 330.0 (M+H)+. 
 
Methyl 2-((1-methoxy-4-nitronaphthalen-2-yl)thio)acetate (47a). Synthesized using reported 
procedures with modification.62-64 To a solution of Cs2CO3 (1.5 g, 4.5 mmol) in dry THF (7 mL) 
under nitrogen was added methylthioglycolate (277 µL, 2.9 mmol). The mixture was stirred at 
room temperature for 10 min. At this time, a solution of ZnCl2 (288 mg, 2.1 mmol) in dry THF 
(3 mL) was added and the mixture was stirred at room temperature for an additional 10 min. 
Meanwhile, in a separate flask Pd(OAc)2 (36 mg, 0.16 mmol) and xantphos (90 mg, 0.15 mmol) 
were premixed in dry THF (5 mL) under nitrogen and stirred at room temperature for about 20 
min. To the solution of thiol, Cs2CO3, and ZnCl2 was added 46 (1.0 g, 3.1 mmol), LiI (200 mg, 
1.5 mmol) and premixed solution of the catalyst and ligand. The mixture was stirred at 60oC 
under nitrogen for 20 h. The reaction mixture was filtered to remove Cs2CO3 and silica was 
NO2
OCH3
I
NO2
OCH3
S
OCH3
O
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added to the mixture and the solvent was removed under reduced pressure. The adsorbed crude 
residue was purified by column chromatography (hexane/EtOAc 4:1) on silica gel to give 47a 
(606 mg, 66%) as a yellow oil which solidified. 1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 8.50 
Hz, 1H), 8.37 (s, 1H), 8.19 (d, J = 8.50 Hz, 1H), 7.70 (t, J = 7.57 Hz, 1H), 7.64 (t, J = 7.57 Hz, 
1H), 4.07 (s, 3H), 3.77 (s, 2H), 3.70 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 169.48, 159.95, 
142.50, 129.73, 128.88, 127.85, 127.22, 125.94, 123.71, 122.93, 122.68, 61.92, 52.72, 35.10; 
ESI MS: m/z 308.1 (M+H)+. 
 
Methyl 3-((1-methoxy-4-nitronaphthalen-2-yl)thio)propanoate (47b). Synthesized using a 
similar procedure used to prepare 47a except using methyl 3-mercaptopropionate. The mixture 
was stirred at 60oC under nitrogen for 5 h. Crude was purified using flash column 
chromatography (hexane/EtOAc 4:1) on silica gel with dry loading to give 47b (194 mg, 66%) as 
a yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.56 (d, J = 8.48 Hz, 1H), 8.27 (s, 1H), 8.16 (d, J = 
8.48 Hz, 1H), 7.70-7.64 (m, 1H), 7.64-7.58 (m, 1H), 4.03 (s, 3H), 3.65 (s, 3H), 3.28 (t, J = 7.24 
Hz, 2H), 2.65 (t, J = 7.24 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 171.64, 159.79, 142.48, 
129.51, 128.93, 127.81, 126.94, 125.60, 123.62, 123.45, 122.57, 61.59, 51.90, 34.11, 28.11; ESI 
MS: m/z 322.0 (M+H)+ , 343.9 (M+Na)+. 
 
Butyl(1-methoxy-4-nitronaphthalen-2-yl)sulfane (47c). Syntehsized using a reported 
procedure.60 A stirred mixture of 46 (300 mg, 0.91 mmol), Pd2(dba)3 (42 mg, 0.05 mmol), Dppf 
(104 mg, 0.18 mmol) and Et3N (0.2 mL) in dry NMP (7 mL) was flushed with nitrogen for 15 
min at room temperature. Butanethiol (83 µL, 0.77 mmol) was then added and the reaction 
mixture was heated to 80oC and stirred for 1.5 h. The mixture was diluted with EtOAc (10 mL) 
and washed with H2O (10 mL x4) and brine (10 mL). The organic layer was dried (MgSO4), 
filtered and silica was added to the filtrate and the solvent was removed under reduced pressure. 
The adsorbed crude residue was purified by flash column chromatography (hexane to 
OCH3
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hexane/EtOAc 99:1) on silica gel to give 47c (189 mg, 71%) as a yellow oil.1H NMR (400 MHz, 
CDCl3) δ 8.58 (ddd, J = 0.72, 1.50, 8.36 Hz, 1H), 8.26 (s, 1H), 8.16 (ddd, J = 0.72, 1.50, 8.36 
Hz, 1H), 7.68-7.59 (m, 2H), 4.03 (s, 3H), 3.03 (t, J = 7.36 Hz, 2H), 1.67 (p, J = 7.36 Hz, 2H), 
1.48 (h, J = 7.36 Hz, 2H), 0.93 (t, J = 7.36 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 158.48, 
142.53, 129.05, 128.81, 127.69, 125.69, 125.57, 125.03, 123.62, 122.34, 61.31, 32.23, 31.10, 
21.92, 13.60; ESI MS: m/z 292.0 (M+H)+.  
 
3-(1-Methoxy-4-nitronaphthalen-2-yl)prop-2-yn-1-ol (47d). Syntehsized using a reported 
procedure.61 A mixture of 46 (453 mg, 1.4 mmol), Pd(PPh3)2Cl2 (48 mg, 0.07 mmol), and CuI 
(28 mg, 0.15 mmol) in Et3N (8 mL) and dry THF (3 mL) was added dropwise to a solution of 2-
propyn-1-ol (0.15 mL, 2.6 mmol) in Et3N (3 mL) under nitrogen at room temperature. Reaction 
mixture was heated to 60oC and stirred for 2 h then diluted with EtOAc (10 mL) and washed 
with saturated aqueous NH4Cl (15 mL x 2) and brine (15 mL). The organic layer was dried 
(MgSO4), filtered, concentrated under reduced pressure. The crude was purified by flash column 
chromatography (hexane/EtOAc 3:2) on silica gel to give 47d (342 mg, 97%) as a yellow solid. 
1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 8.66 Hz, 1H), 8.29 (s, 1H), 8.26 (d, J = 8.66 Hz, 1H), 
7.74-7.66 (m, 1H), 7.64-7.55 (m, 1H), 4.58 (s, 2H), 4.29 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
162.40, 141.04, 130.49, 129.78, 128.26, 127.56, 126.29, 123.44, 123.24, 107.40, 93.96, 80.83, 
61.95, 51.67; ESI MS: m/z 258.1 (M+H)+. 
 
4-(1-Methoxy-4-nitronaphthalen-2-yl)but-3-yn-1-ol (47e). Synthesized using a similar 
procedure used to prepare 47d except using 3-butyn-1-ol as the alkyne. The crude was purified 
by flash column chromatography (hexane/EtOAc 3:2) on silica gel to give 47e (338 mg, 83%) as 
a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 8.56 Hz, 1H), 8.23 (s, 1H), 8.19 (d, J = 
8.56 Hz, 1H), 7.63 (t, J = 7.59 Hz, 1H), 7.53 (t, J = 7.59 Hz, 1H), 4.23 (s, 3H), 3.87 (t, J = 6.14 
Hz, 2H), 2.76 (t, J = 6.14 Hz, 2H), 2.45 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 162.29, 141.11, 
NO2
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130.19, 129.91, 128.36, 127.48, 126.03, 123.43, 123.10, 109.99, 108.73, 93.90, 61.77, 60.96, 
24.07; ESI MS: m/z 272.1 (M+H)+. 
A representative procedure for iron reduction of nitro to amine  
 
Methyl 2-((4-amino-1-methoxynaphthalen-2-yl)thio)acetate (48a). Syntehsized using a 
reported procedure.65 To a suspension of iron powder (538 mg, 9.6 mmol) in glacial acetic acid 
(5 mL) was added 47a (195 mg, 0.63 mmol) dissolved in glacial acetic acid (5 mL). The mixture 
was stirred at 70oC under nitrogen for 1 h when the mixture turned milky. The mixture was then 
diluted with EtOAc (15 mL) and washed with saturated aqueous NaHCO3 (20 mL x 2) and brine 
(20 mL). Organic layer was dried (MgSO4), filtered and the solvent was removed under reduced 
pressure to give 48a as a crude as a purple oil. The crude was used in the next step without 
further purification. 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.29 Hz, 1H), 7.76 (d, J = 8.29 
Hz, 1H), 7.50 (t, J = 7.58 Hz, 1H), 7.43 (t, J = 7.58 Hz, 1H), 6.78 (s, 1H), 3.91 (s, 3H), 3.73 (s, 
2H), 3.68 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.48, 147.81, 138.68, 128.54, 126.54, 
125.33, 124.24, 123.36, 122.45, 121.35, 111.08, 61.41, 52.53, 35.37; ESI MS: m/z 278.1 
(M+H)+, 300.1 (M+Na)+. 
 
Methyl 3-((4-amino-1-methoxynaphthalen-2-yl)thio)propanoate (48b). Synthesized using the 
procedure for 48a except using 47b as the starting material. Crude was used in the next step 
without further purification; 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 8.36 Hz, 1H), 7.75 (d, J 
= 8.36 Hz, 1H), 7.49 (t, J = 7.56 Hz, 1H), 7.42 (t, J = 7.56 Hz, 1H), 6.72 (s, 1H), 6.26 (s, 2H), 
3.89 (s, 3H), 3.65 (s, 3H), 3.22 (t, J = 7.46 Hz, 2H), 2.64 (t, J = 7.46 Hz, 2H); 13C NMR (100 
MHz, CDCl3) δ 172.38, 147.73, 138.77, 128.63, 126.51, 125.12, 123.92, 123.56, 122.36, 121.35, 
110.85, 61.21, 51.78, 34.48, 27.90; ESI MS: m/z 292.0 (M+H)+, 314.0 (M+Na)+. 
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3-(Butylthio)-4-methoxynaphthalen-1-amine (48c). Synthesized using the procedure for 48a 
except using 47c as the starting material. Crude was used in the next step without further 
purification. 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.30 Hz, 1H), 7.75 (d, J = 8.30 Hz, 1H), 
7.49 (t, J = 7.42 Hz, 1H), 7.40 (t, J = 7.42 Hz, 1H), 6.72 (s, 1H), 6.30 (s, 2H), 3.92 (s, 3H), 2.96 
(t, J = 7.33 Hz, 2H), 1.65 (p, J = 7.33 Hz, 2H), 1.47 (h, J = 7.33 Hz, 2H), 0.92 (t, J = 7.33 Hz, 
3H); 13C NMR (100 MHz, CDCl3) δ 146.85, 138.46, 128.54, 126.42, 125.50, 124.73, 123.45, 
122.20, 121.30, 110.24, 61.02, 32.29, 31.50, 22.02, 13.67; ESI MS: m/z 262.0 (M+H)+. 
A representative procedure for hydrogenation reaction  
 
3-(4-Amino-1-methoxynaphthalen-2-yl)propan-1-ol (48d). Syntheszied using a reported 
procedure.66 A stirred solution of 47d (325 mg, 1 mmol) in a mixture of EtOH (12 mL) and 
EtOAc (2mL) was hydrogenated in the presence of 10% Pd/C (80 mg) at room temperature and 
under 30 psi of H2 overnight. The suspension was filtered through a pad of celite and the filtrate 
was concentrated under reduced pressure. The crude was used in the next reaction without 
further purification. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 8.35 Hz, 1H), 7.76 (d, J = 8.35 
Hz, 1H), 7.51-7.43 (m, 1H), 7.43-7.35 (m, 1H), 6.54 (s, 1H), 3.85 (s, 3H), 3.54 (t, J = 6.08 Hz, 
2H), 2.80 (t, J = 7.27 Hz, 2H), 1.85 (p, J = 6.69 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 146.20, 
138.66, 129.80, 128.24, 126.01, 124.51, 123.79, 122.41, 121.33, 111.39, 62.18, 61.32, 33.18, 
25.51; ESI MS: m/z 232.1 (M+H)+. 
 
4-(4-Amino-1-methoxynaphthalen-2-yl)butan-1-ol (48e). Synthesized using the procedure for 
47e except using 47f as the starting material. Crude was used in the next step without further 
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purification. 1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 8.39 Hz, 1H), 7.72 (d, J = 8.39 Hz, 1H), 
7.43 (t, J = 7.33 Hz, 1H), 7.34 (t, J = 7.33 Hz, 1H), 6.52 (s, 1H), 3.79 (s, 3H), 3.56 (t, J = 6.43 
Hz, 2H), 2.67 (t, J = 6.43 Hz, 2H), 1.65 (dt, J = 6.60, 14.36 Hz, 2H), 1.56 (dt, J = 6.60, 14.36 Hz, 
2H); 13C NMR (100 MHz, CDCl3) δ 145.98, 138.36, 130.77, 128.39, 125.85, 124.33, 123.72, 
122.34, 121.36, 111.52, 62.32, 61.97, 32.45, 29.21, 26.89. 
A representative procedure for sulfonamide/amide coupling reaction of aryl amines with 
sulfonyl/acyl chlorides  
 
Methyl 2-((1-methoxy-4-(thiophene-2-sulfonamido)naphthalen-2-yl)thio)acetate (48f). A 
solution of the crude amine 48a dissolved in dry CH2Cl2 (4mL) was added to 2-
thiophenesulfonyl chloride (119mg, 0.65 mmol). Addition of pyridine (0.08 mL, 0.99 mmol) was 
followed and the mixture was stirred at room temperature under nitrogen overnight. The mixture 
was diluted with EtOAc (10 mL) and washed with H2O (10 mL x 3) and brine (10 mL). The 
organic layer was dried (MgSO4), filtered and the solvent was removed under reduced pressure. 
Crude was purified by flash column chromatography (hexane/EtOAc 7:3) on silica gel to give 
48f (176 mg, 66% over two steps) as a purple oil which solidified upon standing. 1H NMR (400 
MHz, CDCl3) δ 8.01 (d, J = 8.40 Hz, 1H), 7.82 (d, J = 8.40 Hz, 1H), 7.49-7.43 (m, 2H), 7.42-
7.39 (m, 1H), 7.39-7.34 (m, 2H), 6.92-6.88 (m, 1H), 3.95 (s, 3H), 3.68 (s, 3H), 3.65 (s, 2H); 13C 
NMR (100 MHz, CDCl3) δ 169.91, 154.12, 139.48, 133.09, 132.51, 130.06, 128.60, 127.74, 
127.39, 126.96, 125.74, 123.39, 122.29, 61.49, 52.68, 35.12; ESI MS: m/z 423.9 (M+H)+, 445.8 
(M+Na)+. 
 
Methyl 2-((1-methoxy-4-(methylsulfonamido)naphthalen-2-yl)thio)acetate (48g). 
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Synthesized using the procedure for 48f except using methanesulfonyl chloride, which afforded 
the title compound (69 mg, 39% over two steps) as a light pink solid. 1H NMR (400 MHz, 
CDCl3) δ 8.13-8.08 (m, 1H), 8.05-8.00 (m, 1H), 7.65 (s, 1H), 7.60-7.54 (m, 2H), 6.80 (s, 1H), 
3.99 (s, 3H), 3.75 (s, 2H), 3.69 (s, 3H), 3.04 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 169.98, 
154.06, 129.61, 128.85, 127.84, 127.36, 127.19, 125.15, 123.67, 122.67, 122.07, 61.50, 52.64, 
39.91, 35.00; ESI MS: m/z 355.9 (M+H)+, 377.9 (M+Na)+. 
 
Methyl 2-((1-methoxy-4-(phenylsulfonamido)naphthalen-2-yl)thio)acetate (48h). 
Synthesized using the procedure for 48g except using benzenesulfonyl chloride, which afforded 
the title compound (119 mg, 64% over two steps) as a purple oil which solidified upon standing. 
1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.40 Hz, 1H), 7.74 (t, J = 9.06 Hz, 3H), 7.47 (q, J = 
8.19, 8.80 Hz, 2H), 7.36 (t, J = 7.61 Hz, 3H), 7.29 (s, 1H), 6.93 (s, 1H), 3.95 (s, 3H), 3.68 (s, 
3H), 3.61 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 169.80, 154.02, 139.11, 132.95, 129.95, 
128.98, 128.63, 127.82, 127.33, 126.95, 126.90, 125.67, 123.36, 122.31, 122.28, 61.49, 52.63, 
35.06; ESI MS: m/z 417.9 (M+H)+, 439.9 (M+Na)+. 
  
Methyl 2-((4-(4-chlorophenylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetate (48i). 
Synthesized using the procedure for 48f except using 4-chlorobenzenesulfonyl chloride, which 
afforded the title compound (280 mg, 67% over two steps) as a light pink solid. 1H NMR (400 
MHz, CDCl3) δ 8.02 (d, J = 8.40 Hz, 1H), 7.74 (d, J = 8.40 Hz, 1H), 7.66 (t, J = 1.96 Hz, 1H), 
7.65 (t, J = 1.96 Hz, 1H), 7.47 (ddd, J = 1.17, 6.86, 8.24 Hz, 1H), 7.38 (ddd, J = 1.17, 6.86, 8.24 
Hz, 1H), 7.35-7.33 (m, 2H), 7.32 (t, J = 1.94 Hz, 1H), 7.07 (s, 1H), 3.95 (s, 3H), 3.69 (s, 3H), 
3.63 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 169.84, 154.18, 139.50, 137.67, 129.86, 129.25, 
128.78, 128.66, 127.49, 127.05, 125.81, 123.42, 122.41, 122.14, 61.50, 52.64, 35.02; ESI MS: 
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m/z 451.9 (M+H)+, 473.8 (M+Na)+. 
 
Methyl 2-((4-(4-bromophenylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetate (40). 
Synthesized using the procedure for 48f except using 4-bromobenzenesulfonyl chloride, which 
afforded the title compound (185 mg, 61% over two steps) as a pink/purple solid. 97% pure by 
HPLC. 1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 8.38 Hz, 1H), 7.72 (d, J = 8.38 Hz, 1H), 7.61-
7.59 (m, 1H), 7.58 (t, J = 2.04 Hz, 1H), 7.54-7.47 (m, 3H), 7.44-7.38 (m, 1H), 7.34 (s, 1H), 6.76 
(s, 1H), 3.97 (s, 3H), 3.71 (s, 3H), 3.64 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 169.83, 154.25, 
138.21, 132.29, 129.91, 128.89, 128.71, 128.07, 127.41, 127.12, 125.92, 123.47, 122.48, 122.17, 
122.09, 61.56, 52.70, 35.03; ESI HRMS: m/z 493.9724 (M-H)-. 
 
Methyl 2-((1-methoxy-4-(4-methoxyphenylsulfonamido)naphthalen-2-yl)thio)acetate (48j). 
Synthesized using the procedure for 48f except using 4-methoxybenzenesulfonyl chloride, which 
afforded the title compound (190 mg, 77% over two steps) as a purple oil which solidified upon 
standing. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 8.42 Hz, 1H), 7.80 (d, J = 8.42 Hz, 1H), 
7.69-7.63 (m, 2H), 7.48 (t, J = 7.64 Hz, 1H), 7.40 (t, J = 7.64 Hz, 1H), 7.29 (s, 1H), 6.86-6.80 
(m, 3H), 3.95 (s, 3H), 3.79 (s, 3H), 3.70 (s, 3H), 3.63 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 
169.82, 163.12, 153.79, 130.64, 129.85, 129.52, 128.61, 128.11, 126.95, 126.90, 125.20, 123.36, 
122.31, 114.12, 61.50, 55.56, 52.65, 35.09; ESI MS: m/z 447.8 (M+H)+, 469.8 (M+Na)+. 
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Methyl 2-((4-(3-bromophenylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetate (48k). 
Synthesized using the procedure for 48f except using 3-bromobenzenesulfonyl chloride, which 
afforded the title compound (331 mg, 74%) as a purple/pink solid. 1H NMR (400 MHz, CDCl3) δ 
8.04 (d, J = 8.40 Hz, 1H), 7.88 (s, 1H), 7.73 (d, J = 8.40 Hz, 1H), 7.62 (t, J = 9.41 Hz, 2H), 7.49 
(t, J = 7.59 Hz, 1H), 7.40 (t, J = 7.59 Hz, 1H), 7.34 (s, 1H), 7.26-7.21 (m, 1H), 6.82 (s, 1H), 3.98 
(s, 3H), 3.70 (s, 3H), 3.65 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 169.72, 154.55, 141.06, 
135.89, 130.41, 130.24, 130.03, 128.75, 127.31, 127.04, 127.02, 126.33, 125.89, 123.45, 122.90, 
122.48, 122.09, 61.48, 52.55, 35.16; ESI MS: m/z 495.8, 497.8 (M+H)+, 517.8, 519.8 (M+Na)+. 
 
Methyl 2-((4-(2-bromophenylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetate (48l). 
Synthesized using the procedure for 48f except using 2-bromobenzenesulfonyl chloride, which 
afforded the title compound (314 mg, 74% over two steps) as a purple oil. 1H NMR (400 MHz, 
CDCl3) δ 8.16-8.11 (m, 1H), 8.05-8.00 (m, 1H), 7.93 (d, J = 7.72 Hz, 1H), 7.78 (d, J = 7.72 Hz, 
1H), 7.54-7.48 (m, 3H), 7.42-7.32 (m, 2H), 7.19 (s, 1H), 7.13 (s, 1H), 3.94 (s, 3H), 3.68 (s, 3H), 
3.49 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 169.52, 154.35, 138.58, 135.17, 133.92, 132.04, 
130.52, 128.75, 127.83, 127.55, 127.11, 127.07, 125.00, 123.16, 122.90, 122.26, 119.94, 61.40, 
52.50, 35.13; ESI MS: m/z 495.8, 597.8 (M+H)+, 517.8, 519.8 (M+Na)+. 
 
 
 
Methyl 2-((4-(benzo[b]thiophene-2-sulfonamido)-1-methoxynaphthalen-2-yl)thio)acetate 
(48m). Synthesized using the procedure for 48f except using 1-benzothiophene-2-sulfonyl 
chloride, which afforded the title compound (132 mg, 57% over two steps) as a purple oil which 
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solidified upon standing. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 8.40 Hz, 1H), 7.90 (d, J = 
8.40 Hz, 1H), 7.79 (d, J = 7.99 Hz, 1H), 7.74 (d, J = 7.99 Hz, 1H), 7.69 (s, 1H), 7.48-7.42 (m, 
2H), 7.41 (s, 1H), 7.40-7.35 (m, 2H), 7.01 (s, 1H), 3.96 (s, 3H), 3.64 (s, 3H), 3.51 (s, 2H); 13C 
NMR (100 MHz, CDCl3) δ 169.77, 154.23, 141.85, 139.53, 137.38, 130.61, 130.05, 128.66, 
127.47, 127.37, 127.06, 125.72, 125.47, 125.44, 123.47, 122.62, 122.34, 122.25, 61.51, 52.58, 
34.95; ESI MS: m/z 473.9 (M+H)+, 495.8 (M+Na)+. 
 
Methyl 2-((4-([1,1'-biphenyl]-4-ylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetate 
(48n). Synthesized using the procedure for 48f except using 4-biphenylsulfonyl chloride, which 
afforded the title compound (152 mg, 71% over two steps) as a purple oil which solidified upon 
standing. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 8.34 Hz, 1H), 7.83-7.76 (m, 3H), 7.58 (d, J 
= 8.31 Hz, 2H), 7.51 (d, J = 7.14 Hz, 2H), 7.49-7.42 (m, 2H), 7.42-7.35 (m, 3H), 7.33 (s, 1H), 
6.90 (s, 1H), 3.96 (s, 3H), 3.65 (s, 3H), 3.60 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 169.75, 
153.99, 145.89, 139.09, 137.68, 129.97, 128.98, 128.66, 128.50, 127.90, 127.86, 127.56, 127.23, 
126.98, 126.93, 125.58, 123.43, 122.35, 122.33, 61.49, 52.58, 35.02; ESI MS: m/z 494.1 
(M+H)+, 516.1 (M+Na)+. 
 
Methyl 2-((4-([1,1'-biphenyl]-3-ylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetate 
(48o). Synthesized using reported procedures with modification.68, 69 A stirred mixture of 48k 
(307 mg, 0.62 mmol), phenylboronic acid (113 mg, 0.91 mmol), 2M aqueous Na2CO3 (0.93 mL), 
Pd(PPh3)4 (72 mg, 0.06 mmol) in THF (6 mL) /H2O (1 mL) was heated at 60 oC under nitrogen 
for 2 h. Mixture was diluted with EtOAc (10 mL) and washed with H2O (15 mL x 2) and brine 
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(15 mL). Organic layer was dried (MgSO4), filtered and concentrated under reduced pressure. 
The crude was purified by flash column chromatography on silica to give 48o (284 mg, 92%) as 
a light brown oil. 1H NMR (400 MHz, CDCl3/ couple of drops of D2O) δ 8.00 (d, J = 8.39 Hz, 
1H), 7.83 (s, 1H), 7.79-7.73 (m, 2H), 7.69 (dd, J = 7.58, 14.09 Hz, 2H), 7.47-7.40 (m, 2H), 7.37-
7.31 (m, 6H), 3.92 (s, 3H), 3.62 (s, 3H), 3.58 (s, 2H); 13C NMR (100 MHz, CDCl3/ couple of 
drops of D2O) δ 169.86, 154.00, 142.22, 139.49, 138.99, 133.60, 131.46, 131.02, 130.00, 129.44, 
128.89, 128.63, 128.14, 127.89, 127.03, 126.98, 126.88, 125.92, 125.87, 125.80, 123.46, 122.38, 
122.27, 61.43, 52.60, 34.97; ESI MS: m/z 494.1 (M+H)+. 
 
Methyl 2-((4-([1,1'-biphenyl]-2-ylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetate 
(48p). Synthesized using the procedure for 48f except using 2-biphenylsulfonyl chloride which 
was synthesized as previously reported.85 The title compound (57 mg, 58% over two steps) was 
obtained as a light orange oil. 1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 8.20 Hz, 1H), 8.00 (d, J 
= 8.20 Hz, 1H), 7.62 (t, J = 7.54 Hz, 1H), 7.51 (q, J = 7.13, 7.54 Hz, 3H), 7.44-7.37 (m, 2H), 
7.37-7.29 (m, 5H), 6.93 (s, 1H), 5.86 (s, 1H), 3.91 (s, 3H), 3.67 (s, 3H), 3.44 (s, 2H); 13C NMR 
(100 MHz, CDCl3) δ 169.66, 152.79, 140.89, 138.72, 138.15, 132.77, 132.73, 129.66, 129.43, 
128.59, 128.52, 128.39, 128.20, 128.11, 127.94, 127.07, 126.69, 123.16, 122.20, 122.04, 120.40, 
61.44, 52.62, 34.96; ESI MS: m/z 494.0 (M+H)+.  
 
Methyl 2-((4-(4'-chloro-[1,1'-biphenyl]-4-ylsulfonamido)-1-methoxynaphthalen-2-
yl)thio)acetate (48q). Synthesized using the procedure for 48f except using 4′-chlorobiphenyl-4-
sulfonyl chloride, which afforded the title compound (284 mg, 80% over two steps) as a pink oil 
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which solidified upon standing. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 7.14 Hz, 1H), 7.80 (d, 
J = 7.14 Hz, 1H), 7.78 (d, J = 7.54 Hz, 2H), 7.54 (d, J = 7.54 Hz, 2H), 7.49-7.44 (m, 2H), 7.44-
7.40 (m, 3H), 7.40-7.35 (m, 1H), 7.33 (s, 1H), 6.97 (s, 1H), 3.96 (s, 3H), 3.65 (s, 3H), 3.61 (s, 
2H); 13C NMR (100 MHz, CDCl3) δ 169.73, 154.05, 144.56, 138.08, 137.53, 134.79, 129.97, 
129.19, 128.67, 128.48, 128.01, 127.80, 127.40, 126.98, 126.93, 125.64, 123.40, 122.35, 122.33, 
61.50, 52.60, 35.03; ESI MS: m/z 528.1 (M+H)+, 550.1 (M+Na)+. 
 
Methyl 2-((4-(2',4'-difluoro-[1,1'-biphenyl]-4-ylsulfonamido)-1-methoxynaphthalen-2-
yl)thio)acetate (48r). Synthesized using the procedure for 48f except using 2′,4′-difluoro-
biphenyl-4-sulfonyl chloride, which afforded the title compound (75 mg, 58% over two steps) as 
a purple oil which solidified upon standing. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 8.41 Hz, 
1H), 7.83-7.76 (m, 3H), 7.50 (d, J = 8.16 Hz, 2H), 7.46 (d, J = 7.94 Hz, 1H), 7.40 (d, J = 7.94 
Hz, 1H), 7.37-7.29 (m, 2H), 6.98 (s, 1H), 6.96-6.86 (m, 2H), 3.96 (s, 3H), 3.66 (s, 3H), 3.61 (s, 
2H); 13C NMR (100 MHz, CDCl3) δ 169.84, 154.01, 139.74, 138.18, 131.40 (dd, J = 4.57, 9.75 
Hz), 130.03, 129.43 (d, J = 3.03 Hz), 128.65, 127.76, 127.61, 127.02, 126.96, 125.70, 123.44, 
122.37, 122.32, 111.98 (dd, J = 3.71, 21.44 Hz), 105.88-103.01 (m), 61.51, 52.63, 34.95; ESI 
MS: m/z 530.1 (M+H)+. 
 
Methyl 2-((1-methoxy-4-(4-phenoxyphenylsulfonamido)naphthalen-2-yl)thio)acetate (48s). 
Synthesized using the procedure for 48f except using 4-phenoxybenzenesulfonyl chloride, which 
afforded the title compound (244 mg, 72% over two steps) as a light brown oil. 1H NMR (400 
MHz, CDCl3) δ 8.02 (d, J = 8.43 Hz, 1H), 7.80 (d, J = 8.43 Hz, 1H), 7.66 (d, J = 8.14 Hz, 2H), 
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7.52-7.46 (m, 1H), 7.42-7.32 (m, 4H), 7.23 (s, 1H), 7.17 (t, J = 7.38 Hz, 1H), 6.94 (d, J = 8.52 
Hz, 2H), 6.87 (d, J = 8.52 Hz, 2H), 3.95 (s, 3H), 3.69 (s, 3H), 3.66 (s, 2H); 13C NMR (100 MHz, 
CDCl3) δ 169.85, 161.65, 155.11, 153.85, 132.59, 130.09, 129.85, 129.59, 128.60, 128.03, 
126.90, 126.85, 125.50, 124.81, 123.42, 122.38, 122.31, 120.02, 117.64, 61.50, 52.67, 35.05; 
ESI MS: m/z 509.8 (M+H)+. 
 
Methyl 2-((4-(4-(4-fluorophenoxy)phenylsulfonamido)-1-methoxynaphthalen-2-
yl)thio)acetate  (48t). Synthesized using the procedure for 48f except using 4-(4-fluoro-
phenoxy)-benzenesulfonyl chloride, which afforded the title compound (93 mg, 72% over two 
steps) as a yellow oil which solidified upon standing. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 
8.42 Hz, 1H), 7.80 (d, J = 8.42 Hz, 1H), 7.66 (d, J = 8.72 Hz, 2H), 7.51-7.45 (m, 1H), 7.42-7.36 
(m, 1H), 7.34 (s, 1H), 7.07-7.00 (m, 2H), 6.94-6.88 (m, 2H), 6.84 (d, J = 8.72 Hz, 2H), 3.95 (s, 
3H), 3.69 (s, 3H), 3.66 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 169.87, 161.82, 160.79, 158.36, 
153.87, 150.83 (d, J = 2.72 Hz), 132.65, 129.83, 129.66, 128.61, 127.99, 126.88 (d, J = 4.95 Hz), 
125.47, 123.39, 122.35 (d, J = 6.41 Hz), 121.67 (d, J = 8.41 Hz), 117.23, 116.86, 116.63, 61.50, 
52.69, 35.06; ESI MS: m/z 528.1 (M+H)+, 550.1 (M+Na)+. 
 
Methyl 2-((1-methoxy-4-(4-phenylpiperazine-1-sulfonamido)naphthalen-2-yl)thio)acetate 
(48u).  
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As reported previously67, to a solution of 1,1’-sulfonyldiimidazole (1.98 g, 10 mmol) in CH2Cl2 
(40 mL) was added methyl trifluoromethanesulfonate (1.64 g, 10 mmol) at 0 oC. The solvent was 
removed after 3 hours stirring.  To the resulting residue in CH3CN (40 mL) was added 1-
phenylpiperazine (1.08 g, 6.67 mmol). After being stirred at room temperature overnight, the 
reaction mixture was concentrated under reduced pressure and the crude was purified using flash 
column chromatography on silica to give 1-((1H-imidazol-1-yl)sulfonyl)-4-phenylpiperazine 
(1.17 g, 60% yield over 2 steps) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.92 (s, 1H), 
7.30-7.23 (m, 3H), 7.16 (s, 1H), 6.93 (t, J = 7.33 Hz, 1H), 6.89-6.84 (m, 2H), 3.37-3.30 (m, 4H), 
3.26-3.20 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 150.21, 136.62, 130.80, 129.34, 121.43, 
117.64, 117.20, 48.89, 46.42; ESI MS: m/z 293.0 (M+H)+. 
 
To a solution of 1-((1H-imidazol-1-yl)sulfonyl)-4-phenylpiperazine (85 mg, 0.29 mmol) in 
CH2Cl2 (3 mL) cooled at 0 oC was added methyl trifluoromethanesulfonate (0.035 mL, 0.32 
mmol). After being stirred for 2h at 0 oC, the reaction mixture was concentrated under reduced 
pressure to give 3-methyl-1-((4-phenylpiperazin-1-yl)sulfonyl)-1H-imidazol-3-ium as a beige 
solid which was used in the next step without further purification.  
A solution of 3-methyl-1-((4-phenylpiperazin-1-yl)sulfonyl)-1H-imidazol-3-ium (0.29 mmol) 
and aniline 48a (0.29 mmol) in CH3CN (3mL) was stirred at 80 oC for 15h. The reaction mixture 
was diluted with EtOAc (10 mL), washed with 1 N HCl, 1 N NaOH, H2O, brine, dried (MgSO4) 
and filtered. The solvent was removed under reduced pressure and the crude was purified using 
flash column chromatography on silica to give 48u (36 mg, 25% over three steps) as a purple 
solid. 1H NMR (400 MHz, CDCl3) δ 8.12-8.06 (m, 1H), 8.06-8.00 (m, 1H), 7.71 (s, 1H), 7.59-
7.52 (m, 2H), 7.22 (t, J = 7.94 Hz, 2H), 6.88-6.81 (m, 3H), 6.75 (s, 1H), 3.98 (s, 3H), 3.74 (s, 
2H), 3.68 (s, 3H), 3.43-3.37 (m, 4H), 3.15-3.08 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 169.86, 
153.45, 150.61, 129.16, 128.93, 128.69, 128.57, 127.15, 127.07, 123.77, 123.51, 122.71, 121.71, 
120.67, 116.73, 61.50, 52.59, 49.15, 46.48, 35.20; ESI MS: m/z 502.1 (M+H)+, 524.1 (M+Na)+. 
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Methyl 2-((4-(4-bromobenzamido)-1-methoxynaphthalen-2-yl)thio)acetate (48v). 
Synthesized using the procedure for 48f except using 4-bromobenzoyl chloride and Et3N as the 
base, which afforded the title compound (245 mg, 66%) as a pink solid. 1H NMR (400 MHz, 
CDCl3) δ 8.14 (s, 1H), 8.09 (d, J = 8.38 Hz, 1H), 7.88 (s, 1H), 7.82- 7.73 (m, 3H), 7.63-7.56 (m, 
2H), 7.56-7.43 (m, 2H), 3.98 (s, 3H), 3.74 (s, 2H), 3.68 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
170.08, 165.42, 153.22, 133.17, 132.01, 131.74, 131.53, 128.82, 128.59, 128.43, 126.80, 126.77, 
123.92, 123.50, 122.67, 121.57, 61.45, 52.57, 35.18; ESI MS: m/z 460.0, 462.0 (M+H)+ , 482.0, 
484 (M+Na)+. 
 
Methyl 2-((4-((4-chlorophenyl)methylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetate 
(48w). Synthesized using the procedure for 48f except using 4-chlorobenzylsulfonyl chloride, 
which afforded the title compound (110 mg, 41% over two steps) as a light pink solid. 1H NMR 
(400 MHz, CDCl3) δ 8.10 (d, J = 8.31 Hz, 1H), 7.75 (d, J = 8.31 Hz, 1H), 7.65 (s, 1H), 7.57 (t, J 
= 7.54 Hz, 1H), 7.50 (t, J = 7.54 Hz, 1H), 7.22-7.16 (m, 4H), 6.73 (s, 1H), 4.37 (s, 2H), 4.00 (s, 
3H), 3.75 (s, 2H), 3.70 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.00, 153.34, 135.04, 132.09, 
128.91, 128.74, 128.31, 127.98, 127.18, 127.08, 126.88, 123.66, 122.67, 122.59, 121.65, 61.55, 
57.41, 52.66, 34.96; ESI MS: m/z 465.8 (M+H)+ , 487.8 (M+Na)+. 
 
Methyl 2-((4-(2-(4-chlorophenyl)acetamido)-1-methoxynaphthalen-2-yl)thio)acetate (48x). 
Synthesized using the procedure for 48f except using 4-chlorophenylacetyl chloride and Et3N as 
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the base, which afforded the title compound (208 mg, 69% over two steps) as a light yellow 
solid. 1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 8.34 Hz, 1H), 7.82 (s, 1H), 7.49 (m, 1H), 7.45-
7.38 (m, 4H), 7.38-7.32 (m, 3H), 3.94 (s, 3H), 3.82 (s, 2H), 3.73 (s, 2H), 3.67 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 170.16, 169.79, 153.07, 133.95, 132.72, 130.93, 129.52, 128.47, 128.24, 
127.90, 126.80, 126.72, 123.43, 123.32, 122.67, 120.80, 61.41, 52.59, 43.65, 35.14; ESI MS: 
m/z 429.9 (M+H)+, 451.8 (M+Na)+.  
 
Methyl 2-((1-methoxy-4-(2-phenylacetamido)naphthalen-2-yl)thio)acetate (48y). 
Synthesized using the procedure for 48f except using phenylacetyl chloride. Crude was triturated 
with cold methylene chloride to yield the title compound (154 mg, 49% over two steps) as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 8.38 Hz, 1H), 7.94 (s, 1H), 7.53-7.44 (m, 
4H), 7.40 (q, J = 7.27 Hz, 2H), 7.33 (s, 1H), 7.29-7.24 (m, 2H), 3.96 (s, 3H), 3.89 (s, 2H), 3.78 
(s, 2H), 3.71 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.10, 169.71, 152.55, 134.54, 129.69, 
129.46, 128.70, 128.40, 127.92, 127.64, 126.59, 123.48, 122.57, 122.48, 120.78, 61.40, 52.61, 
44.64, 35.16; ESI MS: m/z 396.1 (M+H)+ , 418.1 (M+Na)+. 
 
4-Bromo-N-(3-(butylthio)-4-methoxynaphthalen-1-yl)benzenesulfonamide (48z). 
Synthesized using the procedure for 48f except using 48c, and 4-bromobenzenesulfonyl chloride, 
which afforded the title compound (55 mg, 57% over two steps) as a light brown oil which 
solidified. 95% pure by HPLC. 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.44 Hz, 1H), 7.77 (d, 
J = 8.44 Hz, 1H), 7.59 (d, J = 8.36 Hz, 2H), 7.49 (d, J = 8.36 Hz, 2H), 7.46 (d, J = 7.85 Hz, 1H), 
7.35 (t, J = 7.85 Hz, 1H), 7.21 (s, 1H), 7.16 (s, 1H), 3.94 (s, 3H), 2.81 (t, J = 7.24 Hz, 2H), 1.58 
(p, J = 7.24 Hz, 2H), 1.45 (h, J = 7.24 Hz, 2H), 0.92 (t, J = 7.24 Hz, 3H); 13C NMR (100 MHz, 
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CDCl3) δ 152.71, 138.26, 132.23, 128.92, 128.88, 128.65, 127.99, 127.25, 126.93, 126.37, 
125.79, 124.49, 122.19, 122.04, 61.01, 31.92, 31.20, 21.95, 13.67; ESI MS: m/z 479.8, 481.8 
(M+H)+. 
 
2-((4-(4-Bromophenylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetamide (41). 
Synthesized using a reported procedure.70 Compound 40 (82 mg, 0.16 mmol) was added to 
aqueous NH4OH (29%, 3 mL). The mixture was stirred at room temperature for 1h. Workup 
included diluting the mixture with EtOAc (10 mL) and washing with H2O (10 mL x 2) and brine 
(10 mL). Organic layer was dried (MgSO4), filtered and concentrated under reduced pressure to 
give 41 (69 mg, 90%) as a pink solid. Crude was used in the next step without further 
purification. 98% pure by HPLC. 1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 7.95 (d, J = 
8.50 Hz, 1H), 7.85 (d, J = 8.50 Hz, 1H), 7.72 (d, J = 8.20 Hz, 2H), 7.60 (d, J = 8.20 Hz, 2H), 
7.56-7.50 (m, 2H), 7.43-7.37 (m, 1H), 7.21 (s, 1H), 7.15 (s, 1H), 3.88 (s, 3H), 3.53 (s, 2H); 13C 
NMR (100 MHz, DMSO-d6) δ 169.76, 151.88, 139.67, 132.70, 129.69, 129.18, 129.05, 128.23, 
127.46, 127.03, 126.41, 125.24, 124.89, 123.95, 121.82, 61.27, 35.91; ESI MS: m/z 480.7, 482.7 
(M+H)+, 502.7, 504.7 (M+Na)+; ESI HRMS: m/z 478.9742 (M-H)-. 
 
4-Bromo-N-(3-(3-hydroxypropyl)-4-methoxynaphthalen-1-yl)benzenesulfonamide (48aa). 
Synthesized using the procedure for 48f except using 48d and 4-bromobenzenesulfonyl chloride, 
which afforded the title compound (163 mg, 33% over two steps) as a white solid. 1H NMR (400 
MHz, DMSO-d6) δ 10.11 (s, 1H), 7.94 (t, J = 7.53 Hz, 2H), 7.70 (d, J = 8.53 Hz, 2H), 7.53 (d, J 
= 8.53 Hz, 2H), 7.51-7.45 (m, 1H), 7.42-7.35 (m, 1H), 6.86 (s, 1H), 4.47 (s, 1H), 3.79 (s, 3H), 
3.37 (t, J = 5.87 Hz, 2H), 2.69-2.60 (m, 2H), 1.59-1.49 (m, 2H); 13C NMR (100 MHz, DMSO-
d6) δ 152.33, 139.44, 132.62, 130.38, 130.34, 129.28, 128.55, 128.23, 127.00, 126.88, 126.78, 
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126.01, 124.09, 122.21, 62.33, 60.67, 33.79, 25.69; ESI MS: m/z 449.9, 451.9 (M+H)+ , 471.9, 
473.9 (M+Na)+. 
 
4-Bromo-N-(3-(4-hydroxybutyl)-4-methoxynaphthalen-1-yl)benzenesulfonamide (44). 
Synthesized using the procedure for 48f except using 48e and 4-bromobenzenesulfonyl chloride, 
which afforded the title compound (226 mg, 49% over two steps) as a light pink solid. 96% pure 
by HPLC. 1H NMR (400 MHz, DMSO-d6) δ 10.09 (s, 1H), 7.99-7.91 (m, 2H), 7.70 (d, J = 8.43 
Hz, 2H), 7.54 (d, J = 8.43 Hz, 2H), 7.49 (t, J = 7.34 Hz, 1H), 7.40 (t, J = 7.34 Hz, 1H), 6.81 (s, 
1H), 4.33 (t, J = 5.42 Hz, 1H), 3.78 (s, 3H), 3.37 (q, J = 5.42 Hz, 2H), 2.59 (t, J = 7.01 Hz, 2H), 
1.49-1.28 (m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 152.35, 139.45, 132.62, 130.46, 130.42, 
129.33, 128.54, 128.24, 126.97, 126.82, 126.78, 126.02, 124.16, 122.21, 62.36, 60.92, 32.66, 
28.85, 26.90; ESI MS: m/z 464.1, 466.1 (M+H)+, 486.1, 488.1 (M+Na)+; ESI HRMS: m/z 
462.0378 (M-H)-. 
 
N-(3-(((2H-Tetrazol-5-yl)methyl)thio)-4-methoxynaphthalen-1-yl)-4-
bromobenzenesulfonamide (48bb). Synthesized using a reported procdure.71 To a suspension 
of 40 (127mg, 0.26 mmol), sodium azide (255mg, 3.9 mmol) in dry CH3CN (5mL) in a glass 
tube was added SiCl4 (0.15mL, 1.3 mmol) via syringe. The tube was sealed and the stirring 
reaction mixture was heated to 80oC for 15h. The reaction was quenched with 2M Na2CO3. The 
solution was then washed with EtOAc (10 mL x 2). The aqueous phase was acidified with 1 N 
HCl and the mixture was extracted with EtOAc (15 mL x 5). The combined organic extracts 
were washed with brine (20 mL), dried (MgSO4), filtered, and concentrated under reduced 
pressure to give 48bb (66mg, 50%) as a tan solid. The crude was used in the next step without 
further purification.1H NMR (400 MHz, DMSO-d6) δ 10.31 (s, 1H), 7.93 (d, J = 8.40 Hz, 1H), 
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7.83 (d, J = 8.40 Hz, 1H), 7.65 (d, J = 8.04 Hz, 2H), 7.55-7.48 (m, 3H), 7.44-7.38 (m, 1H), 7.14 
(s, 1H), 6.53 (s, 1H), 4.42 (s, 2H), 3.78 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 153.77, 
139.46, 132.64, 130.46, 129.17, 129.07, 128.36, 127.58, 127.06, 126.23, 123.97, 122.53, 122.22, 
61.68, 25.09; ESI MS: m/z 505.8, 507.8 (M+H)+, 527.8, 529.8 (M+Na)+. 
 
Methyl 3-((1-methoxy-4-(naphthalene-2-sulfonamido)naphthalen-2-yl)thio)propanoate 
(48cc). Synthesized using the procedure for 48f except using 48b and 2-naphthalenesulfonyl 
chloride, which afforded the title compound (180 mg, 59% over two steps) as a light pink solid. 
1H NMR (400 MHz, CDCl3) δ 8.30 (s, 1H), 7.98 (d, J = 8.39 Hz, 1H), 7.90-7.85 (m, 2H), 7.85-
7.80 (m, 2H), 7.80-7.76 (m, 1H), 7.59 (t, J = 7.36 Hz, 1H), 7.53 (t, J = 7.36 Hz, 1H), 7.43 (t, J = 
7.39 Hz, 1H), 7.34 (t, J = 7.39 Hz, 1H), 7.19 (s, 1H), 6.98 (s, 1H), 3.89 (s, 3H), 3.64 (s, 3H), 2.94 
(t, J = 7.23 Hz, 2H), 2.40 (t, J = 7.23 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 171.84, 153.85, 
135.99, 134.83, 131.94, 129.66, 129.43, 129.20, 129.02, 128.91, 128.75, 127.82, 127.78, 127.54, 
126.95, 126.72, 125.21, 123.73, 122.39, 122.19, 109.99, 61.20, 51.79, 34.05, 27.65; ESI MS: 
m/z 481.9 (M+H)+ , 503.9 (M+Na)+. 
 
2-((4-(4-Bromophenylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetic acid (39). To a 
solution of 40 (425 mg, 0.85 mmol) in dry THF (2 mL) was added 1N aqueous LiOH (4 mL). 
The mixture was stirred at room temperature under nitrogen for 1 h. Reaction mixture was 
diluted with water (10 mL) and washed with EtOAc (10 mL x 2). Aqueous phase was acidified 
with 1N HCl and extracted with EtOAc (10 mL x 3). Combined organic extracts were washed 
with brine, dried (MgSO4) and filtered. The solvent was removed under reduced pressure. Crude 
was triturated with cold CH2Cl2 to give 39 (305 mg, 74%) as a white/tan solid. >99% pure by 
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HPLC. 1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 7.92 (d, J = 8.38 Hz, 1H), 7.87 (d, J = 
8.38 Hz, 1H), 7.68 (d, J = 8.08 Hz, 2H), 7.57 (d, J = 8.08 Hz, 2H), 7.51 (t, J = 7.56 Hz, 1H), 7.40 
(t, J = 7.56 Hz, 1H), 7.09 (s, 1H), 3.84 (s, 3H), 3.65 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 
170.59, 152.07, 139.60, 132.69, 129.83, 129.18, 129.13, 128.28, 127.54, 127.09, 126.57, 124.60, 
124.56, 124.01, 121.86, 61.30, 34.63; ESI HRMS: m/z 479.9578 (M-H)-. 
 
2-((4-([1,1'-Biphenyl]-4-ylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetic acid (42). 
Synthesized using the procedure for 39 except 48n was used as the starting material. Crude was 
triturated with cold CH2Cl2 to give 42 (88 mg, 70%) as an white solid. 98% pure by HPLC. 1H 
NMR (400 MHz, DMSO-d6) δ 12.74 (s, 1H), 10.21 (s, 1H), 7.95 (d, J = 8.44 Hz, 1H), 7.91 (d, J 
= 8.44 Hz, 1H), 7.79-7.70 (m, 4H), 7.68-7.61 (m, 2H), 7.53-7.48 (m, 1H), 7.45 (t, J = 7.28 Hz, 
2H), 7.39 (t, J = 7.28 Hz, 2H), 7.08 (s, 1H), 3.83 (s, 3H), 3.61 (s, 2H); 13C NMR (100 MHz, 
DMSO-d6) δ 170.52, 151.84, 144.73, 139.09, 138.87, 129.90, 129.50, 128.93, 128.26, 127.89, 
127.78, 127.49, 126.47, 124.56, 124.21, 124.18, 121.77, 61.26, 34.56; ESI HRMS: m/z 478.0787 
(M-H)-. 
 
2-((4-([1,1'-Biphenyl]-3-ylsulfonamido)-1-methoxynaphthalen-2-yl)thio)acetic acid (43). 
Synthesized using the procedure for 39 except 48o was used as the starting material. Crude was 
triturated with cold CH2Cl2 to give 43 (152 mg, 59%) as a white solid. 98% pure by HPLC. 1H 
NMR (400 MHz, DMSO-d6) δ 12.69 (s, 1H), 10.20 (s, 1H), 7.90 (d, J = 8.46 Hz, 1H), 7.86 (d, J 
= 8.46 Hz, 1H), 7.82 (d, J = 7.81 Hz, 1H), 7.72 (s, 1H), 7.63 (d, J = 7.81 Hz, 1H), 7.55 (t, J = 
7.74 Hz, 1H), 7.50- 7.44 (m, 1H), 7.43-7.38 (m, 4H), 7.38-7.30 (m, 2H), 7.11 (s, 1H), 3.82 (s, 
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3H), 3.61 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 170.46, 151.97, 141.49, 140.71, 138.92, 
131.42, 130.33, 129.80, 129.49, 129.43, 128.66, 128.24, 127.47, 127.14, 126.43, 125.88, 125.21, 
124.64, 124.59, 124.04, 121.77, 61.23, 34.56. ESI HRMS: m/z 478.0788 (M-H)-.  
A representative procedure for a single-pot ester hydrolysis and demethylation with BBr3 
 
2-((1-Hydroxy-4-(thiophene-2-sulfonamido)naphthalen-2-yl)thio)acetic acid (1). To a stirred 
solution of 48f (48 mg, 0.12 mmol) suspended in dry CH2Cl2 (1.5 mL) was added BBr3 (1 M in 
CH2Cl2, 0.5 mL, 0.5 mmol) dropwise at 0oC under nitrogen. The mixture was allowed to warm 
up to room temperature. After 1hr stir, the starting material was entirely consumed and the 
product formed as determined by TLC and MS (ESI-). The mixture was slowly added to a stirred 
solution of saturated aqueous NH4Cl (20 mL) at 0oC. The solution was extracted with EtOAc (15 
mL x 2). The combined organic extracts were washed with brine (15 mL), dried (MgSO4), 
filtered, and the solvent was removed under reduced pressure. The crude was purified using a C18 
reverse phase semipreparative HPLC column with solvent A (0.1% of TFA in water) and solvent 
B (0.1% of TFA in CH3CN) as eluents to give 1 (59) (28 mg, 59%) as a white/tan solid. 96% 
pure by HPLC.1H NMR (400 MHz, DMSO-d6) δ 10.10 (s, 1H), 8.17-8.14 (m, 1H), 7.89-7.84 (m, 
2H), 7.52-7.40 (m, 2H), 7.36 (dd, J = 1.32, 3.74 Hz, 1H), 7.09 (s, 1H), 7.07 (dd, J = 3.74, 4.97 
Hz, 1H), 3.56 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 171.54, 152.87, 140.58, 133.57, 
132.80, 131.71, 129.80, 128.03, 127.20, 126.22, 125.46, 124.33, 123.61, 122.83, 113.36, 37.25; 
ESI HRMS: m/z 393.9870 (M-H)-. 
 
2-((1-Hydroxy-4-(methylsulfonamido)naphthalen-2-yl)thio)acetic acid (2). Synthesized using 
the procedure for 1 except 48t was used as the starting material. The title compound (27 mg, 
48%) as a white solid after HPLC purification. 95% pure by HPLC. 1H NMR (400 MHz, 
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DMSO-d6) δ 9.40 (s, 1H), 8.20 (d, J = 8.09 Hz, 1H), 8.14 (d, J = 8.09 Hz, 1H), 7.56 (p, J = 6.86 
Hz, 2H), 7.47 (s, 1H), 3.69 (s, 2H), 2.99 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 171.73, 
152.58, 131.89, 129.38, 127.31, 126.30, 125.65, 125.18, 124.32, 122.82, 113.55, 39.79, 37.03; 
ESI HRMS: m/z 326.0164 (M-H)-. 
 
2-((1-Hydroxy-4-(phenylsulfonamido)naphthalen-2-yl)thio)acetic acid (3). Synthesized using 
the procedure for 1 except 48h was used as the starting material. The title compound (21 mg, 
22%) was obtained as a white solid after HPLC purification. 97% pure by HPLC. 1H NMR (400 
MHz, DMSO-d6) δ 12.76 (s, 1H), 9.91 (s, 1H), 9.79 (s, 1H), 8.14 (d, J = 8.22 Hz, 1H), 7.88 (d, J 
= 8.22 Hz, 1H), 7.67-7.61 (m, 2H), 7.61-7.56 (m, 1H), 7.54-7.47 (m, 3H), 7.46-7.39 (m, 1H), 
7.01 (s, 1H), 3.51 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 171.46, 152.56, 140.16, 133.03, 
131.56, 129.53, 129.44, 127.25, 127.05, 126.17, 125.46, 124.56, 123.76, 122.75, 113.34, 37.16; 
ESI HRMS: m/z 388.0319 (M-H)-. 
 
2-((4-(4-Chlorophenylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid (9). 
Synthesized using the procedure for 1 except 48i was used as the starting material. The title 
compound (48 mg, 20%) was obtained as a white solid after trituration with a mixture of 
CH3CN:H2O 1:1 and cold CH2Cl2 and without a need for HPLC purification. 95% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.77 (s, 1H), 10.03 (s, 1H), 9.84 (s, 1H), 8.15 (d, J = 
8.12 Hz, 1H), 7.85 (d, J = 8.12 Hz, 1H), 7.66-7.59 (m, 2H), 7.59-7.52 (m, 2H), 7.46 (dt, J = 7.28, 
14.85 Hz, 2H), 7.05 (s, 1H), 3.54 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 171.48, 152.72, 
139.06, 137.95, 131.47, 129.66, 129.60, 129.19, 127.15, 126.25, 125.48, 124.24, 123.63, 122.84, 
113.38, 37.11; ESI HRMS: m/z 421.9930 (M-H)-. 
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2-((4-(4-Bromophenylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid (10). 
Synthesized using the procedure for 1 except 39 was used as the starting material. The title 
compound (134 mg, 45%) was obtained as a white solid after trituration with a mixture of 
CH3CN:H2O 1:1 and cold CH2Cl2 and without a need for HPLC purification. 99% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.80 (s, 1H), 10.05 (s, 1H), 9.87 (s, 1H), 8.14 (d, J = 
8.17 Hz, 1H), 7.84 (d, J = 8.17 Hz, 1H), 7.71 (d, J = 8.48 Hz, 2H), 7.54 (d, J = 8.48 Hz, 2H), 
7.48 (t, J = 7.03 Hz, 1H), 7.43 (t, J = 7.03 Hz, 1H), 7.04 (s, 1H), 3.53 (s, 2H); 13C NMR (100 
MHz, DMSO-d6) δ 171.52, 152.74, 139.45, 132.56, 131.45, 129.66, 129.28, 127.18, 126.92, 
126.27, 125.48, 124.21, 123.63, 122.86, 113.38, 37.10; ESI HRMS: m/z 465.9418 (M-H)-. 
 
2-((1-Hydroxy-4-(4-methoxyphenylsulfonamido)naphthalen-2-yl)thio)acetic acid (11). 
Synthesized using the procedure for 1 except 48j was used as the starting material. The title 
compound (25 mg, 29%) was obtained as a white solid after HPLC purification. 95% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 9.70 (s, 1H), 8.10 (d, J = 8.07 Hz, 1H), 7.89 (d, J = 
7.78 Hz, 1H), 7.52 (d, J = 8.63 Hz, 2H), 7.49-7.36 (m, 2H), 7.00-6.93 (m, 3H), 3.75 (s, 3H), 3.47 
(s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 171.47, 162.75, 152.44, 131.81, 131.63, 129.49, 
129.37, 127.05, 126.18, 125.48, 124.92, 123.93, 122.75, 114.57, 113.35, 56.02, 37.24; ESI 
HRMS: m/z 418.0424 (M-H)-. 
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2-((4-(3-Bromophenylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid (12). 
Synthesized using the procedure for 1 except 48k was used as the starting material. The title 
compound (21 mg, 35%) was obtained as a white/tan solid after trituration with a mixture of 
CH3CN:H2O 1:1 and cold CH2Cl2 and without a need for HPLC purification. 88% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 10.08 (s, 1H), 8.15 (d, J = 7.56 Hz, 1H), 7.87-7.78 (m, 
2H), 7.75 (t, J = 1.78 Hz, 1H), 7.62-7.56 (m, 1H), 7.52-7.39 (m, 3H), 7.01 (s, 1H), 3.52 (s, 2H); 
13C NMR (100 MHz, DMSO-d6) δ 171.52, 152.92, 142.07, 135.93, 131.78, 131.49, 129.77, 
129.59, 127.18, 126.34, 126.28, 125.53, 124.02, 123.58, 122.89, 122.35, 113.43, 37.24; ESI 
HRMS: m/z 465.9414 (M-H)-. 
 
2-((4-(2-Bromophenylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid (13). 
Synthesized using the procedure for 1 except 48l was used as the starting material. The title 
compound (34 mg, 40%) was obtained as a white solid after HPLC purification. 90% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.80 (s, 1H), 10.23 (s, 1H), 9.88 (s, 1H), 8.16-8.10 
(m, 1H), 8.07-8.02 (m, 1H), 7.86 (dd, J = 1.52, 7.83 Hz, 1H), 7.78 (dd, J = 1.52, 7.83 Hz, 1H), 
7.52-7.46 (m, 3H), 7.42 (td, J = 1.33, 7.60 Hz, 1H), 7.05 (s, 1H), 3.46 (s, 2H); 13C NMR (100 
MHz, DMSO-d6) δ 171.42, 152.60, 139.23, 135.82, 134.64, 131.92, 131.77, 129.49, 128.52, 
127.18, 126.32, 125.44, 123.98, 123.78, 122.78, 119.92, 113.54, 37.03; ESI HRMS: m/z 
465.9408 (M-H)-. 
 
2-((4-(Benzo[b]thiophene-2-sulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid (14). 
Synthesized using the procedure for 1 except 48m was used as the starting material. The title 
compound (13mg, 22%) was obtained as an orange solid after HPLC purification. 98% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 8.11 (d, J = 8.14 Hz, 1H), 8.02 (d, J = 
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8.14 Hz, 1H), 7.89 (t, J = 8.09 Hz, 2H), 7.72 (s, 1H), 7.47 (t, J = 7.56 Hz, 1H), 7.41 (t, J = 7.35 
Hz, 2H), 7.38-7.32 (m, 1H), 7.14 (s, 1H), 3.40 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 
171.57, 153.29, 141.31, 141.04, 137.80, 131.73, 129.99, 129.94, 127.65, 127.22, 126.21, 125.86, 
125.54, 123.96, 123.54, 123.41, 122.92, 113.33, 37.41; ESI HRMS: m/z 444.0041 (M-H)-. 
 
2-((4-([1,1'-Biphenyl]-4-ylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid (16). 
Synthesized using the procedure for 1 except 48n was used as the starting material. The title 
compound (29mg, 45%) was obtained as a white/tan solid after HPLC purification. 99% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 8.11 (d, J = 7.93 Hz, 1H), 7.90 (d, J = 
7.93 Hz, 1H), 7.76 (d, J = 7.47 Hz, 2H), 7.72-7.62 (m, 4H), 7.50-7.42 (m, 3H), 7.43-7.36 (m, 
2H), 7.02 (s, 1H), 3.46 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 171.52, 152.74, 144.57, 
139.00, 138.90, 131.65, 129.57, 129.52, 128.92, 128.00, 127.63, 127.46, 127.08, 126.18, 125.55, 
124.53, 123.85, 122.81, 113.42, 37.27; ESI HRMS: m/z 464.0630 (M-H)-. 
 
2-((4-([1,1'-Biphenyl]-3-ylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid (17). 
Synthesized using the procedure for 1 except 48o was used as the starting material. The title 
compound (48mg, 34%) was obtained as a white/tan solid after HPLC purification. 99% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.73 (s, 1H), 9.93 (s, 1H), 9.79 (s, 1H), 8.10 (d, J = 
8.25 Hz, 1H), 7.88-7.81 (m, 2H), 7.79 (s, 1H), 7.60-7.50 (m, 2H), 7.50-7.41 (m, 4H), 7.41-7.32 
(m, 3H), 7.04 (s, 1H), 3.45 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 171.44, 152.66, 141.46, 
140.82, 139.01, 131.50, 131.30, 130.18, 129.60, 129.55, 128.66, 127.17, 127.07, 126.23, 126.07, 
125.51, 125.26, 124.59, 123.73, 122.81, 113.44, 37.16; ESI HRMS: m/z 464.0632 (M-H)-. 
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2-((4-([1,1'-Biphenyl]-2-ylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid (18). 
Synthesized using the procedure for 1 except 48p was used as the starting material. The title 
compound (20mg, 43%) was obtained as a white/tan solid after HPLC purification. 84% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.77 (s, 1H), 9.76 (s, 1H), 9.70 (s, 1H), 8.12 (d, J = 
8.03 Hz, 1H), 7.95 (d, J = 8.03 Hz, 1H), 7.74 (d, J = 8.30 Hz, 1H), 7.58 (t, J = 7.46 Hz, 1H), 7.52 
(t, J = 7.46 Hz, 1H), 7.48- 7.41 (m, 1H), 7.41-7.34 (m, 1H), 7.23 (q, J = 4.82, 5.81 Hz, 1H), 7.17 
(t, J = 7.46 Hz, 3H), 7.01-6.95 (m, 1H), 6.93 (s, 1H), 6.91 (s, 1H), 3.43 (s, 2H); 13C NMR (100 
MHz, DMSO-d6) δ 171.57, 152.24, 141.36, 139.92, 138.75, 133.21, 132.68, 131.42, 129.62, 
129.37, 128.85, 128.36, 127.55, 127.48, 126.97, 126.21, 125.49, 124.57, 123.79, 122.69, 113.65, 
37.07; ESI HRMS: m/z 464.0636 (M-H)-. 
 
2-((4-(4'-Chloro-[1,1'-biphenyl]-4-ylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic 
acid (19). Synthesized using the procedure for 1 except 48q was used as the starting material. 
The title compound (36 mg, 25%) was obtained as a white solid after HPLC purification. >99% 
pure by HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.75 (s, 1H), 9.96 (s, 1H), 9.81 (s, 1H), 8.10 
(d, J = 8.09 Hz, 1H), 7.88 (d, J = 8.09 Hz, 1H), 7.77 (d, J = 8.24 Hz, 2H), 7.72-7.64 (m, 4H), 
7.52 (d, J = 8.24 Hz, 2H), 7.47-7.36 (m, 2H), 6.99 (s, 1H), 3.45 (s, 2H); 13C NMR (100 MHz, 
DMSO-d6) δ 171.45, 152.51, 143.18, 139.25, 137.67, 133.88, 131.56, 129.50, 129.39, 129.27, 
128.05, 127.65, 127.09, 126.24, 125.50, 124.54, 123.84, 122.78, 113.44, 37.04; ESI HRMS: m/z 
498.0247 (M-H)-. 
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2-((4-(2',4'-difluoro-[1,1'-biphenyl]-4-ylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic 
acid (20). Synthesized using the procedure for 1 except 48r was used as the starting material. 
The title compound (31 mg, 48%) as a white solid after HPLC purification. 95% pure by HPLC. 
1H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H), 9.97 (s, 1H), 9.80 (s, 1H), 8.10 (d, J = 8.16 Hz, 
1H), 7.86 (d, J = 8.16 Hz, 1H), 7.69 (d, J = 7.72 Hz, 2H), 7.62 (d, J = 7.72 Hz, 2H), 7.59-7.53 
(m, 1H), 7.47-7.34 (m, 3H), 7.19 (t, J = 8.31 Hz, 1H), 7.00 (s, 1H), 3.46 (s, 2H); 13C NMR (100 
MHz, DMSO-d6) δ 171.46, 152.55, 139.44, 138.77, 132.51 (dd, J = 4.88, 9.80 Hz), 131.58, 
129.82 (d, J = 2.86 Hz), 129.50, 127.66, 127.06, 126.23, 125.50, 124.50, 123.81, 122.78, 113.47, 
112.73 (dd, J = 3.78, 21.26 Hz), 105.15 (t, J = 26.72 Hz), 37.04; ESI HRMS: m/z 500.0441 (M-
H)-. 
 
2-((1-Hydroxy-4-(4-phenoxyphenylsulfonamido)naphthalen-2-yl)thio)acetic acid (21). 
Synthesized using the procedure for 1 except 48s was used as the starting material. The title 
compound (18mg, 13%) was obtained as a white solid after HPLC purification. 96% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 9.87 (s, 1H), 9.83 (s, 1H), 8.14 (d, J = 
8.31 Hz, 1H), 7.86 (d, J = 8.31 Hz, 1H), 7.59 (d, J = 8.75 Hz, 2H), 7.50 (t, J = 7.09 Hz, 1H), 7.44 
(t, J = 7.81 Hz, 3H), 7.23 (t, J = 7.09 Hz, 1H), 7.05-6.98 (m, 5H), 3.55 (s, 2H); 13C NMR (100 
MHz, DMSO-d6) δ 171.53, 160.76, 155.60, 152.58, 134.17, 131.57, 130.75, 129.84, 129.76, 
127.06, 126.16, 125.48, 125.07, 124.60, 123.78, 122.80, 120.03, 118.33, 113.38, 37.15; ESI 
HRMS: m/z 480.0579 (M-H)-. 
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2-((4-(4-(4-Fluorophenoxy)phenylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid 
(22). Synthesized using the procedure for 1 except 48t was used as the starting material. The title 
compound (36 mg, 44%) as a white solid after HPLC purification. 98% pure by HPLC. 1H NMR 
(400 MHz, DMSO-d6) δ 12.78 (s, 1H), 9.83 (s, 1H), 9.79 (s, 1H), 8.11 (d, J = 8.21 Hz, 1H), 7.83 
(d, J = 8.21 Hz, 1H), 7.55 (d, J = 8.46 Hz, 2H), 7.44 (dt, J = 6.92, 21.86 Hz, 2H), 7.25 (t, J = 
8.52 Hz, 2H), 7.11-7.02 (m, 2H), 6.99-6.96 (m, 2H), 6.95 (s, 1H), 3.51 (s, 2H). 13C NMR (100 
MHz, DMSO-d6) δ 171.53, 161.09, 152.57, 151.54 (d, J = 2.57 Hz), 134.14, 131.59, 129.86, 
129.68, 127.08, 126.19, 125.48, 124.61, 123.80, 122.80, 122.17 (d, J = 8.70 Hz), 117.90, 117.45, 
117.22, 113.38, 37.17; ESI HRMS: m/z 498.0485 (M-H)-. 
 
2-((1-Hydroxy-4-(4-phenylpiperazine-1-sulfonamido)naphthalen-2-yl)thio)acetic acid (23). 
Synthesized using the procedure for 1 except 48u was used as the starting material. The title 
compound (14.5 mg, 48%) was obtained as a white solid after HPLC purification. 99% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 9.77 (s, 1H), 9.59 (s, 1H), 8.15 (t, J = 7.91 Hz, 2H), 
7.59-7.53 (m, 1H), 7.53-7.48 (m, 2H), 7.20-7.14 (m, 2H), 6.89 (d, J = 7.91 Hz, 2H), 6.77 (t, J = 
7.26 Hz, 1H), 3.64 (s, 2H), 3.24-3.16 (m, 4H), 3.14-3.04 (m, 4H); 13C NMR (100 MHz, DMSO-
d6) δ 171.57, 152.02, 150.84, 131.08, 129.40, 128.56, 127.32, 126.28, 125.52, 125.43, 123.76, 
122.95, 120.04, 116.48, 113.63, 48.54, 46.36, 37.06; ESI HRMS: m/z 472.1002 (M-H)-. 
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2-((4-(4-Bromobenzamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid (25). Synthesized 
using the procedure for 1 except 48v was used as the starting material.The title compound was 
obtained (8.5 mg, 30%) as a white solid after HPLC purification. 98% pure by HPLC. 1H NMR 
(400 MHz, DMSO-d6) δ 10.36 (s, 1H), 8.23 (d, J = 5.36 Hz, 1H), 8.02 (d, J = 8.05 Hz, 2H), 7.83 
(d, J = 5.36 Hz, 1H), 7.78 (d, J = 8.05 Hz, 2H), 7.57-7.50 (m, 3H), 3.72 (s, 2H); 13C NMR (100 
MHz, DMSO-d6) δ 171.74, 165.71, 151.94, 133.90, 131.89, 130.66, 130.30, 128.64, 127.11, 
126.17, 126.13, 125.80, 125.47, 123.80, 122.97, 113.65, 37.15; ESI HRMS: m/z 429.9747 (M-
H)-. 
 
2-((4-((4-Chlorophenyl)methylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid 
(26). Synthesized using the procedure for 1 except 48w was used as the starting material. The 
title compound (15.5 mg, 20%) was obtained as a white solid after HPLC purification. 97% pure 
by HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.86 (s, 1H), 9.84 (s, 1H), 9.55 (s, 1H), 8.20 (d, J 
= 8.36 Hz, 1H), 8.07 (d, J = 8.36 Hz, 1H), 7.60-7.51 (m, 2H), 7.44 (s, 1H), 7.43-7.38 (m, 4H), 
4.49 (s, 2H), 3.71 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 171.81, 152.35, 133.45, 133.18, 
131.79, 129.37, 128.93, 128.72, 127.23, 126.30, 125.63, 124.99, 124.28, 122.79, 113.67, 57.16, 
36.96; ESI HRMS: m/z 436.0086 (M-H)-. 
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2-((4-(2-(4-Chlorophenyl)acetamido)-1-hydroxynaphthalen-2-yl)thio)acetic acid (28). 
Synthesized using the procedure for 1 except 48x was used as the starting material. The title 
compound (19 mg, 10%) was obtained as a white solid after trituration with a mixture of 
CH3CN:H2O 1:1 and cold CH2Cl2 and without a need for HPLC purification. 93% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 9.96 (s, 1H), 8.23-8.17 (m, 1H), 7.89-7.83 (m, 1H), 
7.57-7.50 (m, 3H), 7.47-7.39 (m, 4H), 3.78 (s, 2H), 3.66 (s, 2H); 13C NMR (100 MHz, DMSO-
d6) δ 171.72, 169.89, 151.36, 135.73, 131.66, 131.49, 129.70, 128.69, 127.15, 127.00, 126.11, 
126.07, 125.40, 123.21, 123.02, 113.51, 42.24, 37.21; ESI HRMS: m/z 400.0417 (M-H)-. 
 
2-((1-Hydroxy-4-(2-phenylacetamido)naphthalen-2-yl)thio)acetic acid (29). Synthesized 
using the procedure for 1 except 48y was used as the starting material. The title compound (50 
mg, 61%) was obtained as a white solid after trituration with a mixture of CH3CN:H2O 1:1 and 
cold CH2Cl2 and without a need for HPLC purification. 96% pure by HPLC. 1H NMR (400 
MHz, DMSO-d6) δ 12.78 (s, 1H), 9.97 (s, 1H), 9.66 (s, 1H), 8.26-8.12 (m, 1H), 7.92-7.77 (m, 
1H), 7.59-7.47 (m, 3H), 7.42 (d, J = 7.64 Hz, 2H), 7.37 (t, J = 7.40 Hz, 2H), 7.31-7.24 (m, 1H), 
3.77 (s, 2H), 3.67 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 171.73, 170.25, 151.26, 136.74, 
129.70, 129.58, 128.76, 127.10, 126.97, 126.92, 126.19, 126.06, 125.38, 123.22, 122.99, 113.49, 
43.09, 37.13; ESI HRMS: m/z 366.0802 (M-H)-. 
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4-Bromo-N-(3-(butylthio)-4-hydroxynaphthalen-1-yl)benzenesulfonamide (31). Synthesized 
using the procedure for 1 except 48z was used as the starting material. The title compound (10 
mg, 8%) was obtained as a white solid after HPLC purification. 99% pure by HPLC. 1H NMR 
(400 MHz, CDCl3) δ 8.23 (d, J = 7.40 Hz, 1H), 7.79 (d, J = 7.40 Hz, 1H), 7.59-7.50 (m, 4H), 
7.50-7.45 (m, 1H), 7.37 (s, 1H), 7.26 (s, 1H), 6.60 (s, 1H), 3.49 (s, 1H), 2.65 (t, J = 7.24 Hz, 2H), 
1.52-1.45 (m, 2H), 1.45-1.35 (m, 2H), 0.90 (t, J = 7.24 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
154.04, 138.33, 132.18, 131.86, 131.23, 128.98, 128.09, 127.90, 126.29, 123.80, 123.47, 122.92, 
122.16, 111.25, 36.61, 31.70, 21.74, 13.60; ESI HRMS: m/z 463.9998 (M-H)-. 
 
Methyl 2-((4-(4-bromophenylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetate (32). To 
a suspension of 40 (122 mg, 0.25 mmol) in dry CH2Cl2 (2 mL) was added BBr3 (1M in CH2Cl2, 
1 mL, 1 mmol) dropwise at 0oC. The mixture was allowed to warm up to room temperature and 
stirred under nitrogen. The starting material was entirely consumed as determined by TLC and 
analytical HPLC after 1 h. The mixture was again cooled down to 0oC and MeOH (3 mL) was 
added. After addition, the mixture was allowed to warm up to room temperature and stirred for 
1.5 h till a new spot formed as monitored by TLC. The mixture was slowly added to a stirring 
solution of saturated aqueous NH4Cl (15 mL) at 0oC. The solution was extracted with EtOAc (15 
mL x 2). The combined organic extracts were washed with brine (15 mL), dried (MgSO4), and 
filtered. The solvent was removed under reduced pressure. The crude was triturated with cold 
CH2Cl2 to give 32 (16 mg, 13%) as a light yellow solid. 96% pure by HPLC. 1H NMR (400 
MHz, DMSO-d6) δ 10.08 (s, 1H), 9.90 (s, 1H), 8.15 (d, J = 8.22 Hz, 1H), 7.85 (d, J = 8.22 Hz, 
1H), 7.73 (d, J = 8.58 Hz, 2H), 7.55 (d, J = 8.58 Hz, 2H), 7.52-7.41 (m, 2H), 6.99 (s, 1H), 3.60 
(s, 5H); 13C NMR (100 MHz, DMSO-d6) δ 170.21, 152.67, 139.44, 132.58, 131.45, 129.39, 
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129.23, 127.20, 126.93, 126.30, 125.51, 124.25, 123.67, 122.85, 113.07, 52.64, 36.18; ESI 
HRMS: m/z 479.9586 (M-H)-. 
 
2-((4-(4-Bromophenylsulfonamido)-1-hydroxynaphthalen-2-yl)thio)acetamide (33). 
Synthesized using the procedure for 1 except 41 was used as the starting material. The title 
compound (24 mg, 42%) as a yellow solid after trituration with a mixture of CH3CN:H2O 1:1 
and cold CH2Cl2 and without a need for HPLC purification. 96% pure by HPLC. 1H NMR (400 
MHz, DMSO-d6) δ 11.14 (s, 1H), 9.98 (s, 1H), 8.14 (d, J = 8.15 Hz, 1H), 7.87-7.78 (m, 2H), 
7.69 (d, J = 8.16 Hz, 2H), 7.56-7.48 (m, 3H), 7.44 (p, J = 6.86 Hz, 2H), 6.98 (s, 1H), 3.47 (s, 
2H); 13C NMR (100 MHz, DMSO-d6) δ 173.00, 154.82, 139.41, 132.55, 132.15, 131.51, 129.34, 
127.54, 126.92, 126.20, 125.68, 123.58, 123.23, 112.74; ESI HRMS: m/z 464.9591 (M-H)-. 
 
4-Bromo-N-(4-hydroxy-3-(3-hydroxypropyl)naphthalen-1-yl)benzenesulfonamide (34). 
Synthesized using the procedure for 1 except 48aa was used as the starting material. The title 
compound (16 mg, 32%) was obtained as a white solid after HPLC purification. 99% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 9.87 (s, 1H), 9.17 (s, 1H), 8.11 (d, J = 8.34 Hz, 1H), 
7.82 (d, J = 8.34 Hz, 1H), 7.68 (d, J = 8.50 Hz, 2H), 7.49 (d, J = 8.50 Hz, 2H), 7.38 (t, J = 7.23 
Hz, 1H), 7.31 (t, J = 7.23 Hz, 1H), 6.73 (s, 1H), 3.34 (t, J = 6.35 Hz, 2H), 2.61 (t, J = 7.48 Hz, 
2H), 1.54 (p, J = 6.68 Hz, 2H); 13C NMR (100 MHz, DMSO-d6) δ 149.29, 139.59, 132.49, 
130.41, 129.31, 128.21, 126.80, 126.16, 125.66, 125.40, 123.69, 123.54, 122.46, 122.39, 60.51, 
33.15, 26.18; ESI HRMS: m/z 434.0063 (M-H)-.  
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4-Bromo-N-(4-hydroxy-3-(4-hydroxybutyl)naphthalen-1-yl)benzenesulfonamide (35). 
Synthesized using the procedure for 1 except 44 was used as the starting material. The title 
compound (49 mg, 34%) was obtained as a white solid after HPLC purification. 98% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H), 9.13 (s, 1H), 8.12 (d, J = 8.17 Hz, 1H), 
7.87 (d, J = 8.17 Hz, 1H), 7.69 (d, J = 8.49 Hz, 2H), 7.51 (d, J = 8.49 Hz, 2H), 7.39 (t, J = 7.31 
Hz, 1H), 7.33 (t, J = 7.31 Hz, 1H), 6.67 (s, 1H), 4.36 (s, 1H), 3.42-3.33 (m, 2H), 2.58 (t, J = 5.70 
Hz, 2H), 1.45-1.26 (m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 149.19, 139.58, 132.50, 130.54, 
129.39, 128.16, 126.78, 126.20, 125.66, 125.39, 123.64, 123.61, 122.58, 122.46, 61.16, 32.47, 
29.39, 26.67; ESI HRMS: m/z 448.0223 (M-H)-. 
 
N-(3-(((2H-Tetrazol-5-yl)methyl)thio)-4-hydroxynaphthalen-1-yl)-4-
bromobenzenesulfonamide (36). Synthesized using the procedure for 1 except 48bb was used 
as the starting material. The title compound (3.3 mg, 10%) was obtained as a white solid after 
HPLC purification. 99% pure by HPLC.1H NMR (400 MHz, DMSO-d6) δ 10.00 (s, 1H), 8.13 (d, 
J = 8.04 Hz, 1H), 7.75 (d, J = 8.04 Hz, 1H), 7.64 (d, J = 8.62 Hz, 2H), 7.49-7.43 (m, 3H), 7.42-
7.36 (m, 1H), 6.91 (s, 1H), 4.25 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 153.78, 139.47, 
132.51, 131.79, 130.43, 129.21, 127.45, 126.87, 126.27, 125.59, 124.10, 123.57, 123.08, 26.54; 
ESI HRMS: m/z 489.9647 (M-H)-. 
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3-((1-Hydroxy-4-(naphthalene-2-sulfonamido)naphthalen-2-yl)thio)propanoic acid (37). 
Synthesized using the procedure for 1 except 48cc was used as the starting material. The title 
compound (23 mg, 15%) was obtained as a white solid after HPLC purification. >99% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.31 (s, 1H), 10.01 (s, 1H), 9.60 (s, 1H), 8.23 (s, 1H), 
8.14-8.06 (m, 2H), 8.06-7.97 (m, 3H), 7.80 (d, J = 8.52 Hz, 1H), 7.68 (t, J = 7.36 Hz, 1H), 7.60 
(t, J = 7.36 Hz, 1H), 7.43 (p, J = 6.84 Hz, 2H), 6.87 (s, 1H), 2.62 (t, J = 6.83 Hz, 2H), 2.17 (t, J = 
6.83 Hz, 2H); 13C NMR (100 MHz, DMSO-d6) δ 172.97, 152.44, 137.07, 134.56, 131.90, 
131.48, 129.68, 129.51, 129.23, 129.20, 128.33, 128.20, 128.00, 126.94, 126.22, 125.51, 124.61, 
123.96, 122.93, 122.70, 113.33, 34.12, 29.59; ESI HRMS: m/z 452.0630 (M-H)-. 
 
 
2-((1-Acetoxy-4-(4-bromophenylsulfonamido)naphthalen-2-yl)thio)acetic acid (45). 
Synthesized using a reported procedure.72 A stirred solution of 10 (50 mg, 0.11 mmol) in dry 
THF (1.5 mL) was cooled to 0 oC. Et3N (31 µL, 0.22 mmol) was added and the mixture was 
stirred for 5 min before acetylchloride (10 µL, 0.14 mmol) was added at 0oC. The mixture was 
stirred under nitrogen for an additional 20 min then diluted with EtOAc (10 mL) and washed 
with H2O (10 mL x 3). The organic layer was dried (MgSO4), filtered and concentrated under 
reduced pressure. The crude was subjected to flash column chromatography (hexane/EtOAc 4:1) 
on silica gel to afford 45 (34 mg, 61%) as a white solid. 99% pure by HPLC. 1H NMR (400 
MHz, CDCl3) δ 8.29 (d, J = 8.10 Hz, 1H), 7.96 (d, J = 8.48 Hz, 2H), 7.76 (d, J = 8.10 Hz, 1H), 
7.71 (d, J = 8.48 Hz, 2H), 7.69-7.59 (m, 2H), 7.37 (s, 1H), 3.63 (s, 2H), 1.79 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 170.13, 161.35, 147.04, 137.50, 132.14, 131.33, 131.18, 129.73, 129.46, 
128.87, 128.46, 126.94, 125.55, 122.76, 121.64, 114.58, 28.48, 24.29; ESI HRMS: m/z 507.9533 
(M-H)-. 
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2-Iodo-1-methoxy-4-nitrobenzene (49).73 To a stirred solution of iodoanisole (1 mL, 7.7 mmol) 
in AcOH (2 mL) was added fuming nitric acid (0.8 mL, 17 mmol) dropwise at 0oC. The mixture 
was allowed to warm up to room temperature and then heated up to 50oC and stirred for 1h under 
nitrogen when the color of the mixture became dark red/orange. Solid precipitate formed on 
cooling which was collected by filtration. Solid was washed with a 4:1 mixture of EtOH:H2O (10 
mL) and dried on high vacuum to give 49 (1.2g, 56%) as a light orange solid. 1H NMR (400 
MHz, CDCl3) δ 8.66 (s, 1H), 8.24 (d, J = 8.88 Hz, 1H), 6.85 (d, J = 8.88 Hz, 1H), 3.98 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 163.01, 141.88, 135.10, 125.69, 109.56, 85.13, 57.13; ESI MS: 
m/z 279.8 (M+H)+. 
 
Methyl 2-((2-methoxy-5-nitrophenyl)thio)acetate (50). To a solution of Cs2CO3 (541 mg, 1.66 
mmol) in dry THF (3 mL) under nitrogen was added methylthioglycolate (101 µL, 1.07 mmol). 
The mixture was stirred at room temperature for 10 min. At this time, a solution of ZnCl2 (114 
mg, 0.83 mmol) in dry THF (1 mL) was added and the mixture was stirred at room temperature 
for an additional 10 min. Meanwhile, in a separate flask Pd(OAc)2 (16 mg, 0.07 mmol) and 
xantphos (34 mg, 0.06 mmol) were premixed in dry THF (2 mL) under nitrogen and stirred at 
room temperature for about 20 min. To the solution of thiol, Cs2CO3, and ZnCl2 was added 49 
(299 mg, 1.07 mmol), LiI (74 mg, 0.55 mmol) and premixed solution of the catalyst and ligand. 
The mixture was stirred at 60oC under nitrogen for 6.5 h. The reaction mixture was filtered to 
remove Cs2CO3 and silica was added to the mixture and the solvent was removed under reduced 
pressure. The adsorbed crude residue was purified by column chromatography (hexane/EtOAc 
85:15) on silica gel to give 50 (178 mg, 63%) as a light yellow solid. 1H NMR (400 MHz, 
CDCl3) δ 8.20 (d, J = 2.70 Hz, 1H), 8.12 (dd, J = 2.70, 9.0 Hz, 1H), 6.90 (d, J = 9.0 Hz, 1H), 
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3.98 (s, 3H), 3.72 (s, 3H), 3.69 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 169.36, 161.83, 141.62, 
125.41, 124.74, 124.07, 109.73, 56.65, 52.71, 33.99; ESI MS: m/z 279.9 (M+Na)+. 
 
Methyl 2-((5-(4-bromophenylsulfonamido)-2-methoxyphenyl)thio)acetate (51).  
 
To a suspension of iron powder (374 mg, 6.7 mmol) in glacial acetic acid (5 mL) was added 50 
(171 mg, 0.66 mmol). The mixture was stirred at 70oC under nitrogen for 1 h when the mixture 
turned milky. The mixture was then diluted with EtOAc (10 mL) and washed with saturated 
aqueous NaHCO3 (15 mL x 2) and brine (15 mL). Organic layer was dried (MgSO4), filtered and 
the solvent was removed under reduced pressure to give the crude as a purple oil. The crude was 
used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 6.69 (d, J = 2.60 
Hz, 1H), 6.64 (d, J = 8.58 Hz, 1H), 6.50 (dd, J = 2.60, 8.58 Hz, 1H), 3.74 (s, 3H), 3.64 (s, 3H), 
3.57 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 170.30, 150.99, 140.41, 123.27, 118.30, 115.00, 
112.25, 56.34, 52.38, 34.91; ESI MS: m/z 228.0 (M+H)+, 249.9 (M+Na)+. 
A solution of the crude amine dissolved in dry CH2Cl2 (4mL) was added to 4-
bromobenzenesulfonyl chloride (184mg, 0.70 mmol). Addition of pyridine (0.11 mL, 1.36 
mmol) was followed and the mixture was stirred at room temperature under nitrogen for 30 min 
when TLC did not show any starting material. The mixture was diluted with EtOAc (10 mL) and 
washed with H2O (10 mL x 3) and brine (10 mL). The organic layer was dried (MgSO4), filtered 
and the solvent was removed under reduced pressure. Crude was triturated with cold CH2Cl2 to 
give 51 (122 mg, 41% over two steps) as a white solid 1H NMR (400 MHz, CDCl3) δ 7.58-7.51 
(m, 4H), 7.03 (d, J = 2.50 Hz, 1H), 6.89 (dd, J = 2.50, 8.70 Hz, 1H), 6.70 (d, J = 8.70 Hz, 1H), 
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6.58 (s, 1H), 3.83 (s, 3H), 3.67 (s, 3H), 3.54 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 169.83, 
156.05, 137.82, 132.26, 128.80, 128.72, 127.98, 126.06, 124.19, 123.85, 110.90, 56.04, 52.59, 
34.33; ESI MS: m/z 445.9, 447.9 (M+H)+, 467.8, 469.8 (M+Na)+. 
 
2-((5-(4-Bromophenylsulfonamido)-2-hydroxyphenyl)thio)acetic acid (24). To a stirred 
solution of 51 (82 mg, 0.18 mmol) suspended in dry CH2Cl2 (2.5 mL) was added BBr3 (1 M in 
CH2Cl2, 0.55 mL, 0.55 mmol) dropwise at 0 oC under nitrogen. The mixture was allowed to 
warm up to room temperature. After 30 min stir, the starting material was entirely consumed and 
the product formed as determined by TLC and MS (ESI-). The mixture was slowly added to a 
stirred solution of saturated aqueous NH4Cl (20 mL) at 0oC. The solution was extracted with 
EtOAc (15 mL x 2). The combined organic extracts were washed with brine (15 mL), dried 
(MgSO4), filtered, and the solvent was removed under reduced pressure. The crude was purified 
using a C18 reverse phase semi-preparative HPLC column with solvent A (0.1% of TFA in water) 
and solvent B (0.1% of TFA in CH3CN) as eluents to give 24 (22 mg, 29%) as a white solid. 
97% pure by HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.65 (s, 1H), 9.89 (s, 2H), 7.75 (d, J = 
7.98 Hz, 2H), 7.58 (d, J = 7.98 Hz, 2H), 6.93 (s, 1H), 6.69-6.66 (m, 2H), 3.58 (s, 2H); 13C NMR 
(100 MHz, DMSO-d6) δ 170.87, 153.27, 139.08, 132.62, 129.15, 126.97, 124.00, 122.38, 122.13, 
115.50, 109.99, 34.26; ESI HRMS: m/z 415.9273 (M-H)-. 
 
3-Iodo-4-methoxy-1-naphthaldehyde (52). A mixture of commercially available 1-methoxy-4-
naphthaldehyde (504 mg, 2.7 mmol), N-iodosuccinimide (704 mg, 3.1 mmol) in TFA (10 mL) 
was heated to reflux and stirred for 8 h under nitrogen. The reaction mixture was diluted with 
EtOAc (20 mL), washed with saturated aqueous Na2S2O3 solution (20 mL), saturated aqueous 
NaHCO3 (20 mL x 2), and brine (20 mL). The organic layer was dried (MgSO4), filtered and 
silica was added to filtrate and the solvent was removed under reduced pressure. The adsorbed 
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crude residue was purified by flash column chromatography (hexane/EtOAc 96:4) on silica gel 
to give 52 (648 mg, 77%) as a tan solid. 1H NMR (400 MHz, CDCl3) δ 10.23 (s, 1H), 9.22 (d, J 
= 8.48 Hz, 1H), 8.26 (s, 1H), 8.18 (d, J = 8.48 Hz, 1H), 7.71 (t, J = 7.63 Hz, 1H), 7.62 (t, J = 
7.63 Hz, 1H), 4.04 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 191.28, 162.11, 146.45, 131.97, 
129.69, 129.44, 128.64, 127.75, 125.41, 122.73, 85.22, 62.06; ESI MS: m/z 313.0 (M+H)+. 
 
N-((3-Iodo-4-methoxynaphthalen-1-yl)methyl)benzenesulfonamide (53).  
 
Synthesized using a reported procedure with modification.74 To a solution of 52 (318 mg, 1 
mmol) in dry CH2Cl2  (3.5 mL), benzenesulfonamide (209 mg, 1.3 mmol) and triethylamine 
(0.43 mL, 3.1 mmol) were successive added. After 5 min stir at room temperature, the reaction 
mixture was cooled down to 0 oC, and TiCl4 (0.14 mL, 1.3 mmol) in CH2Cl2 (1 mL) was added 
dropwise. The reaction mixture was continued to stir at 0 oC for 10 min before warming up to 
room temperature. The reaction progress was monitoring by TLC. After 3h, the mixture was 
quenched saturated aqueous NaHCO3 and the aqueous layer was extracted with CH2Cl2 (2 x 15 
mL). The combined organic layers were washed with brine, dried (Na2SO4), and solvent was 
removed under reduced pressure. The crude product was used for the next step without further 
purification. 
 
The previous crude product was dissolved in a mixture of MeOH (3mL) and CH2Cl2  (3mL). 
After cooling to 0°C, NaBH4 (39mg, 1 mmol) was added in small portions, then brought to room 
temperature and stirred for 45 min. The mixture was quenched with H2O, extracted with EtOAc 
(2 x 10 mL). The combined organic layers were washed with brine, dried (Na2SO4), and solvent 
was removed under reduced pressure. The crude product was purified by flash column 
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chromatography (hexane/EtOAc 85:15) on silica gel to give 53 (279 mg, 60% over two steps) as 
a yellow oil which solidified. 1H NMR (500 MHz, CDCl3) δ 8.05 (d, J = 7.7 Hz, 1H), 7.89 (d, J 
= 7.7 Hz, 1H), 7.86 (d, J = 8.3 Hz, 2H), 7.61-7.56 (m, 2H), 7.55-7.47 (m, 5H), 4.48 (s, 2H), 3.92 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 156.92, 139.49, 136.02, 132.85, 132.29, 129.22, 129.13, 
128.40, 127.47, 127.11, 126.88, 123.90, 122.97, 85.83, 61.65, 44.62; ESI MS: m/z 476.0 
(M+Na)+. 
 
Methyl 2-((1-methoxy-4-(phenylsulfonamidomethyl)naphthalen-2-yl)thio)acetate (54). To a 
solution of Cs2CO3 (160 g, 0.49 mmol) in dry THF (2 mL) under nitrogen was added 
methylthioglycolate (31 µL, 0.33 mmol, 95% purity grade). The mixture was stirred at room 
temperature for 10 min. At this time, a solution of ZnCl2 (29 mg, 0.21 mmol) in dry THF (1 mL) 
was added and the mixture was stirred at room temperature for an additional 10 min. Meanwhile, 
in a separate flask Pd(OAc)2 (4 mg, 0.02 mmol) and xantphos (10 mg, 0.02 mmol) were 
premixed in dry THF (1 mL) under nitrogen and stirred at room temperature for about 20 min. 
To the solution of thiol, Cs2CO3, and ZnCl2 was added 53 (151 mg, 0.33 mmol), LiI (20 mg, 0.15 
mmol) and premixed solution of the catalyst and ligand successively. The mixture was stirred at 
60oC under nitrogen for 10 h. The reaction mixture was filtered to remove Cs2CO3 and silica was 
added to the mixture and the solvent was removed under reduced pressure. The adsorbed crude 
residue was purified by column chromatography (hexane/EtOAc 7:3) on silica gel to give 54 (76 
mg, 53%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.18 Hz, 1H), 7.83 (t, J = 
7.87 Hz, 3H), 7.55-7.48 (m, 2H), 7.48 -7.39 (m, 4H), 7.27 (s, 1H), 4.45 (d, J = 5.95 Hz, 2H), 
3.91 (s, 3H), 3.65 (s, 2H), 3.63 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.14, 155.33, 139.57, 
132.66, 131.63, 129.02, 128.44, 128.17, 127.06, 127.02, 126.62, 123.71, 122.53, 122.48, 61.34, 
52.59, 45.00, 35.20; ESI MS: m/z 454.1 (M+Na)+. 
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2-((1-Hydroxy-4-(phenylsulfonamidomethyl)naphthalen-2-yl)thio)acetic acid (27). To a 
stirred solution of 54 (76 mg, 0.18 mmol) suspended in dry CH2Cl2 (2 mL) was added BBr3 (1 M 
in CH2Cl2, 0.54 mL, 0.54 mmol) dropwise at 0oC under nitrogen. The mixture was allowed to 
warm up to room temperature. After 1hr stir, the starting material was entirely consumed and the 
product formed as determined by TLC and MS (ESI-). The mixture was slowly added to a stirred 
solution of saturated aqueous NH4Cl (20 mL) at 0oC. The solution was extracted with EtOAc (15 
mL x 2). The combined organic extracts were washed with brine (15 mL), dried (MgSO4), 
filtered, and the solvent was removed under reduced pressure. The crude was purified using a C18 
reverse phase semipreparative HPLC column with solvent A (0.1% of TFA in water) and solvent 
B (0.1% of TFA in CH3CN) as eluents to give 27 (12.5 mg, 18%) as a white/tan solid. 94% pure 
by HPLC. 1H NMR (400 MHz, DMSO-d6) δ 12.78 (s, 1H), 9.64 (s, 1H), 8.16 (d, J = 7.82 Hz, 
1H), 8.04 (t, J = 5.47 Hz, 1H), 7.92 (d, J = 7.82 Hz, 1H), 7.79 (d, J = 7.22 Hz, 2H), 7.63-7.57 (m, 
1H), 7.57-7.47 (m, 4H), 7.32 (s, 1H), 4.24 (d, J = 5.75 Hz, 2H), 3.61 (s, 2H); 13C NMR (100 
MHz, DMSO-d6) δ 171.84, 153.54, 140.78, 132.75, 132.24, 132.00, 129.53, 127.37, 126.93, 
125.87, 125.44, 124.59, 124.13, 123.24, 112.76, 44.59, 37.47; ESI HRMS: m/z 402.0475 (M-H)-. 
 
1-(benzyloxy)-4-nitronaphthalene (55).75  
 
A stirred solution of 1-nitronaphthalene (1.4 g, 8 mmole) in DMSO (30 mL) was cooled down to 
0oC. KOH (1.8 g, 32 mmole) dissolved in H2O (10 mL) was added dropwise. Color of the 
solution changed from yellow to dark green. Addition of cumene hydroperoxide (technical grade, 
H
N
O2
S
OH
S
OH
O
NO2
OBn
NO2
OH
  90 
1.5mL, 8 mmole) dissolved in DMSO (4mL) via syringe was followed at 0oC to provide a dark 
brown solution which was stirred for 2 h at room temperature. Saturated aqueous Na2S2O3 
solution (10mL) was added and the mixture was stirred for another 15 min at room temperature. 
The mixture was diluted with H2O (10 mL) and washed with EtOAc (30 mL x 2). Aqueous phase 
was acidified with 1N HCl and extracted with EtOAc (30 mL x 3). The organic extracts were 
washed with brine (30 mL), dried (MgSO4) and filtered. The solvent was removed under reduced 
pressure to provide a black oil which was purified by flash column chromatography 
(hexane/EtOAc 3:2) on silica gel to give 4-nitronaphthalen-1-ol (1.03g, 67%) as a yellow/brown 
solid. 1H NMR (400 MHz, DMSO-d6) δ 11.89 (s, 1H), 8.64 (d, J = 8.78 Hz, 1H), 8.38 (d, J = 
9.34 Hz, 1H), 8.30 (d, J = 8.16 Hz, 1H), 7.77 (t, J = 7.62 Hz, 1H), 7.61 (t, J = 7.62 Hz, 1H), 6.95 
(d, J = 8.16 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) δ 160.80, 137.07, 130.79, 128.95, 127.23, 
126.57, 124.70, 123.54, 123.26, 107.19; ESI MS: m/z 190.0 (M+H)+.  
 
To a stirred solution of 4-nitronaphthalen-1-ol (505 mg, 2.7 mmol) in dry DMF (3 mL) was 
added NaH (60 wt% dispersion in oil, 193 mg, 4.8 mmol) suspended in dry DMF (3 mL) at 0oC. 
Benzyl bromide (0.46 mL, 3.9 mmol) in dry THF (3 mL) was added next at 0oC. The mixture 
was warmed up to room temperature and stirred under nitrogen for 2-3 h. Mixture was diluted 
with EtOAc (10 mL), washed with H2O (10 mL x 4) and brine (10 mL). The organic layer was 
dried (MgSO4), filtered, concentrated and purified by column chromatography on silica to give 
55 (465 mg, 64%) as a light brown solid. 1H NMR (400 MHz, CDCl3) δ 8.77 (d, J = 9.40 Hz, 
1H), 8.43 (d, J = 7.70 Hz, 1H), 8.36 (d, J = 7.70 Hz, 1H), 7.73 (t, J = 7.70 Hz, 1H), 7.58 (t, J = 
7.70 Hz, 1H), 7.53-7.47 (m, 2H), 7.46-7.35 (m, 3H), 6.88 (d, J = 9.40 Hz, 1H), 5.34 (s, 2H); 13C 
NMR (100 MHz, CDCl3) δ 159.50, 139.36, 135.54, 130.06, 128.81, 128.50, 127.46, 127.01, 
126.92, 126.60, 125.76, 123.47, 122.88, 103.15, 70.91; ESI MS: m/z 280.0 (M+H)+ , 302.0 
(M+Na)+. 
 
N-(4-(benzyloxy)naphthalen-1-yl)benzenesulfonamide (56).  
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To a suspension of iron powder (601 mg, 10.7 mmol) in glacial acetic acid (6 mL) was added 55 
(301 mg, 1.08 mmol). The mixture was stirred at 70 oC under nitrogen for 1.5 h when the 
mixture turned milky. The mixture was then diluted with EtOAc (10 mL) and washed with 
saturated aqueous NaHCO3 (15 mL x 2) and brine (15 mL). Organic layer was dried (MgSO4), 
filtered and the solvent was removed under reduced pressure to give the crude as a purple oil. 
The crude was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 
8.40-8.35 (m, 1H), 7.87-7.80 (m, 1H), 7.55-7.49 (m, 4H), 7.42 (t, J = 7.36 Hz, 2H), 7.39-7.31 
(m, 3H), 6.78-6.69 (m, 2H), 5.18 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 148.64, 137.56, 134.70, 
128.53, 127.81, 127.38, 126.40, 125.83, 125.46, 125.39, 122.79, 120.98, 110.41, 106.12, 70.56; 
ESI MS: m/z 250.0 (M+H)+. 
 
A solution of the crude amine dissolved in dry CH2Cl2 (5mL) was added to benzenesulfonyl 
chloride (218mg, 1.2 mmol). Addition of pyridine (0.18 mL, 2.2 mmol) was followed and the 
mixture was stirred at room temperature under nitrogen overnight. The mixture was diluted with 
EtOAc (10 mL) and washed with H2O (10 mL x 3) and brine (10 mL). The organic layer was 
dried (MgSO4), filtered and the solvent was removed under reduced pressure. Crude was purified 
by flash column chromatography on silica gel to give 56 (236 mg, 55% over two steps) as a 
brown oil which solidified upon standing. 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 7.94 Hz, 
1H), 7.75-7.66 (m, 3H), 7.49 (t, J = 6.20 Hz, 3H), 7.46-7.39 (m, 4H), 7.38-7.32 (m, 3H), 7.20 (d, 
J = 8.22 Hz, 1H), 6.75 (d, J = 8.22 Hz, 1H), 6.60 (s, 1H), 5.21 (s, 2H); 13C NMR (100 MHz, 
CDCl3) δ 154.17, 139.41, 136.59, 132.70, 131.08, 128.83, 128.60, 128.07, 127.38, 127.30, 
127.14, 126.13, 125.68, 125.61, 123.75, 122.58, 121.75, 104.42, 70.24; ESI MS: m/z 389.9 
(M+H)+ , 411.9 (M+Na)+. 
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N-(4-hydroxynaphthalen-1-yl)benzenesulfonamide (30). A stirred solution of 56 (200 mg, 
0.51 mmol) in MeOH (15 mL) was hydrogenated in the presence of 10% Pd/C (163 mg) at room 
temperature and under 30 psi of H2 for 6 h. The suspension was filtered through a pad of celite. 
The filtrate diluted with EtOAc (20 mL) was washed with saturated aqueous NH4Cl (20 mL x 2). 
The organic layer was dried (MgSO4), filtered and the solvent was removed under reduced 
pressure. The crude was purified using a C18 reverse phase semipreparative HPLC column with 
solvent A (0.1% of TFA in water) and solvent B (0.1% of TFA in CH3CN) as eluents to give 30 
(32 mg, 21%) as a white solid. 99% pure by HPLC. 1H NMR (400 MHz, DMSO-d6) δ 8.07 (d, J 
= 7.83 Hz, 1H), 7.86 (d, J = 7.83 Hz, 1H), 7.63 (d, J = 7.58 Hz, 2H), 7.60-7.53 (m, 1H), 7.48 (t, J 
= 7.37 Hz, 2H), 7.38 (p, J = 6.69 Hz, 2H), 6.85 (d, J = 7.98 Hz, 1H), 6.71 (d, J = 7.98 Hz, 1H); 
13C NMR (100 MHz, DMSO-d6) δ 151.24, 139.13, 131.28, 130.38, 127.80, 125.58, 124.92, 
124.39, 123.71, 123.55, 122.05, 122.01, 120.89, 106.09; ESI HRMS: m/z 298.0547 (M-H)-. 
Protein purification 
 
His-tagged proteins containing Mcl-1 (residues 171–327), Bcl-2 (residues 1-202 with inserted 
Bcl-XL sequence from residues 35 to 50), Bcl-XL (residues 1-209 lacking its C-terminal 
transmembrane domain with a deletion of the flexible loop region 45 – 85), Bcl-w (residues 1-
155), A1/Bfl-1 (residues 1-151), were expressed from the pHis-TEV vector (a modified pET 
vector) in E. coli BL21 (DE3) cells. Cells were grown at 37 ºC in 2×YT containing antibiotics to 
an OD600 density of 0.6. Protein expression was induced by 0.4 mM IPTG at 37 ºC for 4 hours. 
Cells were lysed in 50 mM Tris pH 8.0 buffer containing 500 mM NaCl, 0.1% bME and 40 µl of 
Leupectin/Aprotin. All proteins were purified from the soluble fraction using Ni-NTA resin 
(QIAGEN), following the manufacturer’s instructions. Mcl-1 was further purified on a Source 
Q15 column (Amersham Biosciences) in 25 mM Tris pH 8.0 buffer, with NaCl gradient. Bcl-2 
and Bcl-XL were purified on a Superdex75 column (Amersham Biosciences). All proteins were 
stored in 25 mM Tris pH 8.0 buffers containing 150 mM NaCl and 2 mM DTT and at -80 ºC in 
presence of 25% Glycerol.  
Determination of the Kd values of fluorescent probes to anti-apoptotic proteins 
 
Fluorescein tagged BID BH3 (Bcl-2 Homology 3) peptide was used as a fluorescent probe in the 
FP-based binding assays. Two fluorescent labeled BID BH3 peptide probes were used: i) 
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fluorescein tagged BID peptide (Flu-BID), labeled with fluorescein on the N-terminus of the 
BH3 peptide (79-99); ii) the second tracer was purchased from Abgent (Catalog # SP2121a), 
named as FAM-BID, where the BH3 peptide (80-99) is labeled with 5-FAM. Their Kd values 
were determined to all members of the Bcl-2 family proteins with a fixed concentration of the 
tracer (2 nM of Flu-BID and FAM-BID) and different concentrations of the tested proteins, in a 
final volume of 125 µl in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 µg/ml 
bovine γ-globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). 
Plates were mixed and incubated at room temperature for 2 hours and the polarization values in 
millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an 
emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were calculated by 
fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using 
Graphpad Prism 6.0 software. Based upon analysis of the dynamic ranges for the signals and 
their Kd values, Flu-BID was selected as the tracer in the Mcl-1 and Bcl-2 competitive binding 
assays, while FAM-BID was selected as the tracer for the rest of the proteins, A1/Bfl-1, Bcl-w 
and Bcl-xL. The Kd value of Flu-BID to Mcl-1 was 34 ± 3.5 nM, and to Bcl-2 was 20 ± 0.86 nM 
and the Kd values of FAM-BID to A1/Bfl-1 was 0.83 ± 0.06 nM, to Bcl-w was 5.5 ± 1.6 nM, and 
to Bcl-xL was 10 ± 4.0 nM respectively, in our saturation experiments. 
Fluorescence polarization-based binding assays 
 
Sensitive and quantitative FP-based binding assays were developed and optimized to determine 
the binding affinities of small-molecule inhibitors to the recombinant Mcl-1, A1/Bfl-1, Bcl-w, 
Bcl-2, and Bcl-xL proteins. Protocols for expression and purification of used anti-apoptotic 
proteins and determination of Kd values of fluorescent probes to proteins are provided in the 
Supporting Information. Based on the Kd values, the concentrations of the proteins used in the 
competitive binding experiments were 90 nM for Mcl-1, 40 nM for Bcl-w, 50 nM for Bcl-xL, 60 
nM for Bcl-2, and 4 nM for A1/Bfl-1. The fluorescent probes, Flu-BID and FAM-BID were 
fixed at 2 nM for all assays except for A1/Bfl-1 where FAM-BID was used at 1 nM. 5 µL of the 
tested compound in DMSO and 120 µL of protein/probe complex in the assay buffer (100 mM 
potassium phosphate, pH 7.5; 100 µg/ml bovine gamma globulin; 0.02% sodium azide, 
purchased from Invitrogen, Life Technologies) were added to assay plates (Microfluor 2Black, 
Thermo Scientific), incubated at room temperature for 3 h and the polarization values (mP) were 
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measured at an excitation wavelength at 485 nm and an emission wavelength at 530 nm using the 
plate reader Synergy H1 Hybrid, BioTek. IC50 values were determined by nonlinear regression 
fitting of the competition curves (GraphPad Prism 6.0 Software). The Ki values were calculated 
as described previously.79  
 
Solution competitive surface plasmon resonance-based assay using immobilized biotin-labeled 
Bim BH3 peptide 
 
The solution competitive SPR-based assay was performed on Biacore 2000. N terminal biotin-
labeled Bim BH3 peptide (141 - 166 amino acids), was immobilized on streptavidin (SA) chip 
giving density of 1400 RU (Response Units). The pre-incubated Mcl-1 protein (20 nM) with 
tested small-molecule inhibitors for at least 30 minutes was injected over the surfaces of the chip. 
Response units were measured at 15 seconds in the dissociation phase and the specific binding 
was calculated by subtracting the control surface (Fc1) signal from the surfaces with 
immobilized biotin-labeled Bim BH3. IC50 values were determined by non-linear least squares 
analysis using GraphPad Prism 6.0 software. 
Molecular modeling  
 
Crystal structure of Mcl-1 in complex with mNoxa BH3 peptide (PDB entry 2NLA) and in silico 
Schrödinger’s IFD were used to model the binding poses of our designed compounds with Mcl-
1. IFD is allowing incorporation of the protein and ligand flexibility in the docking protocol, 
which is consisted of the following steps: (i) constrained minimization of the protein with an 
RMSD cutoff of 0.18 Å; (ii) initial Glide docking of the ligand using a softened potential (Van 
der Waals radii scaling); (iii) one round of Prime side-chain prediction for each protein/ligand 
complex, on residues within defined distance of any ligand pose; (iv) prime minimization of the 
same set of residues and the ligand for each protein/ligand complex pose; (v) Glide re-docking of 
each protein/ligand complex structure within a specified energy of the lowest energy structure; 
(vi) estimation of the binding energy (IFDScore) for each output pose. All docking calculations 
were run in the extra precision (XP) mode of Glide. The center of the grid box of the Mcl-1 was 
defined by the Val 249 (in h1), Phe 270 (in h2), Val 220 (in h3/h4) and Val 216 (in h4). The size 
of the grid box was set to 15 Å. Default values were used for all other parameters. Schrödinger’s 
MC/SD dynamic simulation performs constant temperature calculations that take advantage of 
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the strengths of Monte Carlo methods for quickly introducing large changes in a few degree of 
freedom, and stochastic dynamics for its effective local sampling of collective motions. The 
MC/SD dynamic simulation time in our study was set to 100 ps by allowing movement of the 
docked ligand and the residues which is less than 6 Å to the ligand. The force field used was set 
to OPLS_2001. Default values were used for all other parameters. 
NMR studies 
 
15N-labeled or 15N, 13C-labeled Mcl-1 proteins for NMR studies were prepared and purified using 
the same protocol as for unlabeled protein with the exception that the bacteria were grown on M9 
minimal media supported with 3 g/ L of 13C-glucose and/or 1 g/L of (15NH4)2SO4. 15N, 13C-
labeled Mcl-1 was used for backbone reassignment and 80% of residues were reassigned based 
on the work by Liu et al57. Protein samples were prepared in a 20 mM sodium phosphate, 150 
mM NaCl and 1 mM DTT solution at pH 7 in 7% D2O. The binding mode of the compounds has 
been characterized by recording 1H,15N -HSQC experiments with a 138 µL solution of uniformly 
15N-labeled Mcl-1 (75µM) in the absence and presence of added compounds with the indicated 
molar ratio concentrations. All Spectra were acquired at 30 oC on a Bruker 600 MHz NMR 
spectrometer equipped with a cryogenic probe, processed using Bruker TopSpin and rNMR86, 
and were analyzed with Sparky87. Plots of chemical shift changes were calculated as ((Δ1H 
ppm)2 + (0.2(Δ15N ppm))2)0.5 of Mcl-1 amide upon addition of compound. The absence of a bar in 
a chemical shift plot indicates no chemical shift difference, or the presence of a proline or 
residue that is overlapped or not assigned.  
Biotin−streptavidin pull-down experiment 
 
Human breast cancer 2LMP cells, a subclone of the MDA-MB-231 cell line, were lysed in 
CHAPS buffer (10 mM HEPES (pH 7.4), 2.5 mM EDTA, 150 mM NaCl, 1.0% CHAP). Pre-
cleared cell lysates were incubated with different concentrations of compounds followed by 
incubation with biotinylated Noxa BH3 peptide (18-43) and streptavidin−agarose beads to pull-
down Mcl-1 protein bound to Noxa peptide. Beads were washed with CHAPS buffer, and Mcl-1 
protein was eluted by boiling in SDS-PAGE sample buffer and analyzed by Western blotting 
using Mcl-1 antibody (Santa Cruz). 
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Cell culture and cell viability assays 
 
MEFs cells, wild type and Bax/Bak double knock out, were gifts from Shaomeng Wang at the 
University of Michigan and were cultured in DMEM (Life Technologies), supplemented with 
10% fetal bovine serum (FBS) (Thermo Scientific HyClone). The retroviral transduced 
lymphoma cells isolated from Eµ-myc transgenic mice were gifts from Ricky W. Johnstone at 
University of Melbourne, Melbourne, Australia and cultured as previously described.83 Human 
leukemia cell lines HL-60, K-562 and MV-4-11 were obtained from American Type Culture 
Collection (ATCC). The cells were cultured in RPMI 1640 medium (Life Technologies), all 
supplemented with 10% FBS. MEFs cells were seeded in 12-well plates at 0.5 x 106 cells/well. 
The cells were left to adhere and then treated for 15 hours with increasing concentrations of the 
compounds. The cells were harvested, washed with phosphate-buffered saline (PBS) then stained 
with 0.025 mg/ml propidium iodide (MP Biomedicals). The percentage of propodium iodide 
positive population was determined by flow cytometry and calculated using WinList 3.0. The 
Mcl-1 and Bcl-2 retroviral transduced lymphoma Eµ-myc cells were seeded in 24-well plates at 
0.5 x 106 cells/well. They were treated with different concentrations of tested compounds for 16 
hrs. The cells were harvested and stained with violet LIVE/DEAD Fixable Dead Cell Stain Kit 
(Invitrogen) according to manufacturer's protocol.  The percentage of fluorescent positive cells 
was determined by flow cytometry and calculated using WinList 3.0. The effect of the 
compounds on tested leukemia cells viability was evaluated by CellTiter Glo Luminescent Cell 
Viability Assay (Promega). Cells were plated in 12-well plates at 0.5 x 106 cells/well and treated 
with various concentrations of the compounds and incubated for 3 days. Cell viability was 
determined by measuring intracellular ATP levels with the Cell Titer-Glo reagent and reading 
the luminescence with the Synergy H1 Hybrid BioTek plate reader. Percent cell growth was 
calculated relative to DMSO treated cells and IC50 values were calculated by non-linear 
regression analysis using GraphPad Prism 6.0 Software.  
Determination of caspase acitivity 
 
HL-60 cells were seeded in 12-well plates at 0.5 x 106 cells/well. After 20 hrs treatment with 
different concentrations of the compounds, caspase 3 activity was determined using the 
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fluorometric substrates DEVD-AFC following the protocol of the Caspase-3 Fluorometric Assay 
Kit (BioVision). Caspase 3 activity is reported as the fold change relative to DMSO treated cells. 
Analysis of apoptosis  
 
To determine the induction of apoptosis, HL-60 cells were plated in 12-well plates at 0.5 x 106 
cells/well and treated with various concentrations of tested compounds. After 15 hours cells were 
harvested, washed with PBS and treated with Annexin-V FITC and propidium iodide using BD 
Annexin V FITC Assay kit (BD Biosciences Pharmingen). The percentage of cells undergoing 
apoptosis was assessed by flow cytometry within 1 h and analysed using WinList 3.0. 
 
2.10 Contributions  
 
Fardokht Abulwerdi designed, synthesized and characterized all the compounds and 
intermediates except the intermediate for analog 23, which was synthesized and characterized by 
Dr. Lei Miao, as well as expressed and purified labeled Mcl-1, prepared NMR samples and 
analyzed HSQC NMR data with supervision from Dr. Nikolovska-Coleska and Dr. Hollis 
Showalter. Ahmed Mady performed all the biochemical and cellular experiments except for the 
cell growth inhibition studies and caspase activation in leukemia cells which were performed by 
Jordan Gavin. Dr. Chenzhong Liao performed all the molecular docking studies and contributed 
to the design of analogs. Dr. Chenxi Shen performed pull-down assay. Dr. Tomasz Cierpicki 
reassigned the backbone of Mcl-1 for the NMR studies. All the proteins used for biochemical 
assays were expressed and purified in Dr. Jeanne Stuckey lab at LSI. Efficacy studies were 
performed in Dr. Ramzi Mohammad lab at Wayne State University.  
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Chapter 3  
     Development of 1H-pyrazolo[3,4-b]pyridine analogs as a novel class of Mcl-1 inhibitors 
 
 
3.1 Introduction  
 
High throughput screen (HTS) approach is a known strategy for identification of potential 
lead compounds for further development1. To identify novel small-small molecule Mcl-1 
inhibitors, a dual-readout HTS assay that combines two assay technologies, fluorescence 
polarization (FP) and Forster resonance energy transfer (FRET), was developed, optimized and 
miniaturized to a 1,536-well ultra-HTS format2. The assay was used to screen a library of 
102,255 compounds at Emory University Molecular Libraries Screening Center using 
recombinant Mcl-1 and either a labeled Noxa or Bid BH3 derived peptides. The identified hits 
from the both primary screens were subjected to secondary dose-response tests and a total of 
1214 (875 from Mcl-1/Noxa and 509 from Mcl-1/Bid) including 170 overlapping compounds 
were identified. All the dose-response curves were further deposited in the PubChem’s BioAssay 
Database under AID 14173 and 14184.  
A high hit rate in HTS campaigns can make the identification of the most promising hits a 
challenging task and thus novel strategies to simplify this process are desired. Therefore, we 
employed an integrated screening approach by combining in silico target-based screening for 
selection of the most promising hits. For this purpose, molecular docking using the crystal 
structure of Mcl-1 bound to mNoxa (PDB 2NLA)5 was utilized and all identified hits were 
subjected to Schrödinger’s Induced Fit Docking (IFD) protocol6 at the BH3 binding site of Mcl-
1. A pharmacophore model (Figure 3.1) was developed based on the interactions of mNoxa and 
Mcl-1 which included 3 hydrophobic and one hydrogen bond/electrostatic interactions. 
Compounds able to mimic at least two of the 4 conserved interactions of mNoxa with Mcl-1 
were selected. This totaled 67 compounds from which 48 were purchased from commercial 
vendors.  Notably, compounds with hydroxynaphthalenylsulfonamide scaffold of 59 class 
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(Chapter 2) were among selected compounds. All 48 compounds were subjected to rigorous 
biochemical and biophysical assays which included dose-response competitive FP and SPR 
assays against Mcl-1 and HSQC NMR studies.  Compounds which gave consistent results in all 
the binding assays were considered as validated hits and those with promising chemical scaffolds 
were selected for further optimization. 
 
Figure 3.1. Pharmacophore model based on the interaction of mNoxa and Mcl-1. Crystal 
structure of mNoxa bound to Mcl-1 (PDB 2NLA) was used. Mcl-1 is shown in surface 
representation while mNoxa is shown as a purple ribbon. Three hydrophobic residues of mNoxa 
are shown in green and labeled in black. The charged residue is shown and labeled in yellow.  
   
3.2 Identification of HTS lead 38 as a Mcl-1 inhibitor 
 
Compound 38 (Figure 3.2A) was one of the validated hits which showed dose-dependent 
chemical shift changes of Mcl-1 residues in HSQC NMR experiments. Interestingly, compound 
38 has structural features common to the 59 class (chapter 2) as well as to a newly published 
selective small-molecule Mcl-1 inhibitors7 which include a bicyclic core (a 1H-pyrazolo[3,4-
b]pyridine in 38) and a carboxylic acid group. Compound 38 was resynthesized (analog 1) and 
its potency was confirmed (Ki= 26 μM). Despite the low potency of this compound compared to 
the HTS lead 59 (Ki = 2 μM), the simplicity of synthetic modification for analog generation as 
well as its drug-like features as defined by Lipinski’s Rule of Five8 made it a good choice for 
further optimization. 38 has a favorable ligand efficiency of 12.9 which is calculated based on 
the equation below. Ligand efficiency (LE) as calculated below is also referred to as binding 
efficiency index (BEI)9. It has been documented that the optimum LE for small molecules 
targeting protein-protein interactions is around 1210 and 38’s LE nicely falls around this number.   
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LE =    pK!MW  (kDa) 
 
For docking studies of 38, a recently published Mcl-1 crystal structure in complex with a 
synthetic ligand (PDB 4HW2) was utilized7. The Gold-generated docking pose (Figure 3.2B) of 
38 was further validated and confirmed by HSQC NMR studies of Mcl-1 in presence of 2-fold 
excess of 38. Chemical shift perturbation (CSP) plot of compound 38 (Figure 3.2 C) showed 
moderate to significant perturbations of V249, M250 and M231, which are part of the p2 pocket 
of Mcl-1, consistent with the predicted binding model where 3-chlorophenyl of 38 binds to p2 
hydrophobic pocket. Significant perturbations of L267 and R263 as well as residues in their 
vicinity (I264, V265) are also observed. L267 is predicted to interact with the 3-methyl while 
R263 forms an electrostatic interaction with 4-carboxylic acid of 38. It should, however, be 
mentioned that the predicted distance for the electrostatic interaction is 4.2 Å, which is not 
optimal for a hydrogen bond. Finally, the 6-furyl is predicted to interact with residues in the 
p2/p3 pockets, mainly A227, F228, F270, G271 M231 which are moderately to significantly 
perturbed. In addition to the residues mentioned above which are predicted to interact with 38 by 
docking studies, significant chemical shift perturbations of V216, V220, Q221 (on C-terminal of 
α-helix 2), K234, L235 (on C-terminal of α-helix 3), N239 (on the disordered loop connecting α-
helix 3 and 4) and V243 and V253 (on α-helix 4) are observed. Overall analysis of the chemical 
shift changes of 38 in complex with Mcl-1 shows that 38 affects the residues in the BH3-binding 
groove of Mcl-1 and provides a strong support for the binding of this compound to Mcl-1.   
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Figure 3.2. Docking and NMR studies of 38. (A) Structure of the HTS lead compound 38 or 1. 
(B) Putative binding mode of 38 to Mcl-1 (4HW2). The surface of Mcl-1 is colored according to 
the chemical shift intensity. Residues of Mcl-1 labeled in black are predicted to interact with 38. 
(C) Plot of chemical shift changes of Mcl-1 amide upon addition of 38 (Mcl-1:38 ratio of 1:2) as 
a function of Mcl-1 residue numbers. Color legend: Significant shift (> 0.09 ppm) is represented 
with purple, moderate shift (≥ 0.03 ppm and ≤ 0.09 ppm) represented with pink. 
 
 
The strong evidence of binding of 38 to Mcl-1 based on computational studies supported by 
NMR gave us the confidence to undertake the optimization of this class of compounds utilizing 
structure-based design strategy. Therefore an SAR plan was devised to make changes to the N-1 
and C-6 aryl positions denoted as R and R’ respectively (Scheme 3.1). We wished to achieve the 
following goals: 1) understand the contribution of R and R’ to the overall binding of Mcl-1 and 
2) incorporate moieties into R from the 59 class of compounds (R1 substituents) (Chapter 2) that 
resulted in improved potency to increase the potency of this class of compounds.  
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3.3 Synthesis  
  
A short, efficient and convergent synthesis of 38 class analogs was established based on 
literature methodology with the majority of compounds made utilizing Scheme 3.1. 
 
Scheme 3.1. Generation of 1, 6-disubstituted-3-methyl-pyrazolopyridine-4-carboxylic acid 
analogsa. 
 
aReagents and conditions: (a) AcOH, reflux, 2 h, 7%-97%; (b) KOH, iPrOH, reflux, 1 h, 20%-
100%.  
 
 Acyl pyruvates 20 and 21 were obtained by Claisen condensation of 2-acetyl furan or 
acetone and diethyl oxalate11 (Scheme 3.2). This introduced the first diversity point of the library 
which is termed R’.  
 
Scheme 3.2. Synthesis of acylpyruvates 20 and 21a. 
 
aReagents and conditions: (a) Na, MeOH, rt, 1h, 26%-35%. 
 
The second diversity point (R) was introduced with varying substitutions at the pyrazole N-1 
position. Two sets of aminopyrazoles were prepared by two distinct approaches. The first series 
of aminopyrazoles (22-25) were obtained from a Michael addition of substituted hydrazines to 3-
aminocrotononitrile12 (Scheme 3.3).  
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Scheme 3.3. Synthesis of aminopyrazoles 22-25 from substituted hydrazinesa. 
 
aReagents and conditions: (a) 1N HCl, reflux, 3h, 20%-98%. 
 
For analog 11 (311), the substituted hydrazine (33) was not available but was easily 
prepared (Scheme 3.4) by alkylation of 1-phenol by 1,3-dibromopropane13 followed by 
displacement of bromide with hydrazine14.  
 
Scheme 3.4. Synthesis of aminopyrazole 34a. 
 
aReagents and conditions: (a) Br(CH2)3Br, K2CO3, acetone, reflux, 19 h, 77%; (b) H2NNH2. 
H2O, EtOH, 80 oC, 3h 30 min; (c) 2N HCl, CH2Cl2, rt, overnight; (d) H2N(CH3)=CHCN, 1N 
HCl, reflux, 3 h, 48% over three steps. 
 
When the substituted hydrazines were not commercially available or easily accessible, the 
multicomponent condensation of hydrazine, crotononitrile and arylaldehyde afforded the desired 
aminopyrazoles (26-31) (Scheme 3.5) as reported previously15, 16. The proposed mechanism by 
which this reaction works is as following: first, the Michael adduct is formed between reaction of 
crotononitrile and hydrazine. Treatment of this adduct with a desired arylaldehyde provides the 
intermediate imine (structure shown) which is not isolated, but is directly converted to the 
corresponding pyrazole via base-promoted cyclization and isomerization (Scheme 3.5). Having 
the desired acylpyruvates and aminopyrazoles in hand, the penultimate intermediates (35-48) 
were obtained from the reaction between these two building blocks in acetic acid17 (Scheme 3.1). 
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Hydrolysis of ester using potassium hydroxide in 2-propanol provided the final analogs 1-1417 
(Scheme 3.1).  
 
Scheme 3.5. Synthesis of aminopyrazoles 26-31 from arylaldehydesa. 
 
aReagents and conditions: (a) H2NNH2. H2O, THF, 40 oC, 2 h; (b) ArCHO, 40 oC, 2 h (c) t-
BuONa, iPrOH, 100 oC, 2 h 30 min or t-BuONa, n-PrOH, 110 oC, 2 h 30 min, 20%-42% over 
three steps. 
 
For analogs 15-19, Scheme 3.6 was utilized. 3-methyl-1-(4-phenoxybenzyl)-1H-pyrazol-5-
amine (28) was condensed with diethyl oxalacetate to provide ring-opened intermediate 
(structure not shown) which was cyclized to pyridinol 49 by refluxing in glacial acetic acid18. 
Chlorination of pyridone 49 with POCl3 was not successful as previously reported18. Neither did 
the use of a stoichiometric amount of Vilsmeier reagent under mild conditions yield the desired 
product. However, use of a large excess of Vilsmeier reagent under reflux conditions19 overnight 
cleanly provided 50 in high yield. Intermediate 50 then underwent Pd-catalyzed carbon-carbon 
coupling reactions20-22 with phenylvinylboronic acid or phenylacetylene to provide 52 and 53 
respectively. Intermediate 54 was obtained via hydrogenation23 of 52. Direct amination23 of 50 
with 2-aminomethylfuran or 4-(2-aminoethyl)morpholine under high temperature and long 
reaction time provided 51 and 55 respectively. Ester intermediates were hydrolyzed as 
previously described in Scheme 3.1 to provide acid analogs 15-19.  
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Scheme 3.6. Generation of analogs 15-19a. 
 
aReagents and conditions: (a) EtO2CC(ONa)=CHCO2Et , toluene/glacial AcOH/H2O, 80 oC, 
overnight; (b) glacial AcOH, reflux, 2 h, 67% over two steps; (c) (COCl)2, DMF, 1,2 DCE, 0 oC 
to rt to reflux, overnight, quantitative; (d) for 52: phenylvinylboronic acid, Pd(PPh3)4, Na2CO3, 
1,4 dioxane/H2O, 90 oC, overnight, 90% or for 53: phenylacetylene, Pd(PPh3)2Cl2, CuI, 
Et3N/THF, 60 oC, overnight, 31%; (f) for 51: 2-aminomethylfuran, iPrOH, 100 oC to 150 oC, 2 
days, 30% or for 55: 4-(2-aminoethyl)morpholine, iPrOH/NMP, 150 oC, overnight, 26%; (g) 
Pd/C, H2 (1 atm), EtOH/THF, rt, overnight, 84%; (h) KOH, iPrOH/THF, reflux, 2 h, 39%-94%  
or for 15: 1N NaOH, THF, reflux, 3 h, 61%.   
 
3.4 Structure-activity relationships 
 
In an absence of a crystal structure of 38 with Mcl-1, we set to study the contributions of R 
and R’ of 38 and gain further insight into their binding sites by systematically removing each 
group and study the obtained fragments (Table 3.1) in HSQC NMR. First, analog 2 was 
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synthesized in which a phenyl was substituted for the 3-chlorophenyl which led to 6-fold 
decrease in potency compared to 38. Subsequently removal of either the phenyl at R or the furyl 
at R’ or both, and their replacements with a methyl to give fragments 3-5 respectively, were 
studied. All three analogs did not bind up to 800 μM and showed little to no perturbations in 
HSQC NMR studies at 2-fold excess (final fragment concentration of 150 μM). This lack of 
perturbation is interesting as analog 2 (also a high micromolar binder) but having both aromatic 
groups at R and R’, shows dose-dependent perturbations of Mcl-1 residues. This result confirms 
the importance of both aromatic rings at R and R’ and their contributions to the overall potency. 
Next, the phenyl in 2 was replaced with a benzyl group in 6 which led to a 2-fold increase in 
potency. More importantly, the NMR studies (Figure 3.2) of these two analogs led to an 
important finding. When the chemical shift changes of 2 were subtracted from those caused by 6 
and the residues were mapped onto the structure of Mcl-1 (Figure 3.3A-B), it became clear that 
the residues most affected by the changes between the two structures, mainly clustered on the C-
terminal of α-helix 3 and α-helix 4, which are the residues lining the p2 pocket of Mcl-1. This 
finding indicates that the benzyl group of 6 inserts into the h2 pocket and forms additional 
hydrophobic interactions with p2 pocket. 
 
Table 3.1. Binding affinities of 38 and fragments. 
 
Cpd R R’ 
FP 
IC50 ± SD (µM) 
FP 
Ki ± SD (µM) 
LE 
1(38)  
  
103.5 ± 12.4 26.4 ± 3.1 12.9 
2  
  
580.9 ± 27.5 148.5 ± 7.0 12.0 
3   
 
> 800 > 200 -- 
4  
 
 > 800 > 200 -- 
N
N
N
OHO
R'
R
Cl O
O
CH3 O
CH3
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5    > 800 > 200 -- 
6 
  
353.1 ± 21.7 90.2 ± 5.6 12.1 
 
 
Figure 3.3. Mapping the binding site of R substituent. (A) Residues of Mcl-1 (PDB 4HW2) 
perturbed significantly in presence of 6 (green) and 2 (red) are shown and labeled. (B) Chemical 
shift perturbation (CSP) difference plot as generated by subtraction of CSP of 2 from 6 (Mcl-
1:cpd ratio of 1:2). Significant CSP difference of  >-0.015 ppm is highlighted in red and >0.015 
ppm is highlighted in green. 
 
Our NMR studies of 2 and 6 further validated our molecular docking model in which R is 
predicted to insert into the p2 pocket of Mcl-1. Therefore, we decided to synthesize analogs 
introducing R1 substituents from our first class of Mcl-1 inhibitors that led to a gain in potency as 
R1 was confirmed to also interact with h2 pocket of Mcl-1 (Table 3.2). Para-biphenylmethyl and 
para-phenoxybenzyl were introduced at R in 7 and 8, which gratifyingly exhibited Ki of 4	  μM 
and 2 μM, respectively, and an overall 7- to 12-fold improvement over 38. Both 7 and 8 have 
improved LE values compared to 38 with 8 giving the best LE of 13.3 indicating a higher free 
energy of binding per atom. The molecular docking of 7 places the para-biphenylmethyl deeper 
CH3 CH3
O
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into the p2 pocket (Figure 3.4A) which is supported by the NMR studies showing moderate to 
significant perturbations of F228, M250, and F270 of p2 pocket, clearly demonstrating the 
importance of the hydrophobic interactions in this sub-pocket (Figure 3.4B). 
 
Table 3.2. Binding affinities of analogs with variations at R. 
 
Cpd R FP
 
IC50 ± SD (µM) 
FP 
Ki ± SD (µM) 
SPR 
IC50 ± SD (µM) 
LE cLogPa 
1(38) 
  
103.5 ± 12.4 26.4 ± 3.1 160.0 12.9 3.71 
7 
 
14.8 ± 2.5 3.78 ± 0.63 11.6 13.2 4.82 
8 
 
8.6 ± 1.9 2.2 ± 0.5 6.3 13.3 4.68 
9 
 
54.6 ± 4.8 14.0 ± 1.25 19.4 11.4 -- 
10 
 
239.6 ± 19.6 61.2 ± 5.0 80.1 9.9 -- 
11 
 
> 200 > 51 -- -- 3.61 
12 
 
> 800 > 200 -- -- 3.02 
13 
 
608.1 ± 96.9 155.4 ± 24.7 -- 10.1 -- 
       a Calculated using MarvinSketch 6.2.4, ChemAxon.  
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Figure 3.4. Docking and NMR studies of 7. (A) Putative binding modes of 7 to Mcl-1 (4HW2). 
The surface of Mcl-1 is colored according to the chemical shift intensity. Residues of Mcl-1 
labeled in black are predicted to interact with 7. (B) Plot of chemical shift changes of Mcl-1 
amide upon addition of 7 (Mcl-1:7 ratio of 1:2) as a function of Mcl-1 residue numbers. Color 
legend: Significant shift (> 0.09 ppm) is represented with purple, moderate shift (≥ 0.03 ppm and 
≤ 0.09 ppm) represented with pink. 
 
The CSP plot of 8 (Figure 3.5A) also confirmed its binding to Mcl-1. To examine how the 
position of the distal phenyl ring in R substituent will affect the binding, compounds with meta- 
(9) and ortho-phenoxybenzyl substituents (10) were synthesized. Analog 9 showed a 6-fold 
decrease in binding compared to 8 while 10 decreased binding by a significant 27 fold indicating 
that there is a clear preference for the para-phenoxybenzyl in the pocket. The CSP plots derived 
from HSQC NMR (Figure 3.5A-C) of these three isomers supported the binding affinity data 
with 8 and 9 showing the highest magnitude of perturbations of residues. In addition, CSP 
demonstrated that the phenoxybenzyl substituent was placed in the p2 pocket through the 
chemical shift perturbations of V249, M250 and M231. In addition residues A227, F228, F270, 
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R263 and L267 are perturbed suggesting that carboxylic acid forms a hydrogen bond interaction 
and the 6-furyl is placed in the p3 pocket. 
        
Figure 3.5. NMR studies of 8, 9, 10. (A) Plots of chemical shift changes of Mcl-1 amide upon 
addition of  8 (Mcl-1:8 ratio of 1:2) (B) 9 (Mcl-1:9 ratio of 1:2) (C) 10 (Mcl-1:10 ratio of 1:2) as 
a function of Mcl-1 residue numbers. Color legend: Significant shift (> 0.09 ppm) is represented 
with purple, moderate shift (≥ 0.03 ppm and ≤ 0.09 ppm) represented with pink.  
 
Attempts aimed at introducing polar groups and improving clogP by incorporation of a 
para-4-pyridinebenzyl substituent in 11 or a para-methoxybenzyl in 12 (Table 3.2) led to a 
decrease in binding affinity, clearly indicating that the pocket does not tolerate polar or 
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hydrophilic groups. Finally, in analog 13, a propylphenoxy substituent was introduced at R. The 
design of this analog was based on the work of Friberg et al.7 in which it was shown that flexible 
aryl groups off the bicyclic core occupied the p2 pocket of Mcl-1. In our case, this strategy did 
not work which can be explained by a different anchoring point of the flexible aryl due to core 
scaffold differences as well as differences in distance between the aryl and the carboxylic acid 
functions.  
Next, we focused on the contribution of R’ to the overall binding affinity (Table 3.3). While 
from our earlier studies of analog 2 and its fragment, 4, missing the furyl at R’, it became clear 
that removal of furyl resulted in drop in binding affinity. The low potencies of both analogs and 
lack of CSP with 4 did not allow for in-depth NMR studies and binding site mapping of furyl 
ring. Therefore, our most potent analog 8 from Table 3.2 was selected and a corresponding 
fragment 14, where the furyl was replaced with a methyl, was synthesized and evaluated. Analog 
14 decreased binding by a significant 20 fold compared to 8 further highlighting the importance 
of the furyl to the overall binding. The NMR studies of these two compounds did not provide a 
clear picture of the binding site of R’ (Figure 3.6). The CSP difference plot of 14 and 8 (Figure 
3.6B) showed that the residues affected by the furyl are spread along α-helices 2 to 5. The reason 
for this wide area to be affected can be explained because of the nature of R’ substituent. A furyl 
at R’ of 8 is much larger than a methyl in 14, and its accommodation into the pocket requires 
conformational change by the protein which results in more perturbations.   
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Figure 3.6. Mapping the binding site of R’ substituent. (A) Residues of Mcl-1 (PDB 4HW2) 
perturbed significantly in presence of 8 (green) and 14 (red) are shown and labeled. (B) 
Chemical shift perturbation (CSP) difference plot as generated by subtraction of CSP of 14 from 
8 (Mcl-1:cpd ratio of 1:2). Significant CSP difference of  >-0.03 ppm is highlighted in red and 
>0.03 ppm is highlighted in green. 
 
Since para-phenoxybenzyl at R (8) provided the most potent analog from our series with R 
variations as well as exhibited an acceptable clogP, we decided to retain that moiety at R and 
optimize R’. Based on the docking poses of earlier analogs, while the furan was predicted to 
interact with residues in p3 pocket, its direct attachment to the bicyclic core made its placement 
in p3 pocket dependent on the R substituent. Therefore, incorporation of linkers to provide more 
degrees of freedom and a better placement in the p3 pocket were assessed. Our attempts at 
homologation of the furyl group were not successful using our synthetic Scheme 3.1; however, 
using a different chemistry (Scheme 3.6), analog 15 with an aminomethyl furan at R’ was 
obtained.  This analog exhibited a Ki = 42 µM and a 5-fold decrease in binding compared to 8. 
The decrease in binding affinity can be attributed to the introduction of a polar amine linker or an 
unfavorable direction of the furan ring in the p3 pocket. Next, analogs 16-18 with a phenyl in 
place of furyl and aliphatic linkers with different directional geometries were synthesized. All 
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three analogs 16-18 have improved potencies compared to 15, which confirms that aliphatic 
linkers are preferred, but they show 2- to 3-fold loss of binding affinity compared to 8. A more 
unexpected result for us was the similar potencies of these three analogs. While the ethyl linker 
in 18 is flexible and would allow for the phenyl to find its most favorable conformation, the trans 
ethenyl linker in 16 or the ethynyl linker in 17 with their linear geometry would provide very 
distinct and different orientations of the phenyl group. We contribute these to the different modes 
of binding of these analogs as predicted by their docking poses (Figure 3.7) in which 16 only 
provided a flipped pose (Figure 3.7A) compared to 17 and 18 (Figure 3.7B). Our attempts to 
validate the docking poses with NMR studies were not successful as all three analogs are quite 
lipophilic and were marginally soluble in our NMR assay resulting in poor quality spectra. 
Additionally, incorporation of a polar, hydrophilic group in 19 led to a decrease in binding by 
14-fold compared to 8, once again illustrating the hydrophobic nature of the pocket.  
 
Table 3.3. Binding affinities of analogs with variations at R’. 
 
Cpd R’ 
FP 
IC50 ± SD (µM) 
FP 
Ki ± SD (µM) 
LE cLogPa 
14  175.6 ± 11.3 44.9 ± 2.9 11.6 3.71 
15 
 
42.3 ± 3.7 10.8 ± 1.0 10.9 4.44 
16 
 
13.0 ± 1.0 3.3 ± 0.2 11.9 6.16 
17 
 
17.7 ± 3.2 4.5 ± 0.8 11.6 6.09 
N
N
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18 
 
22.6 ± 2.1 5.8 ± 0.5 11.3 5.99 
19 
 
193.8 ± 8.4 49.5 ± 2.1 8.82 3.45 
                               a Calculated using MarvinSketch 6.2.4, ChemAxon.  
 
              
Figure 3.7. Docking poses of 16, 17, 18. (A) Putative binding pose of 16. (B) Overlaid putative 
binding mode of 17 (yellow) and 18 (light pink).  
 
Next, the contribution of the 4-carboxylic acid, which is predicted to form an electrostatic 
interaction with R263 of Mcl-1, was investigated. The potency of methyl ester intermediates 39 
and 40 were assessed in FP-based assay. However, it was noted that the methyl ester analogs 
were fluorescent and therefore, FP-based assay cannot be used for determination of their binding 
affinity.  In addition, HSQC NMR studies of the ester analogs were not successful due to their 
inferior solubility at high concentration in our NMR assay. Thus, competitive surface plasmon 
resonance (SPR)-based assay was used, which is not interfered by the intrinsic fluorescence of 
small molecules, to determine binding affinities of these analogs. As was expected, 39 and 40 
resulted in decreased binding compared to their corresponding free acid parents (analogs 7 and 8 
respectively). 40 with an IC50 = 37 µM exhibited a 6-fold loss of binding compared to 8 
illustrating the importance of the carboxylic acid to the overall binding to Mcl-1.  
 
 
 
 
N
H
N
O
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Table 3.4. Binding affinities of esters 39 and 40. 
 
Cpd R 
SPRa 
IC50 (µM) 
cLogPb 
39 
 
> 50 5.17 
40 
 
37.2 5.02 
                                                  a Values are the mean of two experiments. b Calculated using MarvinSketch 6.2.4, ChemAxon. 
 
3.5 Selectivity studies  
 
The selectivity profile of analogs 8, 16-18 was determined against four other Bcl-2 anti-
apoptotic proteins (Bcl-2, Bcl-XL, Bcl-w, Bfl-1/A1) utilizing a competitive FP-based assays, and 
Ki values were calculated using equations developed previously24 (Table 3.5).  
 
Table 3.5. Selectivity of selected analogs against Bcl-2 anti-apoptotic proteins. 
Cpd Mcl-1 Ki ± SD (µM) 
Bfl-1/A1 
Ki ± SD (µM) 
Bcl-2 
Ki ± SD (µM) 
Bcl-w 
Ki ± SD (µM) 
Bcl-XL 
Ki ± SD (µM) 
8 2.2 ± 0.5 > 20* 16.2 > 17* > 23* 
16 3.3 ± 0.2 10.0 ± 3.2 4.6 ± 0.8 12.1 ± 1.8 23.2 ± 0.1 
17 4.5 ± 0.8 > 20* 10.9 > 17* > 23* 
18 5.8 ± 0.5 > 20* 8.5 > 17* > 23* 
            *Compounds were tested up to 100 µM. 
 
Analogs 8, 17, 18 inhibited Mcl-1 most potently with Ki values from 2.2 µM to 5.8 µM, 
followed by Bcl-2 with Ki values from 8.5 µM to 16.2 µM. While 8 showed more potent 
inhibition of Mcl-1 with an 8-fold selectivity over Bcl-2, 17 and 18 inhibited both proteins 
N
N
N
R
O OCH3
O
O
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equipotently. All three analogs showed no inhibition of Bfl-1/A1, Bcl-w, and Bcl-XL up to 100 
µM. 
Interestingly, analog 16 showed inhibition of all four anti-apoptotic proteins with a slight 
selectivity for Mcl-1, Bfl-1/A1 and Bcl-2 (Ki values ≈ 4 µM) over Bcl-w (3 fold) and Bcl-XL (6 
fold). Analog 16 shares a similar substituent at R with 17 and 18 and only differs in the geometry 
of two-carbon linker bearing a phenyl at R’. These three analogs exhibited similar binding 
affinities to Mcl-1 despite their distinct and different orientations of R’ group as discussed above, 
which we speculated can be due to the predicted flipped binding pose of 16 (Figure 3.7A). 
Therefore, it is possible that the different selectivity profile of 16 over 17 and 18 is due to its 
different binding mode. Further studies, however, are needed to confirm the binding results and 
provide evidence for analog 16 binding pose.   
3.6 Conclusions 
 
A novel class of small-molecule Mcl-1 inhibitors based on a HTS lead 38 was developed. 
Systematic removal of side chains of 38 and detailed NMR analysis of the obtained fragments 
mapped the binding site of this class of inhibitors in the BH3-binding groove of Mcl-1. The 
structure-based lead optimization was guided by computational modeling supported by NMR 
studies.  In addition our knowledge gained through the development of the 59 class of Mcl-1 
inhibitors (Chapter 2) was also applied to design more potent analogs. Utilizing an efficient 
synthetic route, 19 analogs were synthesized and their binding affinity was determined by FP- 
and SPR-based assays. An initial SAR was established, and a more potent analog 8 with an Ki of 
2 µM and 12-fold improvement in binding potency compared to 38 was developed. Analog 8 
also showed improved ligand efficiency compared to the lead compound 38 illustrating that a 
gain in molecular weight of 8 over 38 is justified by its improved binding affinity.  Selectivity 
profile of the most potent analog 8 further illustrated that it inhibited Mcl-1 most potently, 
followed by Bcl-2, but it did not show binding to A1, Bcl-w and Bcl-XL up to 100 µM. 
Interestingly, compound 16 showed similar binding affinity against Mcl-1 and Bcl-2, followed 
by A1 and Bcl-w with only 3-fold decrease in binding affinity, and an 8-fold less binding affinity 
to Bcl-XL suggesting that 16 is a pan inhibitor. Further studies are needed to confirm the 
selectivity results. Overall, 38 class of compounds with 1H-pyrazolo[3,4-b]pyridine scaffold is a 
promising class of Mcl-1 inhibitors which can be developed as dual Mcl-1 and Bcl-2 inhibitors.  
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3.7 Experimental 
Chemistry  
 
All anhydrous reactions were run under an atmosphere of dry nitrogen. Reagents were used as 
supplied without further purification. Reactions were monitored by TLC using precoated silica 
gel 60 F254 plates. Silica gel chromatography was performed with silica gel (220–240 mesh) 
obtained from Silicycle. Purities of final compounds were assessed by analytical HPLC 
performed on a Shimadzu system with a Restek Ultra C18 (4.6 x 150 mm, 5µm particle size) 
column or an Agilent 1100 series with an Agilent Zorbax Eclipse Plus−C18 column and a 
gradient of acetonitrile with 0.1 vol% TFA (10-90%) in water with 0.1 vol% TFA. All NMR 
spectra were obtained in DMSO-d6 or CDCl3 and results were recorded at 400 MHz on a Varian 
400 instrument or at 500 MHz on a Varian 500 instrument. Mass spectrometry analysis was 
performed using a Waters LCT time-of-flight mass spectrometry instrument utilizing 
electrospray ionization operating in positive-ion (ESI+) or negative-ion (ESI-) modes where 
indicated.  
 
A representative procedure for synthesis of acyl pyruvates.  
 
Methyl 4-(furan-2-yl)-2,4-dioxobutanoate (20).11 To a stirred solution of MeOH (150 mL) at 
room temperature under nitrogen, freshly cut Na (1.81g, 78.7 mmol) was added in pieces and 
with care. After all the sodium dissolved, a mixture of 2-acetylfuran (6 mL, 59.8 mmol) and 
diethyl oxalate (8.14 mL, 59.9 mmol) was added dropwise over a period of 3 min at room 
temperature. The resulting mixture was continued to stir. Brown precipitates formed after 20 min 
stir. The mixture was stirred for a total of 1h. The reaction mixture was cooled to 0oC, and a 
mixture of concentrated H2SO4 and ice was added. Some solid precipitated at this point which 
was filtered off but was not the desired product by 1H NMR. The filterate was extracted with 
CH2Cl2 (50 mL x 2). The combined organic layers were washed with brine, dried (Na2SO4), 
filtered, and concentrated under reduced pressure. The crude was recrystallized from hot iPrOH 
to give the title compound (4.15 g, 35%) as a dark brown solid. 1H NMR (400 MHz, CDCl3) δ 
7.67-7.65 (m, 1H), 7.33 (d, J = 3.6 Hz, 1H), 6.93 (s, 1H), 6.60 (dd, J = 3.5, 1.5 Hz, 1H), 3.91 (s, 
O O
O
OCH3
O
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3H). 13C NMR (100 MHz, CDCl3) δ 181.01, 165.39, 162.43, 150.82, 147.73, 118.58, 113.14, 
99.17, 53.18. 
 
Methyl 2,4-dioxopentanoate (21). Synthesized using the procedure for 20 except acetone was 
used as one of the starting material. Crude was subjected to flash column chromatography on 
silica gel to provide the title compound (1.36 g, 26%) as a white gel. 1H NMR (500 MHz, 
CDCl3) δ 6.38 (s, 1H), 3.90 (s, 3H), 2.26 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 199.96, 166.58, 
162.48, 102.20, 53.10, 27.61. 
 
A representative procedure for synthesis of aminopyrazoles from substituted hydrazines.  
 
1-(3-Chlorophenyl)-3-methyl-1H-pyrazol-5-amine (22).12 A solution of 3-aminocrotonitrile 
(mixture of cis and trans) (1.50 g, 17.5 mmol) and 3-chlorophenylhydrazine hydrochloride (3.0 
g, 16.2 mmol) in 25 mL of 1N HCl was heated to reflux for 3 h under nitrogen. The reaction 
mixture was diluted with H2O (30 mL) and extracted with EtOAc (20 mL x 2). The combined 
organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The crude was recrystallized from hot iPrOH to give the title compound (677 mg, 20%) 
as a beige fluffy solid. 1H NMR (500 MHz, CDCl3) δ 7.62 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.37 
(t, J = 8.0 Hz, 1H), 7.28 (d, J = 9.5 Hz, 1H), 5.46 (s, 1H), 2.22 (s, 3H). 13C NMR (125 MHz, 
CDCl3) δ 149.95, 145.30, 139.87, 135.05, 130.32, 126.86, 123.67, 121.28, 91.41, 13.89. 
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3-Methyl-1-phenyl-1H-pyrazol-5-amine (23). Synthesized using the procedure for 22 except 
phenyl hydrazine was used as the hydrazine. Recrystallization of crude from hot EtOH provided 
the title compound (1.28 g, 37%) as pink crystals. 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 
7.51 (s, 1H), 7.44 (t, J = 7.5 Hz, 2H), 7.30 (t, J = 7.4 Hz, 1H), 5.43 (s, 1H), 3.77 (s, 2H), 2.22 (s, 
3H). 13C NMR (100 MHz, CDCl3) δ 149.37, 145.21, 138.65, 129.38, 126.99, 123.77, 90.68, 
13.93. 
 
1,3-Dimethyl-1H-pyrazol-5-amine (24). Synthesized using the procedure for 22 except methyl 
hydrazine was used as the hydrazine. Recrystallization of crude from hot CH2Cl2 provided the 
title compound (908 mg, 45%) as clear crystals. 1H NMR (400 MHz, CDCl3) δ 5.30 (s, 1H), 3.55 
(s, 3H), 2.11 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 147.16, 144.96, 90.79, 33.83, 13.78. 
 
1-Benzyl-3-methyl-1H-pyrazol-5-amine (25). Synthesized using the procedure for 22 except 
benzyl hydrazine dihydrochloride was used as the hydrazine. After the reaction mixture was 
stopped and cooled to room temperature, solid precipitated which was filtered off and dried in 
vacuum oven to provide the title compound (3.6 g, 98%) as a white solid. 1H NMR (400 MHz, 
DMSO-d6) δ 7.40-7.34 (m, 2H), 7.34-7.27 (m, 3H), 5.57 (s, 1H), 5.35 (s, 2H), 2.18 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ 151.48, 146.65, 135.16, 129.19, 128.61, 128.00, 91.19, 49.13, 11.44. 
 
A representative procedure for synthesis of aminopyrazoles from arylaldehydes.  
 
N
N NH2
N
N NH2
N
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1-([1,1'-Biphenyl]-4-ylmethyl)-3-methyl-1H-pyrazol-5-amine (26).16 To a solution of 
hydrazine monohydrate (hydrazine 78-82%) (0.51 ml, 10.5 mmol) in TΗF (2 mL), crotononitrile 
(mixture of cis and trans) (0.82 ml, 10.1 mmol) was added dropwise. The mixture was stirred at 
40 0C for 2 h. The mixture was allowed to cool to room temperature and biphenyl-4-
carboxaldehyde (1.82 g, 10.0 mmol) was added. The mixture was stirred at 40 0C for 2 h. The 
mixture was concentrated under reduced pressure. To the resulting yellow solid was added 
iPrOH (15 mL) and the suspension was transferred to a pressure vessel. t-BuONa (993 mg, 10.3 
mmol) was added and the mixture was stirred at 100 0C for 2 h 30 min. The mixture was allowed 
to cool to room temperature and diluted with water (50 mL). The mixture was extracted with 
Et2O (50 mL x 2). The combined organic layers were extracted with IN aq. HCl (2 x 30 mL). 
The combined aqueous phases were basified to pΗ 14 with 50 % aq. NaOH and extracted with 
Et2O (50 mL x 2). The combined organic layers were washed with brine, dried (Na2SO4), 
filtered, and concentrated under reduced pressure to provide the title compound (885 mg, 34% 
over three steps) as a yellow solid.  Crude was used in the next reaction without further 
purification. 1H NMR (500 MHz, DMSO-d6) δ 7.68-7.61 (m, 4H), 7.45 (t, J = 7.5 Hz, 2H), 7.39 
(d, J = 7.9 Hz, 2H), 7.37-7.33 (m, 1H), 5.59 (s, 1H), 5.38 (s, 2H), 2.20 (s, 3H). 13C NMR (125 
MHz, DMSO-d6) δ 151.46, 146.77, 140.52, 139.98, 134.32, 129.40, 128.62, 128.09, 127.51, 
127.14, 91.23, 48.92, 11.54. 
 
3-Methyl-1-(4-phenoxybenzyl)-1H-pyrazol-5-amine (27). Synthesized using the procedure for 
26 except 4-phenoxybenzaldehyde was used as the aldehyde. Title compound (994 mg, 35% 
over three steps) was obtained as a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 7.38 (dd, J = 
17.2, 8.5 Hz, 4H), 7.17-7.13 (m, 1H), 7.03-6.98 (m, 4H), 5.58 (s, 1H), 5.32 (s, 2H), 2.19 (s, 3H). 
13C NMR (125 MHz, DMSO-d6) δ 157.12, 156.73, 151.33, 146.70, 130.56, 130.06, 130.04, 
124.17, 119.24, 119.12, 91.24, 48.61, 11.51. 
A modified procedure for synthesis of aminopyrazoles from arylaldehydes.  
N
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3-Methyl-1-(3-phenoxybenzyl)-1H-pyrazol-5-amine (28).15 To a solution of hydrazine 
monohydrate (hydrazine 78-82%) (0.80 ml, 16.5 mmol) in TΗF (3 mL), crotononitrile (mixture 
of cis and trans) (1.1 ml, 13.5 mmol) was added dropwise. The mixture was stirred at 40 0C for 2 
h. The mixture was allowed to cool to room temperature and 3-phenoxybenzaldehyde (2.14 ml, 
12 mmol) was added dropwise. The mixture was stirred at 40 0C for 2 h. The mixture was 
concentrated under reduced pressure. To the resulting intermediate was added nPrOH (10 mL) 
and the suspension was transferred to a pressure vessel. t-BuONa (1.41 g, 14.7 mmol) was added 
and the mixture was stirred at 110 0C for 2 h 30 min. The mixture was allowed to cool to room 
temperature and diluted with water (50 mL). The mixture was extracted with Et2O (50 mL x 2). 
The combined organic layers were extracted with 1N aq. HCl (2 x 30 mL). The combined 
aqueous phases were basified to pΗ 14 with 50 % aq. NaOH and extracted with Et2O (50 mL x 
2). The combined organic layers were washed with brine, dried (Na2SO4), filtered, and 
concentrated under reduced pressure to provide the title compound (670 mg, 20% over three 
steps) as an orange oil. Crude was used in the next reaction without further purification. 1H NMR 
(500 MHz, CDCl3) δ 7.32 (t, J = 7.0 Hz, 2H), 7.25 (t, J = 7.8 Hz, 1H), 7.10 (t, J = 6.9 Hz, 1H), 
6.98 (d, J = 7.8 Hz, 2H), 6.85 (t, J = 7.6 Hz, 2H), 6.80 (s, 1H), 5.37 (d, J = 2.6 Hz, 1H), 5.10 (s, 
2H), 2.17 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 157.81, 156.75, 147.74, 145.05, 139.08, 
130.19, 129.75, 123.46, 121.22, 119.04, 117.63, 116.99, 91.65, 50.86, 13.92. 
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3-Methyl-1-(2-phenoxybenzyl)-1H-pyrazol-5-amine (29). Synthesized using the procedure for 
28 except 2-phenoxybenzaldehyde was used as the aldehyde. Title compound (485 mg, 34% 
over three steps) was obtained as an off-white solid. Crude was used in the next reaction without 
further purification.  1H NMR (500 MHz, CDCl3) δ 7.34 (t, J = 7.1 Hz, 2H), 7.24-7.17 (m, 2H), 
7.12 (t, J = 7.1 Hz, 1H), 7.08 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 7.9 Hz, 2H), 6.84 (d, J = 8.1 Hz, 
1H), 5.32 (s, 1H), 5.15 (s, 2H), 3.63 (s, 2H), 2.17 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 156.75, 
153.93, 147.82, 145.11, 129.94, 129.69, 129.09, 127.98, 124.16, 123.61, 118.48, 118.38, 90.68, 
45.69, 14.00. 
 
3-Methyl-1-(4-(pyridin-4-yl)benzyl)-1H-pyrazol-5-amine (30). Synthesized using the 
procedure for 28 except 4-pyridine-4-benzaldehyde was used as the aldehyde. The title 
compound (274 mg, 20% over three steps) was obtained as a white solid. Crude was used in the 
next reaction without further purification. 1H NMR (500 MHz, CDCl3) δ 8.63 (d, J = 4.5 Hz, 
2H), 7.58 (d, J = 8.1 Hz, 2H), 7.45 (d, J = 4.5 Hz, 2H), 7.26 (d, J = 7.3 Hz, 2H), 5.42 (s, 1H), 
5.19 (s, 2H), 3.38 (s, 2H), 2.20 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 150.26, 147.88, 147.72, 
144.98, 138.06, 137.49, 127.48, 121.48, 91.83, 50.82, 13.97. 
 
1-(4-Methoxybenzyl)-3-methyl-1H-pyrazol-5-amine (31). Synthesized using the procedure for 
26 except p-anisaldehyde was used as the aldehyde. Title compound (910 mg, 42% over three 
steps) was obtained as a yellow oil which solidified upon standing.  Crude was used in the next 
reaction without further purification.1H NMR (500 MHz, DMSO-d6) δ 7.09 (d, J = 8.3 Hz, 2H), 
6.84 (d, J = 8.3 Hz, 2H), 5.10 (s, 2H), 5.07 (s, 1H), 4.90 (s, 2H), 3.70 (s, 3H), 1.94 (s, 3H). 13C 
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NMR (125 MHz, DMSO-d6) δ 158.73, 147.58, 146.13, 130.82, 129.05, 114.05, 88.29, 55.49, 
49.31, 14.30. 
 
(3-Bromopropoxy)benzene (32).13 1-Phenol (1.03 g, 10.9 mmol), 1,3-dibromopropane (16 mL, 
158 mmol), and K2CO3 (7.43 g, 53.8 mmol) were combined and suspended in acetone (100 mL). 
The mixture was stirred under reflux for 19 h, then filtered to remove the base and concentrated 
under reduced pressure. The crude was placed on high vacuum and provide the title compound 
(1.81 g, 77%) as a clear oil. Crude was used in the next reaction without further purification. 1H 
NMR (400 MHz, CDCl3) δ 7.29 (t, J = 7.6 Hz, 2H), 6.96 (t, J = 7.8 Hz, 1H), 6.91 (d, J = 7.8 Hz, 
2H), 4.10 (t, J = 5.8 Hz, 2H), 3.61 (t, J = 6.1 Hz, 2H), 2.37-2.28 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 158.62, 129.48, 120.89, 114.47, 65.12, 32.39, 30.12. 
 
(3-Phenoxypropyl)hydrazine hydrochloride (33).14  32 (1.80 g, 8.4 mmol) was dissolved in 
EtOH (9 mL) followed by addition of hydrazine monohydrate (hydrazine 78-82%) (4.5 ml, 93 
mmol). The solution was heated at 80 °C for 3h 30 min. After cooling to room temperature, the 
reaction mixture was concentrated under reduced pressure and the crude was treated with 2N 
HCI (7 mL) and dichloromethane (4 mL) while stirring at room temperature overnight. The 
crude was placed on high vacuum to remove solvent and then used without further purification in 
the next reaction.  
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3-Methyl-1-(3-phenoxypropyl)-1H-pyrazol-5-amine (34). Synthesized using the procedure for 
22 except 33 was used as crude and as the hydrazine. After the reaction mixture was stopped and 
cooled down to room temperature, the reaction mixture was diluted with H2O and extracted with 
EtOAC (2x). Combined organic layers were washed with brine, dried (Na2SO4), filtered, and 
concentrated under reduced pressure. Crude was subjected to flash column chromatography on 
silica gel to provide the title compound (663 mg, 48% over two steps) as a yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 7.23 (t, J = 7.2 Hz, 2H), 6.92 (t, J = 7.0 Hz, 1H), 6.84 (d, J = 8.0 Hz, 2H), 
5.21 (s, 1H), 4.03 (t, J = 6.2 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 3.65 (s, 2H), 2.22-2.14 (m, 2H), 
2.11 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 158.19, 147.73, 145.69, 129.59, 121.12, 114.43, 
90.07, 63.94, 42.66, 29.16, 13.92. 
 
A representative procedure for synthesis of esters. 
 
Methyl 1-(3-chlorophenyl)-6-(furan-2-yl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (35).17 A solution of 22 (306 mg, 1.47 mmol) and 20 (295 mg, 1.50 mmol) in 
glacial AcOH (10 mL) was heated to reflux for 3 h. When the reaction mixture was cooled down 
to room temperature, yellow precipitates formed which were filtered and washed with H2O. 
Filtercake was placed in a vacuum oven to give the title compound (470 mg, 87%) as a yellow 
solid. 1H NMR (500 MHz, CDCl3) δ 8.48 (s, 1H), 8.29 (d, J = 9.1 Hz, 1H), 8.06 (s, 1H), 7.62 (s, 
1H), 7.43 (t, J = 8.1 Hz, 1H), 7.28-7.23 (m, 2H), 6.63-6.59 (m, 1H), 4.06 (s, 3H), 2.75 (s, 3H). 
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13C NMR (125 MHz, CDCl3) δ 165.53, 152.95, 151.82, 148.42, 144.43, 143.32, 140.31, 134.59, 
133.91, 129.93, 125.41, 120.77, 118.52, 113.87, 112.57, 112.24, 110.94, 52.73, 16.21. 
 
Methyl 6-(furan-2-yl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylate (36). 
Synthesized using the procedure for 35 except 23 was used as the amine. After reaction mixture 
was stopped and cooled down to room temperature, yellow precipitates formed which were 
filtered, washed with H2O and dried in vacuum oven to give the title compound (971 mg, 97%) 
as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 8.6 Hz, 2H), 8.05 (s, 1H), 7.59 (s, 
1H), 7.52 (t, J = 7.7 Hz, 2H), 7.29 (t, J = 7.2 Hz, 1H), 7.23 (s, 1H), 6.58 (s, 1H), 4.04 (s, 3H), 
2.76 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 165.73, 153.12, 151.69, 148.28, 144.27, 142.68, 
139.24, 133.75, 128.94, 125.73, 121.17, 113.67, 112.45, 111.91, 110.70, 52.68, 16.19. 
 
Methyl 6-(furan-2-yl)-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylate (37).  
Synthesized using the procedure for 35 except 24 was used as the pyrazole amine. Crude was 
subjected to flash column chromatography on silica gel to provide the title compound (616mg, 
76%) as a light pink solid. 1H NMR (400 MHz, CDCl3) δ 7.93 (s, 1H), 7.59-7.56 (m, 1H), 7.17 
(d, J = 3.4 Hz, 1H), 6.55 (dd, J = 3.4, 1.7 Hz, 1H), 4.07 (s, 3H), 3.99 (s, 3H), 2.65 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ 165.82, 153.11, 152.14, 147.83, 144.15, 140.61, 133.27, 113.10, 
112.33, 110.30, 109.86, 52.52, 33.62, 16.00. 
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Methyl 1-benzyl-6-(furan-2-yl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylate (38). 
Synthesized using the procedure for 35 except 25 was used as the pyrazole amine. Crude was 
subjected to flash column chromatography on silica gel to provide the title compound (97 mg, 
9%) as a light yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.67 (s, 1H), 7.33 (d, J = 
7.2 Hz, 2H), 7.28 (t, J = 7.2 Hz, 2H), 7.26-7.21 (m, 1H), 7.08-7.04 (m, 1H), 6.61 (dd, J = 3.5, 1.8 
Hz, 1H), 5.73 (s, 2H), 4.04 (s, 3H), 2.72 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 165.99, 152.08, 
150.69, 146.13, 144.45, 141.45, 137.02, 133.86, 128.53, 127.97, 127.62, 114.14, 112.40, 112.23, 
111.85, 53.00, 50.45, 16.69. 
 
Methyl 1-([1,1'-biphenyl]-4-ylmethyl)-6-(furan-2-yl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-
4-carboxylate (39). Synthesized using the procedure for 35 except 26 was used as the pyrazole 
amine. Crude was subjected to flash column chromatography on silica gel to provide the title 
compound (87 mg, 7%) as an off-white solid. 1H NMR (500 MHz, CDCl3) δ 8.10 (s, 1H), 7.70 
(s, 1H), 7.54 (t, J = 7.5 Hz, 4H), 7.42 (dd, J = 14.2, 7.9 Hz, 4H), 7.32 (t, J = 7.4 Hz, 1H), 7.08 (d, 
J = 3.4 Hz, 1H), 6.64 (dd, J = 3.4, 1.7 Hz, 1H), 5.79 (s, 2H), 4.07 (s, 3H), 2.76 (s, 3H). 13C NMR 
(125 MHz, CDCl3) δ 166.00, 152.12, 150.72, 146.21, 144.47, 141.55, 140.79, 140.60, 136.05, 
133.93, 128.71, 128.46, 127.33, 127.24, 127.06, 114.20, 112.42, 112.26, 111.92, 53.01, 50.20, 
16.71.  
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Methyl 6-(furan-2-yl)-3-methyl-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (40). Synthesized using the procedure for 35 except 27 was used as the pyrazole 
amine. Crude was subjected to flash column chromatography on silica gel to provide the title 
compound (478 mg, 43%) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 8.03 (s, 1H), 7.61 (s, 
1H), 7.37 (d, J = 8.3 Hz, 2H), 7.30 (t, J = 7.7 Hz, 2H), 7.25 (d, J = 3.4 Hz, 1H), 7.08 (t, J = 7.4 
Hz, 1H), 6.97 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.3 Hz, 2H), 6.61-6.58 (m, 1H), 5.66 (s, 2H), 4.04 
(s, 3H), 2.70 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 165.91, 157.01, 156.82, 153.27, 152.10, 
148.09, 144.18, 141.35, 133.53, 132.00, 129.70, 129.59, 123.29, 118.95, 118.79, 113.33, 112.41, 
110.37, 110.19, 52.59, 49.88, 16.12. 
 
Methyl 6-(furan-2-yl)-3-methyl-1-(3-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (41). Synthesized using the procedure for 35 except 28 was used as the pyrazole 
amine. Crude was subjected to flash column chromatography on silica gel to provide the title 
compound (563 mg, 82%) as a yellow viscous oil. 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 
7.58 (s, 1H), 7.30-7.20 (m, 3H), 7.18-7.14 (m, 1H), 7.09-7.02 (m, 2H), 7.00 (s, 1H), 6.97-6.92 
(m, 2H), 6.89-6.83 (m, 1H), 6.57 (s, 1H), 5.65 (s, 2H), 4.03 (s, 3H), 2.69 (s, 3H). 13C NMR (100 
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MHz, CDCl3) δ 165.89, 157.48, 156.78, 153.17, 152.21, 148.11, 147.73, 144.13, 141.47, 139.13, 
133.52, 129.84, 129.66, 123.32, 122.47, 119.03, 118.18, 117.69, 113.36, 112.40, 110.42, 52.59, 
50.11, 16.11. ESI MS: m/z 440.1 (M+H)+. 
 
Methyl 6-(furan-2-yl)-3-methyl-1-(2-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (42). Synthesized using the procedure for 35 except 29 was used as the pyrazole 
amine. Crude was subjected to flash column chromatography on silica gel to provide the title 
compound (551 mg, 81%) as a yellow oil which formed a foam upon standing. 1H NMR (500 
MHz, CDCl3) δ 7.98 (s, 1H), 7.57 (s, 1H), 7.27-7.18 (m, 3H), 7.13-7.10 (m, 1H), 7.09-7.05 (m, 
1H), 7.05-6.99 (m, 2H), 6.90 (t, J = 7.1 Hz, 3H), 6.56-6.53 (m, 1H), 5.80 (s, 2H), 4.03 (s, 3H), 
2.66 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 165.95, 157.40, 154.05, 153.25, 152.40, 147.97, 
144.01, 141.35, 133.34, 129.48, 129.39, 128.98, 128.84, 123.88, 122.70, 119.32, 117.90, 113.19, 
112.32, 110.35, 109.99, 52.53, 45.19, 16.09. 
 
Methyl 6-(furan-2-yl)-3-methyl-1-(4-(pyridin-4-yl)benzyl)-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (43). Synthesized using the procedure for 35 except 30 was used as the pyrazole 
amine. Crude was subjected to flash column chromatography on silica gel to provide the title 
compound (261 mg, 62%) as an off-white solid. 1H NMR (500 MHz, CDCl3) δ 8.64-8.58 (m, 
2H), 8.03 (s, 1H), 7.60 (s, 1H), 7.55 (d, J = 7.8 Hz, 2H), 7.46 (d, J = 7.8 Hz, 2H), 7.45-7.40 (m, 
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2H), 7.27-7.22 (m, 1H), 6.58 (s, 1H), 5.73 (s, 2H), 4.03 (s, 3H), 2.69 (s, 3H). 13C NMR (125 
MHz, CDCl3) δ 165.84, 153.21, 152.25, 150.19, 148.18, 147.87, 144.21, 141.62, 138.19, 137.46, 
133.62, 128.70, 127.21, 121.49, 113.42, 112.40, 110.42, 110.21, 52.59, 50.00, 16.10. 
 
Methyl 6-(furan-2-yl)-1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (44). Synthesized using the procedure for 35 except 31 was used as the pyrazole 
amine. Crude was subjected to flash column chromatography on silica gel to provide the title 
compound (458 mg, 40%) as a light yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 
7.59 (s, 1H), 7.33 (d, J = 7.1 Hz, 2H), 7.27- 7.20 (m, 1H), 6.81 (d, J = 7.1 Hz, 2H), 6.62-6.55 (m, 
1H), 5.61 (s, 2H), 4.01 (s, 3H), 3.74 (s, 3H), 2.67 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 165.94, 
159.07, 153.31, 152.01, 147.98, 144.10, 141.16, 133.43, 129.45, 129.37, 113.89, 113.22, 112.38, 
110.26, 110.17, 55.21, 52.56, 49.93, 16.11. 
 
Methyl 6-(furan-2-yl)-3-methyl-1-(3-phenoxypropyl)-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (45). Synthesized using the procedure for 35 except 32 was used as the pyrazole 
amine. Crude was subjected to flash column chromatography on silica gel to provide the title 
compound (388 mg, 35%) as an off-white solid. 1H NMR (500 MHz, CDCl3) δ 7.99 (s, 1H), 7.58 
(s, 1H), 7.27-7.21 (m, 2H), 7.10 (s, 1H), 6.91 (t, J = 6.9 Hz, 1H), 6.87 (d, J = 8.7 Hz, 2H), 6.55 
(dd, J = 3.3, 1.7 Hz, 1H), 4.72 (t, J = 6.8 Hz, 2H), 4.04 (s, 3H), 4.03-4.01 (m, 2H), 2.70 (s, 3H), 
2.45 (p, J = 6.4 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ 165.96, 158.82, 153.18, 152.21, 147.93, 
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144.06, 140.90, 133.39, 129.34, 120.62, 114.52, 113.21, 112.36, 110.29, 110.02, 65.08, 52.57, 
43.83, 29.58, 16.06. 
 
Methyl 3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylate (46). Synthesized 
using the procedure for 35 except 21 and 23 were used as the starting materials. Crude was 
subjected to flash column chromatography on silica gel to provide the title compound (309 mg, 
36%) as a light yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 7.6 Hz, 2H), 7.53-7.46 
(m, 3H), 7.31-7.24 (m, 1H), 4.01 (s, 3H), 2.74 (s, 3H), 2.72 (s, 3H). 13C NMR (100 MHz, CDCl3) 
δ 166.04, 158.80, 151.85, 142.31, 139.23, 132.97, 128.94, 125.77, 121.38, 118.13, 111.10, 52.56, 
24.91, 16.15. 
 
Methyl 1,3,6-trimethyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylate (47). Synthesized using the 
procedure for 35 except 21 and 24 were used as the starting materials. Crude was subjected to 
flash column chromatography on silica gel to provide the title compound (266 mg, 40%) as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 7.41 (s, 1H), 4.06 (s, 3H), 3.99 (s, 3H), 2.68 (s, 3H), 
2.65 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 166.20, 158.21, 152.29, 140.27, 132.69, 117.38, 
109.19, 52.44, 33.61, 24.70, 15.96. 
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Methyl 3,6-dimethyl-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylate (48). 
Synthesized using the procedure for 35 except 20 and 27 were used as starting materials. Crude 
was subjected to flash column chromatography on silica gel to provide the title compound (67 
mg, 12%) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.45 (s, 1H), 7.33-7.28 (m, 4H), 7.08 (t, 
J = 7.4 Hz, 1H), 6.98 (d, J = 7.7 Hz, 2H), 6.92 (d, J = 7.3 Hz, 2H), 5.63 (s, 2H), 4.01 (s, 3H), 
2.71 (s, 3H), 2.68 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 166.21, 158.43, 157.06, 156.71, 
152.26, 140.98, 132.78, 132.14, 129.68, 129.35, 123.25, 118.91, 118.79, 117.65, 109.33, 52.45, 
49.62, 24.77, 16.08. 
 
Ethyl 6-hydroxy-3-methyl-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 
(49).18 A solution of diethyl oxaloacetate sodium salt (516 mg, 2.46 mmol) and 28 (646 mg, 2.31 
mmol) in a mixture of toluene: H2O: glacial AcOH  (5 mL/5 mL/0.5 mL) was heated at 80 °C 
overnight. The mixture was diluted with H2O (20 mL) and extracted with EtOAc (20 mL x 2). 
Combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure to provide the desired crude. Crude was used in the next reaction without 
further purification. 
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A suspension of diethyl 2-(5-amino-3-methyl-1-(4-phenoxybenzyl)-1H-pyrazol-4-yl)-2-
hydroxysuccinate (crude from above) (2.31 mmol) from x in glacial AcOH (14 mL) was refluxed 
for 2 h. The mixture was concentrated under reduced pressure as much as possible. Then MeOH 
was added and the product crystallized as a white solid which was filtered, washed with cold 
MeOH and dried in a vacuum oven to provide the title compound (628 mg, 67% over two steps) 
as a tan solid. 1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 8.3 Hz, 2H), 7.31 (t, J = 7.3 Hz, 2H), 
7.09 (t, J = 7.4 Hz, 1H), 6.97 (d, J = 8.0 Hz, 2H), 6.92 (d, J = 8.4 Hz, 2H), 6.78 (s, 1H), 5.50 (s, 
2H), 4.44 (q, J = 7.1 Hz, 2H), 2.53 (s, 3H), 1.43 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) 
δ 164.83, 164.75, 157.17, 156.81, 143.45, 143.12, 139.06, 130.59, 129.72, 129.51, 123.43, 
119.11, 118.70, 113.27, 103.16, 62.13, 50.60, 15.44, 14.16. ESI MS: m/z 404.1 (M+H)+. 
 
Ethyl 6-chloro-3-methyl-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 
(50).19 Fresh Vilsmeier’s reagent was prepared as follows: to a stirring solution of 1,2 DCE (4 
mL) was added DMF (0.2 mL, 2.6 mmol). The resulting solution was cooled down to 0 oC and 
(COCl)2 (0.22 mL, 2.6 mmol) was added dropwise. The viscous suspension was stirred at room 
temperature for 10 min, and then 49 (104 mg, 0.26 mmol) was added to the mixture. The 
suspension was heated to reflux overnight. The mixture was diluted with H2O (10 mL) and 
extracted with EtOAc (15mL x 2). The organic layers were washed with brine, dried (Na2SO4) 
and concentrated under reduced pressure to provide the title compound (120 mg, quantitative 
yield) as a yellow oil. Crude was used in the next reaction without further purification. 1H NMR 
(500 MHz, CDCl3) δ 7.56 (s, 1H), 7.31 (t, J = 8.2 Hz, 4H), 7.08 (t, J = 7.4 Hz, 1H), 6.97 (d, J = 
7.7 Hz, 2H), 6.93 (d, J = 8.5 Hz, 2H), 5.59 (s, 2H), 4.48 (q, J = 7.1 Hz, 2H), 2.69 (s, 3H), 1.46 (t, 
J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 164.34, 157.00, 156.91, 151.20, 150.30, 141.77, 
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135.67, 131.25, 129.71, 129.54, 123.37, 119.00, 118.78, 117.69, 110.41, 62.31, 50.03, 16.16, 
14.20. 
 
Ethyl 6-((furan-2-ylmethyl)amino)-3-methyl-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-
b]pyridine-4-carboxylate (51).23 A pressure vessel was charged with 50 (119 mg, 0.28 mmol), 
2-aminomethylfuran (0.12 mL, 1. 36 mmol) and iPrOH (4mL). The vessel was sealed and the 
reaction mixture was heated at 100 °C overnight. An additional 1 mL (11.3 mmol) of amine was 
added and the mixture was heated at 150 °C overnight. The reaction mixture was diluted with 
H2O (10 mL) and extracted with EtOAc (15 mL x 2). Combined organic layers were washed 
with brine, dried (Na2SO4) and concentrated under reduced pressure. Crude was subjected to 
flash column chromatography on silica gel to provide the title compound (40 mg, 30%) as an 
orange oil. 1H NMR (400 MHz, CDCl3) δ 7.36-7.24 (m, 5H), 7.07 (t, J = 7.3 Hz, 1H), 6.97 (d, J 
= 8.2 Hz, 2H), 6.91 (d, J = 8.2 Hz, 2H), 6.80 (s, 1H), 6.30 (s, 1H), 6.22 (s, 1H), 5.47 (s, 2H), 5.14 
(t, J = 5.4 Hz, 1H), 4.68 (d, J = 5.5 Hz, 2H), 4.43 (q, J = 7.1 Hz, 2H), 2.58 (s, 3H), 1.42 (t, J = 
7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 165.83, 157.16, 156.86, 156.51, 152.16, 152.06, 
141.97, 141.27, 134.71, 132.57, 129.67, 129.44, 123.17, 118.82, 110.40, 107.27, 106.91, 104.45, 
61.66, 49.53, 38.75, 16.15, 14.23. ESI MS: m/z 483.1 (M+H)+. 
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(E)-Ethyl 3-methyl-1-(4-phenoxybenzyl)-6-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 
(52).20, 21 To a mixture of 50 (205 mg, 0.49 mmol), Pd(PPh3)4 (27 mg, 0.02 mmol) and (E)-2-
phenylvinylboronic acid (112 mg, 0.74 mmol) in 1,4-dioxane: H2O (3mL/2mL) was added 
Na2CO3 (153 mg, 1.45 mmol), followed by stirring at 90 °C overnight. To the reaction mixture 
was added H2O (10 mL) and the aqueous layer was extracted with EtOAc (10 mL x 2). The 
combined organic layer was washed with brine, dried (Na2SO4), filtered and concentrated under 
reduced pressure. Crude was subjected to flash column chromatography on silica gel to provide 
the title compound (216 mg, 90%) as a light yellow oil which solidified upon standing. 1H NMR 
(500 MHz, CDCl3) δ 7.80 (d, J = 16.1 Hz, 1H), 7.74 (s, 1H), 7.63 (d, J = 7.6 Hz, 2H), 7.41 (t, J = 
7.6 Hz, 2H), 7.39-7.33 (m, 3H), 7.30 (t, J = 7.7 Hz, 3H), 7.07 (t, J = 7.4 Hz, 1H), 6.98 (d, J = 8.6 
Hz, 2H), 6.95 (d, J = 8.3 Hz, 2H), 5.69 (s, 2H), 4.51 (q, J = 7.1 Hz, 2H), 2.71 (s, 3H), 1.49 (t, J = 
7.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 165.76, 157.04, 156.79, 154.93, 152.39, 141.19, 
136.28, 134.74, 133.60, 132.13, 129.69, 129.50, 128.81, 127.69, 127.33, 123.28, 118.94, 118.82, 
116.48, 110.28, 61.93, 49.80, 16.30, 14.30. 
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Ethyl 3-methyl-1-(4-phenoxybenzyl)-6-(phenylethynyl)-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (53).22 A mixture of 50 (95 mg, 0.22 mmol), Pd(PPh3)2Cl2 (16 mg, 0.02 mmol), and 
CuI (8.6 mg, 0.04 mmol) in Et3N (0.5 mL) and dry THF (1 mL) was added dropwise to a 
solution of phenylacetylene (40 µL, 0.36 mmol) in Et3N (0.5 mL) under nitrogen at room 
temperature. Reaction mixture was heated to 60oC and stirred overnight then diluted with EtOAc 
(10 mL) and washed with saturated aqueous NH4Cl (15 mL x 2) and brine (15 mL). The organic 
layer was dried (Na2SO4), filtered, concentrated under reduced pressure. The crude was purified 
by flash column chromatography on silica gel to give the title compound (33 mg, 31%) as an 
orange oil.  1H NMR (500 MHz, CDCl3) δ 7.81 (s, 1H), 7.68-7.63 (m, 2H), 7.42-7.37 (m, 3H), 
7.35-7.29 (m, 4H), 7.08 (t, J = 7.6 Hz, 1H), 6.97 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 
5.68 (s, 2H), 4.50 (q, J = 7.1 Hz, 2H), 2.72 (s, 3H), 1.47 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, 
CDCl3) δ 165.08, 157.02, 156.83, 152.00, 141.84, 141.44, 133.56, 132.20, 131.77, 129.69, 
129.47, 129.36, 128.45, 123.28, 121.86, 121.06, 118.94, 118.81, 110.56, 90.88, 88.87, 62.09, 
49.81, 16.24, 14.26. 
 
Ethyl 3-methyl-6-phenethyl-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 
(54).23 To a suspension of 10% Pd/C (70 mg) in EtOH (5 mL) was added 52 (186 mg, 0.38 
mmol) dissolved in THF (1.5 mL). The suspension was stirred under an atmosphere of hydrogen 
(ca. 1 atm, balloon) overnight. The suspension was filtered through a pad of celite and the filtrate 
was concentrated under reduced pressure to provide the title compound (159 mg, 84%) as a light 
brown oil. Crude was used in the next reaction without further purification. 1H NMR (500 MHz, 
CDCl3) δ 7.44 (s, 1H), 7.36-7.31 (m, 3H), 7.31-7.26 (m, 3H), 7.26-7.22 (m, 2H), 7.19 (t, J = 7.0 
Hz, 1H), 7.09 (t, J = 7.4 Hz, 1H), 7.00 (d, J = 7.9 Hz, 2H), 6.95 (d, J = 8.5 Hz, 2H), 5.67 (s, 2H), 
4.49 (q, J = 7.1 Hz, 2H), 3.35-3.27 (m, 2H), 3.24-3.17 (m, 2H), 2.73 (s, 3H), 1.47 (t, J = 7.1 Hz, 
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3H). 13C NMR (125 MHz, CDCl3) δ 165.85, 161.09, 157.08, 156.78, 152.23, 141.30, 140.97, 
133.36, 132.21, 129.72, 129.55, 128.49, 128.41, 126.04, 123.30, 118.95, 118.80, 117.33, 109.68, 
61.83, 49.83, 39.82, 35.23, 16.31, 14.30. ESI MS: m/z 516.9 (M+H)+. 
 
Ethyl 3-methyl-6-((2-morpholinoethyl)amino)-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-
b]pyridine-4-carboxylate (55).23 A pressure vessel was charged with 50 (121 mg, 0.29 mmol), 
4-(2-aminoethyl)morpholine (1.0 mL, 7.6 mmol) and iPrOH (3 mL) and NMP (1 mL). The 
vessel was sealed and the reaction mixture was heated at 150 °C overnight. The reaction mixture 
was diluted with EtOAc (20 mL) and washed with H2O (10 mL x 3) to remove NMP. Combined 
organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated under reduced 
pressure. Crude was subjected to flash column chromatography on silica gel to provide the title 
compound (40 mg, 26%) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.29 (q, J = 7.1, 6.6 Hz, 
4H), 7.07 (t, J = 7.1 Hz, 1H), 6.96 (d, J = 8.6 Hz, 2H), 6.91 (d, J = 8.3 Hz, 2H), 6.78 (s, 1H), 
5.46 (s, 2H), 4.43 (q, J = 7.1 Hz, 2H), 3.76-3.70 (m, 4H), 3.55 (q, J = 5.0 Hz, 2H), 2.63 (t, J = 
5.7 Hz, 2H), 2.58 (s, 3H), 2.49 (s, 4H), 1.42 (t, J = 7.1 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 
166.00, 157.47, 157.15, 156.51, 152.39, 141.23, 134.44, 132.67, 129.66, 129.31, 123.18, 118.83, 
118.77, 107.03, 103.90, 66.92, 61.62, 57.03, 53.40, 49.37, 37.75, 16.16, 14.26. 
 
A representative procedure for synthesis of carboxylic acids. 
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1-(3-Chlorophenyl)-6-(furan-2-yl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 
(1).17 A solution of ester 35 (108 mg, 0.29 mmol) and KOH (29 mg, 0.52 mmol) in iPrOH (6 
mL) was refluxed for 1 h 30 min. Reaction mixture was diluted with H2O (10 mL) and washed 
with EtOAc (10 mL x 2). Aqueous layer was acidified with 1N HCl and extracted with EtOAc 
(10 mL x 2). Combined organic extracts were washed with brine, dried (Na2SO4), filtered, and 
concentrated under reduced pressure to give 1 (88 mg, 86%) as a bright yellow solid. 99% pure 
by HPLC. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.29 (d, J = 8.5 Hz, 1H), 7.96 (s, 1H), 
7.92 (s, 1H), 7.55 (t, J = 8.1 Hz, 1H), 7.37-7.31 (m, 2H), 6.76-6.71 (m, 1H), 2.62 (s, 3H). 13C 
NMR (100 MHz, DMSO-d6) δ 166.48, 152.40, 151.70, 148.29, 146.21, 143.65, 140.42, 136.54, 
133.86, 131.32, 125.57, 119.83, 118.66, 113.69, 113.32, 112.21, 112.10, 16.20. ESI MS: m/z  
354.0 (M+H)+. 
 
6-(Furan-2-yl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (2). 
Synthesized using the procedure for 1 except ester 36 was used as the starting material. The title 
compound (288 mg, 90%) was obtained as a white solid. 100% pure by HPLC. 1H NMR (400 
MHz, DMSO-d6) δ 8.26 (d, J = 7.7 Hz, 2H), 7.95 (s, 2H), 7.55 (t, J = 7.5 Hz, 2H), 7.39 (s, 1H), 
7.32 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 2.65 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 166.68, 
152.54, 151.60, 148.24, 146.07, 142.86, 139.27, 136.37, 129.60, 126.17, 120.94, 113.46, 113.27, 
112.07, 111.82, 16.17. ESI MS: m/z 320.1 (M+H)+. 
 
6-(Furan-2-yl)-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (3). Synthesized 
using the procedure for 1 except ester 37 was used as the starting material. After the work up and 
acidifying the aqueous layer with 1N HCl, solid precipitated which was filtered off and dried on 
high vacuum to provide the title compound (203 mg, 79%) as a beige solid. 100% pure by 
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HPLC. 1H NMR (400 MHz, DMSO-d6) δ 13.91 (s, 1H), 7.91 (s, 1H), 7.85 (s, 1H), 7.33 (d, J = 
2.9 Hz, 1H), 6.72-6.67 (m, 1H), 3.98 (s, 3H), 2.55 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 
166.91, 152.73, 152.00, 147.61, 145.67, 140.08, 135.59, 113.13, 112.56, 111.40, 109.74, 33.82, 
15.92. ESI MS: m/z 258.0 (M+H)+. 
 
3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (4). Synthesized using 
the procedure for 1 except ester 46 was used as the starting material. After the work up and 
acidifying the aqueous layer with 1N HCl, solid precipitated which was filtered off and dried on 
high vacuum to provide the title compound (165 mg, 81%) as a light yellow solid. 100% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 13.90 (s, 1H), 8.19 (d, J = 7.7 Hz, 2H), 7.56-7.48 (m, 
3H), 7.29 (t, J = 7.3 Hz, 1H), 2.65 (s, 3H), 2.63 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 
167.04, 159.52, 151.67, 142.43, 139.35, 135.32, 129.49, 126.12, 121.13, 118.29, 111.04, 24.92, 
16.12. ESI MS: m/z 268.1 (M+H)+. 
 
1,3,6-Trimethyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (12). Synthesized using the 
procedure for 1 except ester 47 was used as the starting material. The title compound (157 mg, 
84%) was obtained as a white solid. 95% pure by HPLC. 1H NMR (400 MHz, DMSO-d6) δ 7.37 
(s, 1H), 3.92 (s, 3H), 2.60 (s, 3H), 2.53 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.25, 158.47, 
152.04, 139.56, 134.57, 117.22, 108.94, 33.73, 24.66, 15.89. ESI MS: m/z 206.1 (M+H)+. 
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1-Benzyl-6-(furan-2-yl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (6). 
Synthesized using the procedure for 1 except ester 38 was used as the starting material. The title 
compound (67 mg, quantitative yield) was obtained as a light yellow solid. 100% pure by HPLC. 
1H NMR (500 MHz, DMSO-d6) δ 8.08-8.03 (m, 1H), 8.03-7.98 (m, 1H), 7.43 (s, 1H), 7.33-7.27 
(m, 2H), 7.27-7.20 (m, 3H), 6.78 (s, 1H), 5.67 (s, 2H), 2.65 (s, 3H). 13C NMR (125 MHz, 
DMSO-d6) δ 166.49, 151.92, 150.08, 147.52, 146.28, 140.99, 137.81, 133.82, 128.98, 127.93, 
113.74, 113.56, 113.34, 110.95, 50.03, 16.86. ESI MS: m/z 334.2 (M+H)+. 
 
1-([1,1'-Biphenyl]-4-ylmethyl)-6-(furan-2-yl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-
carboxylic acid (7). Synthesized using the procedure for 1 except ester 39 was used as the 
starting material. The title compound (58 mg, 87%) was obtained as a light yellow solid. 100% 
pure by HPLC. 1H NMR (500 MHz, DMSO-d6) δ 13.47 (s, 1H), 8.04 (d, J = 16.4 Hz, 1H), 7.59 
(d, J = 7.4 Hz, 5H), 7.45-7.39 (m, 3H), 7.33 (d, J = 7.6 Hz, 3H), 6.78 (s, 1H), 5.72 (s, 2H), 2.67 
(s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 166.48, 151.95, 150.09, 147.53, 146.30, 141.05, 
140.19, 139.91, 136.98, 133.86, 129.34, 128.57, 127.89, 127.35, 127.07, 113.77, 113.60, 113.35, 
111.00, 49.75, 16.89. ESI MS: m/z 410.2 (M+H)+. 
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6-(Furan-2-yl)-3-methyl-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 
(8). Synthesized using the procedure for 1 except ester 40 was used as the starting material. The 
title compound (63 mg, 43%) was obtained as an orange solid. 99% pure by HPLC. 1H NMR 
(500 MHz, DMSO-d6) δ 7.94 (s, 1H), 7.91 (s, 1H), 7.40 (d, J = 3.4 Hz, 1H), 7.34 (t, J = 7.8 Hz, 
2H), 7.31 (d, J = 8.4 Hz, 2H), 7.10 (t, J = 7.2 Hz, 1H), 6.95 (t, J = 8.1 Hz, 4H), 6.74-6.71 (m, 
1H), 5.61 (s, 2H), 2.59 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 166.87, 156.95, 156.51, 
152.71, 151.97, 147.92, 145.83, 140.95, 135.93, 132.85, 130.46, 129.94, 123.92, 119.10, 119.04, 
113.21, 112.86, 111.69, 109.96, 49.50, 16.04. ESI MS: m/z 426.0 (M+H)+. 
 
6-(Furan-2-yl)-3-methyl-1-(3-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 
(9). Synthesized using the procedure for 1 except ester 41 was used as the starting material. The 
title compound (84 mg, 86%) was obtained as a light orange solid. 99% pure by HPLC. 1H NMR 
(500 MHz, DMSO-d6) δ 7.91 (s, 1H), 7.89 (s, 1H), 7.33-7.26 (m, 4H), 7.09 (t, J = 7.4 Hz, 1H), 
6.97 (d, J = 7.6 Hz, 1H), 6.93 (d, J = 8.3 Hz, 2H), 6.88 (s, 1H), 6.85 (d, J = 9.8 Hz, 1H), 6.72-
6.69 (m, 1H), 5.60 (s, 2H), 2.56 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 166.83, 157.39, 
156.47, 152.64, 152.08, 147.91, 145.80, 141.07, 140.01, 135.92, 130.63, 130.41, 124.11, 122.72, 
119.34, 117.73, 117.65, 113.17, 112.89, 111.65, 109.95, 49.77, 16.01. ESI MS: m/z 426.2 
(M+H)+. 
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6-(Furan-2-yl)-3-methyl-1-(2-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 
(10). Synthesized using the procedure for 1 except ester 42 was used as the starting material. The 
title compound (86 mg, quantitative yield) was obtained as a yellow oil which solidified upon 
standing. 100% pure by HPLC. 1H NMR (500 MHz, DMSO-d6) δ 13.88 (s, 1H), 7.90 (s, 1H), 
7.84 (s, 1H), 7.31-7.20 (m, 4H), 7.11-7.06 (m, 2H), 7.01 (t, J = 7.4 Hz, 1H), 6.89 (d, J = 8.0 Hz, 
1H), 6.80 (d, J = 7.7 Hz, 2H), 6.70-6.66 (m, 1H), 5.65 (s, 2H), 2.53 (s, 3H). 13C NMR (125 MHz, 
DMSO-d6) δ 166.84, 157.37, 153.97, 152.72, 152.16, 147.73, 145.69, 140.97, 135.69, 130.19, 
130.12, 129.76, 129.16, 124.60, 123.28, 119.94, 117.86, 113.11, 112.76, 111.43, 109.86, 45.04, 
16.02. ESI MS: m/z 426.1 (M+H)+. 
 
6-(Furan-2-yl)-3-methyl-1-(4-(pyridin-4-yl)benzyl)-1H-pyrazolo[3,4-b]pyridine-4-
carboxylic acid (11). Synthesized using the procedure for 1 except ester 43 was used as the 
starting material. The title compound (31 mg, 32%) was obtained as an off-white solid. 1H NMR 
(400 MHz, DMSO-d6) δ 8.68 (d, J = 5.8 Hz, 2H), 7.94 (s, 1H), 7.92 (s, 1H), 7.85-7.80 (m, 3H), 
7.79 (s, 1H), 7.42 (s, 1H), 7.40 (s, 2H), 6.74-6.70 (m, 1H), 5.71 (s, 2H), 2.59 (s, 3H). 13C NMR 
(100 MHz, DMSO-d6) δ 166.85, 152.65, 152.12, 149.44, 148.39, 147.99, 145.89, 141.18, 139.74, 
136.00, 128.91, 127.90, 122.31, 113.22, 112.97, 111.79, 109.99, 49.69, 16.06. ESI MS: m/z  
411.1 (M+H)+. 
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6-(Furan-2-yl)-1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 
(12). Synthesized using the procedure for 1 except ester 44 was used as the starting material. The 
title compound (158 mg, 99%) was obtained as an off-white solid. 100% pure by HPLC. 1H 
NMR (500 MHz, DMSO-d6) δ 13.92 (s, 1H), 7.94 (s, 1H), 7.88 (s, 1H), 7.39 (s, 1H), 7.24 (d, J = 
6.9 Hz, 2H), 6.85 (d, J = 6.8 Hz, 2H), 6.72 (s, 1H), 5.54 (s, 2H), 3.68 (s, 3H), 2.57 (s, 3H). 13C 
NMR (125 MHz, DMSO-d6) δ 166.90, 159.13, 152.77, 151.87, 147.81, 145.78, 140.74, 135.94, 
129.79, 129.59, 114.35, 113.19, 112.74, 111.58, 109.96, 55.49, 49.63, 16.01. ESI MS: m/z 364.2 
(M+H)+. 
 
6-(Furan-2-yl)-3-methyl-1-(3-phenoxypropyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 
(13). Synthesized using the procedure for 1 except ester 45 was used as the starting material. The 
title compound (122 mg, 81%) was obtained as a yellow solid. 99% pure by HPLC. 1H NMR 
(400 MHz, DMSO-d6) δ 13.91 (s, 1H), 7.90 (s, 1H), 7.84 (s, 1H), 7.25-7.16 (m, 3H), 6.90-6.81 
(m, 3H), 6.70-6.63 (m, 1H), 4.58 (t, J = 6.4 Hz, 2H), 3.97 (t, J = 5.2 Hz, 2H), 2.57 (s, 3H), 2.35-
2.24 (m, 2H). 13C NMR (101 DMSO-d6) δ 166.93, 158.83, 152.70, 152.02, 147.61, 145.64, 
140.43, 135.68, 129.81, 120.92, 114.83, 113.10, 112.66, 111.37, 109.87, 65.17, 43.71, 29.32, 
16.04. ESI MS: m/z 378.2 (M+H)+. 
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3,6-Dimethyl-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (14). 
Synthesized using the procedure for 1 except ester 48 was used as the starting material. The title 
compound (11 mg, 20%) was obtained as an off-white solid. 97% pure by HPLC. 1H NMR (400 
MHz, DMSO-d6) δ 7.42 (s, 1H), 7.34 (t, J = 7.6 Hz, 2H), 7.22 (d, J = 8.1 Hz, 2H), 7.10 (t, J = 6.8 
Hz, 1H), 6.98-6.88 (m, 4H), 5.55 (s, 2H), 2.63 (s, 3H), 2.55 (s, 3H). 13C NMR (100 MHz, 
DMSO-d6) δ 167.28, 158.92, 156.97, 156.39, 152.02, 140.48, 133.05, 130.46, 129.66, 123.90, 
119.09, 119.00, 117.53, 109.99, 109.14, 49.25, 24.80, 15.98. ESI MS: m/z 374.0 (M+H)+. 
 
6-((Furan-2-ylmethyl)amino)-3-methyl-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-
carboxylic acid (15).18 A solution of ester 51 (40 mg, 0.08 mmol) and 1N NaOH (3.5 mL, 3.5 
mmol) in THF (1.5 mL) was refluxed for 3 h. Reaction mixture was diluted with water (10 mL) 
and washed with EtOAc (10 mL x 2). Aqueous layer was acidified with 1N HCl and extracted 
with EtOAc (10 mL x 2). Combined organic extracts were washed with brine, dried (Na2SO4) 
and filtered. The solvent was removed under reduced pressure to give the title compound (22 mg, 
61%) as an orange solid. 99% pure by HPLC. 1H NMR (500 MHz, DMSO-d6) δ 7.79 (t, J = 5.1 
Hz, 1H), 7.54 (s, 1H), 7.34 (t, J = 7.6 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H), 7.10 (t, J = 6.8 Hz, 1H), 
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6.95 (d, J = 7.9 Hz, 2H), 6.90 (d, J = 8.3 Hz, 2H), 6.86 (s, 1H), 6.33 (s, 1H), 6.25 (s, 1H), 5.35 (s, 
2H), 4.57 (d, J = 5.2 Hz, 2H), 2.41 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 167.35, 157.85, 
157.05, 156.29, 153.26, 152.02, 142.37, 140.38, 135.41, 133.48, 130.46, 130.44, 130.08, 123.85, 
118.98, 118.97, 110.81, 107.38, 103.37, 49.09, 37.87, 15.96. ESI MS: m/z 455.0 (M+H)+. 
 
A modified procedure for synthesis of carboxylic acids. 
 
(E)-3-methyl-1-(4-phenoxybenzyl)-6-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 
(16). A solution of ester 52 (56 mg, 0.11 mmol) and KOH (19 mg, 0.34 mmol) in iPrOH:THF (2 
mL/ 1mL) was refluxed at 87 oC for 2 h. Reaction mixture was diluted with water (10 mL) and 
washed with EtOAc (10 mL x 2). Aqueous layer was acidified with 1N HCl and extracted with 
EtOAc (10 mL x 2). Combined organic extracts were washed with brine, dried (Na2SO4) and 
filtered. The solvent was removed under reduced pressure to give the title compound (45 mg, 
94%) as a yellow solid. 88% pure by HPLC. 1H NMR (500 MHz, DMSO-d6) δ 13.86 (s, 1H), 
7.87 (d, J = 16.2 Hz, 1H), 7.81 (s, 1H), 7.74 (d, J = 7.8 Hz, 2H), 7.52 (d, J = 16.2 Hz, 1H), 7.42 
(t, J = 7.5 Hz, 2H), 7.37-7.29 (m, 5H), 7.09 (t, J = 7.4 Hz, 1H), 6.98-6.92 (m, 4H), 5.64 (s, 2H), 
2.58 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 167.16, 156.97, 156.47, 155.22, 152.20, 140.74, 
136.47, 135.39, 134.92, 133.00, 130.46, 129.90, 129.30, 128.04, 127.87, 123.90, 119.11, 119.02, 
116.60, 110.13, 49.41, 16.02. ESI MS: m/z 462.0 (M+H)+. 
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3-Methyl-1-(4-phenoxybenzyl)-6-(phenylethynyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic 
acid (17). Synthesized using the procedure for 16 except ester 53 was used as the starting 
material. The title compound (13 mg, 39%) was obtained as a light brown solid. 98% pure by 
HPLC. 1H NMR (500 MHz, DMSO-d6) δ 7.75 (s, 1H), 7.69 (d, J = 7.1 Hz, 2H), 7.51-7.45 (m, 
3H), 7.35 (t, J = 7.6 Hz, 2H), 7.24 (d, J = 8.3 Hz, 2H), 7.10 (t, J = 6.9 Hz, 1H), 6.96 (t, J = 8.4 
Hz, 4H), 5.63 (s, 2H), 2.61 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 166.45, 156.94, 156.51, 
151.85, 141.39, 141.14, 132.72, 132.43, 130.46, 130.35, 129.62, 129.37, 123.93, 121.34, 120.69, 
119.13, 119.05, 110.56, 90.88, 89.26, 49.53, 15.97. ESI MS: m/z 460.0 (M+H)+. 
 
3-Methyl-6-phenethyl-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 
(18). Synthesized using the procedure for 16 except ester 54 was used as the starting material. 
The title compound (67 mg, 91%) was obtained as a white solid. 96% pure by HPLC. 1H NMR 
(500 MHz, DMSO-d6) δ 13.75 (s, 1H), 7.44 (s, 1H), 7.34 (t, J = 7.5 Hz, 2H), 7.24 (d, J = 8.0 Hz, 
2H), 7.22-7.17 (m, 4H), 7.11 (t, J = 6.8 Hz, 2H), 6.95 (d, J = 8.2 Hz, 2H), 6.91 (d, J = 8.0 Hz, 
2H), 5.57 (s, 2H), 3.24 (t, J = 7.6 Hz, 2H), 3.09 (t, J = 7.5 Hz, 2H), 2.55 (s, 3H). 13C NMR (125 
MHz, DMSO-d6) δ 167.24, 161.61, 156.94, 156.49, 151.91, 141.54, 140.43, 134.92, 132.98, 
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130.46, 129.89, 128.85, 128.64, 126.26, 123.95, 119.08, 119.00, 117.34, 109.43, 49.45, 34.84, 
15.99. ESI MS: m/z 464.1 (M+H)+. 
 
3-Methyl-6-((2-morpholinoethyl)amino)-1-(4-phenoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-
4-carboxylic acid (19). Synthesized using the procedure for 1 except ester 55 was used as the 
starting material. The title compound (35 mg, 89%) was obtained as a white solid. 100% pure by 
HPLC. 1H NMR (400 MHz, DMSO-d6) δ 13.50 (s, 1H), 11.03 (s, 1H), 7.79-7.71 (m, 1H), 7.39-
7.32 (m, 2H), 7.32-7.26 (m, 2H), 7.14-7.07 (m, 1H), 6.99-6.90 (m, 3H), 6.81 (s, 1H), 5.40 (s, 
2H), 4.05-3.97 (m, 2H), 3.84-3.73 (m, 3H), 3.40-3.26 (m, 3H), 2.42 (s, 3H), 1.97 (s, 2H), 1.19-
1.12 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 167.26, 157.73, 157.04, 156.29, 151.98, 
140.48, 135.53, 133.48, 130.47, 129.99, 123.88, 119.05, 118.97, 107.78, 103.53, 63.55, 60.20, 
55.24, 51.64, 49.09, 21.22, 16.00, 14.54. ESI MS: m/z 488.0 (M+H)+. 
Protein purification 
 
His-tagged proteins containing Mcl-1 (residues 171–327), Bcl-2 (residues 1-202 with inserted 
Bcl-XL sequence from residues 35 to 50), Bcl-XL (residues 1-209 lacking its C-terminal 
transmembrane domain with a deletion of the flexible loop region 45 – 85), Bcl-w (residues 1-
155), A1/Bfl-1 (residues 1-151), were expressed from the pHis-TEV vector (a modified pET 
vector) in E. coli BL21 (DE3) cells. Cells were grown at 37 ºC in 2×YT containing antibiotics to 
an OD600 density of 0.6. Protein expression was induced by 0.4 mM IPTG at 37 ºC for 4 hours. 
Cells were lysed in 50 mM Tris pH 8.0 buffer containing 500 mM NaCl, 0.1% bME and 40 µl of 
Leupectin/Aprotin. All proteins were purified from the soluble fraction using Ni-NTA resin 
(QIAGEN), following the manufacturer’s instructions. Mcl-1 was further purified on a Source 
Q15 column (Amersham Biosciences) in 25 mM Tris pH 8.0 buffer, with NaCl gradient. Bcl-2 
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and Bcl-XL were purified on a Superdex75 column (Amersham Biosciences) in 25 mM Tris pH 
8.0 buffers containing 150 mM NaCl and 2 mM DTT and at -80 ºC in presence of 25% Glycerol.  
Determination of the Kd values of fluorescent probes to anti-apoptotic proteins 
 
Fluorescein tagged BID BH3 (Bcl-2 Homology 3) peptide was used as a fluorescent probe in the 
FP-based binding assays. Two fluorescent labeled BID BH3 peptide probes were used: i) 
fluorescein tagged BID peptide (Flu-BID), labeled with fluorescein on the N-terminus of the 
BH3 peptide (79-99); ii) the second tracer was purchased from Abgent (Catalog # SP2121a), 
named as FAM-BID, where the BH3 peptide (80-99) is labeled with 5-FAM. Their Kd values 
were determined to all members of the Bcl-2 family proteins with a fixed concentration of the 
tracer (2 nM of Flu-BID and FAM-BID) and different concentrations of the tested proteins, in a 
final volume of 125 µl in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 µg/ml 
bovine γ-globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). 
Plates were mixed and incubated at room temperature for 2 hours and the polarization values in 
millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an 
emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were calculated by 
fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using 
Graphpad Prism 6.0 software. Based upon analysis of the dynamic ranges for the signals and 
their Kd values, Flu-BID was selected as the tracer in the Mcl-1 and Bcl-2 competitive binding 
assays, while FAM-BID was selected as the tracer for the rest of the proteins, A1/Bfl-1, Bcl-w 
and Bcl-xL. The Kd value of Flu-BID to Mcl-1 was 34 ± 3.5 nM, and to Bcl-2 was 20 ± 0.86 nM 
and the Kd values of FAM-BID to A1/Bfl-1 was 0.83 ± 0.06 nM, to Bcl-w was 5.5 ± 1.6 nM, and 
to Bcl-xL was 10 ± 4.0 nM respectively, in our saturation experiments. 
Fluorescence polarization-based binding assays 
 
Sensitive and quantitative FP-based binding assays were developed and optimized to determine 
the binding affinities of small-molecule inhibitors to the recombinant Mcl-1, A1/Bfl-1, Bcl-w, 
Bcl-2, and Bcl-xL proteins. Protocols for expression and purification of used anti-apoptotic 
proteins and determination of Kd values of fluorescent probes to proteins are provided in the 
Supporting Information. Based on the Kd values, the concentrations of the proteins used in the 
competitive binding experiments were 90 nM for Mcl-1, 40 nM for Bcl-w, 50 nM for Bcl-xL, 60 
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nM for Bcl-2, and 4 nM for A1/Bfl-1. The fluorescent probes, Flu-BID and FAM-BID were 
fixed at 2 nM for all assays except for A1/Bfl-1 where FAM-BID was used at 1 nM. 5 µL of the 
tested compound in DMSO and 120 µL of protein/probe complex in the assay buffer (100 mM 
potassium phosphate, pH 7.5; 100 µg/ml bovine gamma globulin; 0.02% sodium azide, 
purchased from Invitrogen, Life Technologies) were added to assay plates (Microfluor 2Black, 
Thermo Scientific), incubated at room temperature for 3 h and the polarization values (mP) were 
measured at an excitation wavelength at 485 nm and an emission wavelength at 530 nm using the 
plate reader Synergy H1 Hybrid, BioTek. IC50 values were determined by nonlinear regression 
fitting of the competition curves (GraphPad Prism 6.0 Software). The Ki values were calculated 
as described previously24.  
 
Solution competitive surface plasmon resonance-based assay using immobilized biotin-labeled 
Bim BH3 peptide 
 
The solution competitive SPR-based assay was performed on Biacore 2000. N terminal biotin-
labeled Bim BH3 peptide (141 - 166 amino acids), was immobilized on streptavidin (SA) chip 
giving density of 1400 RU (Response Units). The pre-incubated Mcl-1 protein (20 nM) with 
tested small-molecule inhibitors for at least 30 minutes was injected over the surfaces of the chip. 
Response units were measured at 15 seconds in the dissociation phase and the specific binding 
was calculated by subtracting the control surface (Fc1) signal from the surfaces with 
immobilized biotin-labeled Bim BH3. IC50 values were determined by non-linear least squares 
analysis using GraphPad Prism 6.0 software. 
Molecular modeling  
 
Crystal structure of Mcl-1 in complex with mNoxa BH3 peptide (PDB entry 2NLA) and in silico 
Schrödinger’s IFD were used to model the binding poses of our designed compounds with Mcl-
1. IFD is allowing incorporation of the protein and ligand flexibility in the docking protocol, 
which is consisted of the following steps: (i) constrained minimization of the protein with an 
RMSD cutoff of 0.18 Å; (ii) initial Glide docking of the ligand using a softened potential (Van 
der Waals radii scaling); (iii) one round of Prime side-chain prediction for each protein/ligand 
complex, on residues within defined distance of any ligand pose; (iv) prime minimization of the 
same set of residues and the ligand for each protein/ligand complex pose; (v) Glide re-docking of 
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each protein/ligand complex structure within a specified energy of the lowest energy structure; 
(vi) estimation of the binding energy (IFDScore) for each output pose. All docking calculations 
were run in the extra precision (XP) mode of Glide. The center of the grid box of the Mcl-1 was 
defined by the Val 249 (in h1), Phe 270 (in h2), Val 220 (in h3/h4) and Val 216 (in h4). The size 
of the grid box was set to 15 Å. Default values were used for all other parameters. Schrödinger’s 
MC/SD dynamic simulation performs constant temperature calculations that take advantage of 
the strengths of Monte Carlo methods for quickly introducing large changes in a few degree of 
freedom, and stochastic dynamics for its effective local sampling of collective motions. The 
MC/SD dynamic simulation time in our study was set to 100 ps by allowing movement of the 
docked ligand and the residues which is less than 6 Å to the ligand. The force field used was set 
to OPLS_2001. Default values were used for all other parameters. 
NMR studies 
 
15N-labeled or 15N, 13C-labeled Mcl-1 proteins for NMR studies were prepared and purified using 
the same protocol as for unlabeled protein with the exception that the bacteria were grown on M9 
minimal media supported with 3 g/ L of 13C-glucose and/or 1 g/L of (15NH4)2SO4. 15N, 13C-
labeled Mcl-1 was used for backbone reassignment and 80% of residues were reassigned based 
on the work by Liu et al26. Protein samples were prepared in a 20 mM sodium phosphate, 150 
mM NaCl and 1 mM DTT solution at pH 7 in 7% D2O.  The binding mode of the compounds has 
been characterized by recording 1H,15N -HSQC experiments with a 138 µL solution of uniformly 
15N-labeled Mcl-1 (75µM) in the absence and presence of added compounds with the indicated 
molar ratio concentrations. All Spectra were acquired at 30 oC on a Bruker 600 MHz NMR 
spectrometer equipped with a cryogenic probe, processed using Bruker TopSpin and rNMR25, 
and were analyzed with Sparky27. Plots of chemical shift changes were calculated as ((Δ1H 
ppm)2 + (0.2(Δ15N ppm))2)0.5 of Mcl-1 amide upon addition of compound. The absence of a bar in 
a chemical shift plot indicates no chemical shift difference, or the presence of a proline or 
residue that is overlapped or not assigned.  
 
 
 
  157 
3.8 Contributions  
 
Fardokht Abulwerdi designed, synthesized and characterized all the compounds and as well as 
expressed and purified labeled Mcl-1, prepared NMR samples and analyzed HSQC NMR data 
with supervision from Dr. Nikolovska-Coleska and Dr. Hollis Showalter. Ahmed Mady 
performed all the biochemical experiments. Dr. Chenzhong Liao performed the in silico target-
based screen and identified the potential leads. Dr. Andrej Perdih performed all the molecular 
docking studies. All the proteins used for biochemical assays were expressed and purified in Dr. 
Jeanne Stuckey lab at LSI.  
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Chapter 4  
Summary and future directions 
 
 
4.1 Summary  
 
Apoptosis, an evolutionary-conserved genetic program for the removal of unwanted cells, is 
triggered by the extrinsic or the intrinsic (mitochondrial) apoptotic pathways. Bcl-2 family of 
proteins regulate the mitochondrial apoptotic pathway through a network of protein-protein 
interactions (PPIs) between the anti- and pro-apoptotic members. Myeloid cell leukemia-1 (Mcl-
1) is a potent anti-apoptotic protein, and together with Bcl-XL, Bcl-2, Bcl-w, Bcl-b and Bfl-1/A1, 
belongs to the pro-survival Bcl-2 subfamily. Structural studies of pro-survival members show 
that these proteins share up to four conserved helical domains known as Bcl-2 homology (BH) 
domains of which BH1-3 are involved in forming a well-defined, hydrophobic cleft on the 
surface of pro-survival members known as BH3-binding site. This conserved binding site 
interacts and sequesters the BH3 domain of pro-apoptotic proteins and is essential for the anti-
apoptotic function of anti-apoptotic members. 
Functional studies have demonstrated that Mcl-1 is capable of blocking apoptosis induced 
by various apoptotic stimuli, including chemotherapy and radiation1,2 while its down-regulation 
enhances the induction of apoptosis3-5. Thus, Mcl-1 represents an attractive molecular target for 
developing a new class of anti-cancer therapy for treatment of cancer and overcoming resistance 
to apoptosis.  In addition, Mcl-1’s structural differences (e.g. larger size, electropositive BH3-
binding site, etc) as compared to other anti-apoptotic members as well as its short half-life and 
tight regulation at the transcriptional and post-translational levels suggest that Mcl-1 has a 
distinct and non-redundant function, and its activities can be modulated to allow for different 
cellular functions6, 7.      
Binding studies have shown that interactions between Bcl-2 family proteins appear to be 
selective and specific8 (Figure 1.5, Chapter 1). The selective binding of pro-survival Bcl-2 
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proteins to their pro-apoptotic BH3-only ligands strongly suggests that specific targeting is 
possible and that highly specific small molecules can be designed.  Indeed, there are several 
successful examples9-11 of potent small molecules, binding to the BH3-binding groove of a 
subset (Bcl-2/Bcl-XL) or a single (Bcl-2 or Bcl-XL) anti-apoptotic protein(s), that are being 
advanced in clinical trials. However, development of selective and potent small molecules 
against Mcl-1 has proved difficult and lagged behind.   
The research described in this dissertation aimed at developing novel small-molecule 
inhibitors of Mcl-1. We utilized a traditional approach of high throughput screening (HTS) to 
identify small molecules capable of binding to Mcl-1 and disrupt its interaction with BH3 
peptides. HTS has been a common and popular way to identify small molecules as starting points 
for further development12. To triage the HTS hits and select the most promising compounds for 
follow-up evaluation, structural knowledge of the interaction between Mcl-1 and BH3 peptides 
coupled with molecular docking and supported by protein NMR spectroscopy were utilized, and 
compounds were selected based on the their ability to mimic the conserved interactions between 
Mcl-1 and BH3-only proteins.  
Chapter 2 described the development of a class of selective Mcl-1 inhibitors based on the 
first HTS lead, compound 59, bearing a hydroxynaphthalenylsulfonamide scaffold. Structure-
based design supported by NMR led to the design of new analogs, which were synthesized 
through a modular and efficient synthetic route. A library of more than 40 analogs of 59 with 
variations at four sites was generated and a SAR was established through two orthogonal 
biochemical assays. A potent and selective inhibitor, compound 21, was identified which binds 
to Mcl-1 with a Ki of 180 nM and an overall 9-fold improvement in potency over 59. Compound 
21 maintained the specificity profile of 59 and selectively inhibited Mcl-1 over the other anti-
apoptotic members. Compound 21 selectively sensitizes Eµ-myc lymphomas overexpressing 
Mcl-1, but not Eµ-myc lymphomas overexpressing Bcl-2 which correlates well with its in vitro 
biochemical inhibition and selectivity profile. Furthermore, it was demonstrated that 21 disrupts 
the interaction of endogenous Mcl-1 and biotinylated Noxa-BH3 peptide and causes cell death 
through a Bak/Bax-dependent mechanism. Treatment of human leukemic cell lines with 
compound 21 resulted in dose-dependent cell death, through activation of caspase-3 and 
induction of apoptosis. Additionally, another potent analog from this series, 10, was used as a 
chemical tool to validate Mcl-1 as a potential therapeutic target in pancreatic cancer (PC).  The 
  162 
in vitro and in vivo efficacy studies in a panel of pancreatic cancer cell lines and PC xenograft 
model, showed single-agent antitumor activity, demonstrating the therapeutic potential of Mcl-1 
inhibitors against PC13.  
Chapter 3 described the development of a second class of Mcl-1 inhibitors based on a 
second HTS lead, compound 38, with a 1H-pyrazolo[3,4-b]pyridine scaffold. Systematic 
removal of side chains of 38 and detailed NMR studies of the fragments mapped the binding site 
of this class of compounds in the Mcl-1 BH3-binding site. Through structure-based design and 
our knowledge from the first class of Mcl-1 inhibitors, analogs were deigned and synthesized 
using a short and convergent synthetic route. An initial SAR was established and analog 8 (Ki = 
2.2 µM) with an overall 12-fold improvement in binding affinity over 38 was developed.  8 
inhibits Mcl-1 most potently with an 8-fold selectivity over Bcl-2, and shows no inhibition of 
Bfl-1/A1, Bcl-w, and Bcl-XL up to 100 µM.  
4.2 Significance of the study 
 
This work showcases a successful use of structure-based design in conjunction with a series 
of biochemical and biophysical techniques toward developing small molecules as PPI inhibitors 
for a challenging target such as Mcl-1. More specifically the following scientific contributions 
were made.   
-A novel synthetic route was established for the synthesis of 59 class of compounds with 
a hydroxynaphthalenylsulfonamide scaffold. 
-Two classes of novel Mcl-1 inhibitors with hydroxynaphthalenylsulfonamide and 1H-
pyrazolo[3,4-b]pyridine scaffolds were developed.  
-Over 150 compounds including intermediates were synthesized and characterized. 
-Binding of potent inhibitors to Mcl-1 was verified and further mapped to the BH3-
binding site of Mcl-1.    
-Binding of both classes of inhibitors to Mcl-1 was further analyzed by computational 
studies and validated by NMR studies. 
-SARs of both classes of analogs were established and more potent analogs were 
identified.  
-Selectivity profile of inhibitors was determined against five anti-apoptotic proteins. 
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-Most potent inhibitors were characterized in cell-based assays and the mechanism of 
induction of apoptosis was elucidated.  
-Efficacy of most potent inhibitors were studied in human leukemia and pancreatic 
cancers. 
Overall through this work, the importance of targeting Mcl-1 in cancer with small molecules 
to overcome the Mcl-1-mediated resistance to cell death was highlighted. Finally, both classes of 
compounds can be further optimized and potentially lead to drug candidates for cancers that rely 
on Mcl-1 or can be used as probes to elucidate the role of Mcl-1 in cancer and normal 
physiology.  
4.3 Future directions 
Crystallography studies 
 
To optimize both classes of Mcl-1 inhibitors for improved potency, potent analogs with 
acceptable physicochemical properties from each class should be selected for crystallography 
trials.  Indeed crystallography trials are ongoing in collaboration with the Center for Structural 
Biology at UM with inhibitors from both classes. Crystallography studies with Mcl-1 in the 
presence of a small molecule have been challenging compared to Bcl-2 and Bcl-XL possibly due 
its higher degree of plasticity over other anti-apoptotic proteins. However, recently two crystal 
structures of Mcl-1 in complex with small molecules14, 15 have been solved. We also obtained a 
crystal structure of Mcl-1 bound to a small-molecule inhibitor form a different chemical class 
using higher concentrations of polyethylene glycol and a more alkaline pH, which produced 
crystals with sharp edges and clean faces. Similar conditions have been applied to the classes 
developed here and produced crystals for Mcl-1 bound to 37, from our 59 series, and 8, 
belonging to the 38 series. Currently we are screening around these conditions to obtain 
diffraction-quality crystals. A co-crystal of Mcl-1 bound to our inhibitor can provide a molecular 
picture of binding of our inhibitor to Mcl-1 and further guide the design of potent analogs.  
Improving the binding affinity through targeting p4 pocket  
 
Most of the binding affinity of potent analogs developed through this work comes from the 
hydrophobic interactions within the p2 and p3 pockets of Mcl-1. Structural data comparison of 
ABT-737 (Bcl-XL/Bcl-2 selective), ABT-199 (Bcl-2 selective) and WEHI-539 (Bcl-XL 
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selective), show that all three inhibitors bind to the p2 and p4 pockets of their respective 
protein(s) and therefore exhibit sub-nanomolar potency16. Thus, one strategy to improve potency 
of our inhibitors is to reach into the p4 pocket of Mcl-1. For this purpose, NMR or in silico 
fragment-based screening17-19 can be utilized in the presence of an inhibitor from either class to 
identify fragments that bind to p4 pocket. Once fragments were identified from either strategy 
and their binding was validated, medicinal chemistry efforts can be utilized to link the desired 
fragment to the current scaffolds which is by itself a challenging task and can be greatly 
circumvented through structural information. 
Studies toward understanding the selectivity of inhibitors  
 
Understanding the binding determinants that dictate similarities and differences among 
BH3-binding sites of anti-apoptotic proteins presents a significant drug design challenge20. 
Through this work, we developed two classes of Mcl-1 inhibitors with different selectivity 
profiles against the anti-apoptotic proteins. While inhibitors from 59 class show high selectivity 
in binding to Mcl-1 over other anti-apoptotic members, 38 class of compounds, show a mixed 
profile of selectivity. For example, analog 8 shows a slight 8-fold selectivity for Mcl-1 over Bcl-
2, but both 17 and 18 equipotently inhibit both proteins. Interestingly, 16 is a pan inhibitor of all 
anti-apoptotic proteins. The selectivity profile observed for both classes of inhibitors is 
interesting and requires further studies to fully understand their binding to Bcl-2 anti-apoptotic 
proteins. Point mutation(s) of the proteins coupled with computational modeling can help in 
identifying the binding determinants of different anti-apoptotic proteins and to assist in the 
design of analogs with tailored specificity toward each anti-apoptotic member. It is still unclear 
whether selective or pan inhibition of anti-apoptotic proteins is desirable for cancer therapy. 
Thus, development of such molecules can shed light on this question.  
 
Overall, the work presented in this dissertation contributes to our understanding of 
developing selective Mcl-1 inhibitors. The continued development of such inhibitors can 
elucidate the role of Mcl-1 in cancer and identify a subset of cancers most susceptible to Mcl-1 
inhibition which can further lead to more effective targeted therapies.   
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Appendix  
Development of second-generation 59 inhibitors of Mcl-1 
 
 
A.1 Introduction 
 
Despite the favorable properties of our 59 series of analogs (Chapter 2) with a 
hydroxynaphthalenylsulfonamide scaffold as defined by Lipinki’s Rule of Five1, the 
hydronaphthoiminoquinone part of the scaffold is prone to oxidation over time to a 
naphthoiminoquinone (Figure A.1A). While we never noticed any differences in our 
binding/NMR studies using old or freshly prepared stocks, we were pleased to see identification 
of compounds with naphthoiminoquinone as Mcl-1 inhibitors in the HTS leads identified from 
our screening effort at Emory University (Chapter 3). Additionally, compounds with 
naphthoiminoquinone scaffold have been identified recently as selective Mcl-1 inhibitors by 
Cohen et al2.  
 
Figure A.1. Development of 2nd generation 59 series. A) Oxidation of 
hydronaphthoiminoquinone to naphthoiminoquinone B) General structures for 1st and 2nd 
generation 59 series. 
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Therefore, we set to develop second-generation analogs of our hydronaphthoiminoquinone 
series that would maintain similar potency to the first generation analogs but display an 
improved stability toward oxidation. We envisioned synthesizing compounds with the general 
structure as shown in Figure A.1 B in which a methylene linker is added in between the 
naphthalene scaffold and the amine which is linked to an aryl group by an aliphatic linker (X). 
The inspiration for the design of this compound with a flexible linker came from a recent work 
by Friberg et al3. in which selective Mcl-1 inhibitors have been developed. The structural 
features of Friberg inhibitors include substituted aryls which are linked to a core scaffold (an 
indole or a benzothiophene) by a flexible ether linkage. An example of such an inhibitor 
crystallized in complex with Mcl-1 is compound 53 (Figure A.2 A). The crystal structure of 53 in 
complex with Mcl-1 (PDB 4HW2) showed that the substituted aryl group inserts into the p2 
pocket of Mcl-1 (Figure A.2 B). Utilizing the same crystal structure, a docking pose of the 
proposed analog I-1 (Figure A.2 C) predicted that the phenyl is placed in the p2 pocket while the 
carboxylate is predicted to form an electrostatic interaction with R263 (Figure A.2 D). 
Interestingly, the naphthalene core is placed away from the p3 pocket and closer toward the 
opening of the p2 pocket. Encouraged by our computational studies, we developed a synthetic 
route to synthesize compound I-1 and its analogs. Synthesized analogs were then assessed in our 
competitive fluorescence polarization (FP)-based assay against Mcl-1 to determine their binding 
affinities.  
 
 
Figure A.2. Comparison of crystal structure of 53 and docking pose of 1-I. A) Structure of 
compound 53 B) Crystal structure of 53 in complex with Mcl-1 (4HW2). C) Structure of 
compound 1-I D) Putative binding pose of 1-I (4HW2)  
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A.2 Synthesis  
 
To synthesize I-1 and its analogs, Scheme A.1 was utilized. 4-methoxy-1-naphthaldehyde 
was first subjected to N-iodosuccinamide to provide 3 via electrophilic aromatic substitution 
(SEAr). Intermediate 3 underwent reductive amination4 with the desired amines, which were 
either available commercially or synthesized using Scheme A.2, to provide the corresponding 
imine which was reduced using sodium borohydride. Intermediates 4 were subjected to C-S 
coupling with methyl thioglycolate using conditions reported previously5. Intermediates 5 were 
subjected to boron tribromide to provide analogs 1-I through 1-IV with a free hydroxyl and a 
carboxylic acid. To preserve the methyl ester in analog 2-IV, analog 5-IV was subjected to boron 
tribromide followed by a quench with MeOH. 
 
Scheme A.1. Synthesis of analogs 1-I–1-IVa. 
 
 
 
aReagents and conditions: (a) NIS, TFA, reflux, 8 h, 77%; (b) phenylethylamine or benzylamine 
or phenylpropylamine or 6, EtOH, reflux, 2 h; (c) NaBH4, EtOH, reflex, 1 h, 47%-88% over two 
steps; (d) HSCH2COOCH3, Pd2(dba)3, Xantphos, DIEA, 1,4-dioxane, 95 oC, 2 h, 62%-82%; (e) 
BBr3, CH2Cl2, 0 oC to rt, 1 h, 8%-60% or BBr3, CH2Cl2, 0 oC to rt, 1 h, quench with MeOH at 0 
oC, 73%. 
 
As mentioned previously, most of the amines were available commercially except 2-(4-
chloro-3,5-dimethylphenoxy)ethanamine which was synthesized using Scheme A.2. 4-Chloro-
3,5-dimethylphenol was subjected to Mitsunobu conditions6 in the presence of 2-bromoethanol 
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to provide intermediate 6. Displacement of bromide in 6 with an azide7 and reduction of the 
azide to an amine using tin chloride8 provided the desired amine 7. 
 
Scheme A.2. Synthesis of amine 7a. 
 
 
aReagents and conditions: (a) 2-BrCH2CH2OH, PPh3, DIAD, THF, 0oC to rt, overnight, 68%; (b) 
NaN3, DMF, 60 oC, overnight, 97%; (c) SnCl2, MeOH, rt, 1 h, 98%. 
 
A.3 Results  
 
Compound I-1 was the first proposed compound with a phenylethyl at X-R that was 
synthesized using Scheme I.1 and gratifyingly it exhibited an IC50 of 13 µM  (Table A.1) which 
was comparable to analog 3 from our first-generation 59 series (Chapter 2) with a 
phenylsulfonamido group suggesting that our linking strategy works. Encouraged by our results, 
we wished to vary the length of the aliphatic linker and determine the optimum length. For that 
purpose, analogs 1-II and 1-III having one and three methylene(s), respectively, in between the 
amine and the phenyl ring were synthesized and evaluated. Interestingly both displayed similar 
binding affinities compared to I-1. These findings can be explained based on an overlay of the 
predicted docking poses of analogs 1-I, 1-II, and 1-III (Figure A.3 A) suggesting that the phenyl 
in these analogs reaches the same distance despite the variation in the length of the linker. 
 
 
 
 
 
 
 
 
 
OHCl OCl
Br
OCl
NH2
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Table A.1. Binding affinities of 1-I and its analogs. 
 
Cpd X-R R’ R” 
FP 
IC50 ± SD (µM) 
Analog 3 
 
13.02 ± 1.62 
1-I 
 
-OH -OH 13.2 ± 1.7 
1-II 
 
-OH -OH 15.9 
1-III 
 
-OH -OH 18.0 
5-IV 
 
-OCH3 -OCH3 613.9 
1-IV 
 
-OH -OH 28.1 
2-IV 
 
-OCH3 -OH > 100 
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Figure A.3. Docking poses of analogs 1-I, 1-II, 1-III and 1-IV. (A) Overlay of putative 
binding poses of 1-I (dark green), 1-II (orange), 1-III (magenta). (B) Putative binding mode of 
1-IV. 
 
 
The predicted binding poses of second-generation 59 analogs suggested that the aryl group 
at R inserts into the p2 pocket of Mcl-1 and based on our previous knowledge from 59 as well as 
38 classes of compounds, the majority of the gain in binding affinity came from introduction of 
halogenated aromatic or bi-aromatic rings. Furthermore, Friberg and coworkers reported 
improved potencies for their analogs when 3,5-dimethyl-4-chloro-phenyl or naphthyl were 
introduced in place of a phenyl. Therefore, to improve the potency, analog 1-IV with a 3,5-
dimethyl-4-chloro-phenoxyethyl at X-R was synthesized and evaluated. However, surprisingly 
this analog did not show any improvement in binding compared to 1-I despite its favorable 
docking pose (Figure A.3 B). Furthermore, to our surprise, analog 1-IV proved to be quite 
unstable even at -20 oC and underwent chemical transformation.  
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Figure A.4. Stability studies with 1-IV and 2-IV. 1D HNMR of analogs 1-IV (left) and 2-IV 
(right) in DMSO-d6. Arrows point to newly forming peaks.   
 
1D HNMR study of a sample of analog 1-IV in deuterated DMSO kept at -20 oC and then at 
room temperature showed that this compound undergoes chemical transformation by the 
appearance of a new set of peaks (Figure A.4). This transformation however appeared to stop at 
60% conversion of 1-IV to a new species and did not proceed further from comparison of a 
sample stored at room temperature for 18 h and 90 h. Interestingly, the transformation did not 
take place with analog 2-IV (Figure A.4) suggesting that the free acid plays a role in this 
transformation possibly by providing a proton source for the amine to generate an ammonium 
species, which is an excellent leaving group. A possible mechanism of unraveling of 1-IV has 
been proposed which involves fragmentation to quinomethide as well as the amine (Figure A.5 
A). In-depth studies are needed to prove this mechanism; however, preliminary studies with 
liquid chromatography/mass spectrometry (LCMS) supported our proposed mechanism. LCMS 
chromatogram of the NMR sample of 1-IV after 90 h period resulted in two peaks with a ratio of 
1 (30%) to 2 (60%) (Figure A.5 B) matching the percentage conversion seen in 1D HNMR 
spectrum for the desired product versus the newly formed species. Additionally, MS analysis of 
the aforementioned peaks resulted in molecular mass of the desired product for the smaller peak 
(Figure A.5 C) and the molecular masses of the fragments in the larger peak (Figure A.5 D).   
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Figure A.5. LCMS trace of 1-IV after 90 h monitor. (A) Proposed mechanism for unraveling 
of 1-IV. (B) LCMS chromatogram of NMR sample of 1-IV after 90 h period. (C) MS trace of the 
smaller peak at 10.17 min. (D) MS trace of the larger peak at 11.17 min. 
 
It should be mentioned that NMR studies of other earlier analogs also resulted in the same 
type of conversion observed with 1-IV indicating that this transformation is universal to this 
scaffold.  
A.4 Conclusions  
 
A second-generation 59 class of compounds was designed to improve the stability of the 
oxidation-prone hydronaphthoiminoquinone scaffold of 59 class. The design idea involved 
removal of the sulfonamide linker of first-generation compounds and introduction of an aliphatic 
amine linker inspired by the design of the recently reported selective Mcl-1 inhibitors. The 
proposed analog 1-I provided a favorable docking pose and therefore was synthesized and 
resulted in reasonable potency compared to a similar analog from first-generation series. The 
impact of the length of the linker was briefly studied and did not greatly affect the potency. 
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However, additional elaboration of the phenyl ring of 1-I to increase hydrophobic interactions at 
the p2 pocket of Mcl-1 and improve potency in analog 1-IV was not successful. 1D NMR studies 
of analog 1-IV showed that this analog is inherently unstable. A possible unraveling mechanism 
for this class of analogs was proposed which is supported by LCMS data.  
A.5 Experimental  
Chemistry  
 
All anhydrous reactions were run under an atmosphere of dry nitrogen. Reagents were used as 
supplied without further purification. Reactions were monitored by TLC using precoated silica 
gel 60 F254 plates. Silica gel chromatography was performed with silica gel (220–240 mesh) 
obtained from Silicycle. Purities of final compounds were assessed by analytical HPLC 
performed on a Shimadzu system with a Restek Ultra C18 (4.6 x 150 mm, 5µm particle size) 
column or an Agilent 1100 series with an Agilent Zorbax Eclipse Plus−C18 column and a 
gradient of acetonitrile with 0.1 vol% TFA (10-90%) in water with 0.1 vol% TFA. Semi-
preparative HPLC was performed on a Shimadzu system with a Restek Ultra C18 (21.2 x 150 
mm, 5µm particle size) column. All NMR spectra were obtained in DMSO-d6 or CDCl3 and 
results were recorded at 400 MHz on a Varian 400 instrument or at 500 MHz on a Varian 500 
instrument. Mass spectrometry analysis was performed using a Waters LCT time-of-flight mass 
spectrometry instrument utilizing electrospray ionization operating in positive-ion (ESI+) or 
negative-ion (ESI-) modes where indicated.  
 
3-Iodo-4-methoxy-1-naphthaldehyde (3). A mixture of commercially available 1-methoxy-4-
naphthaldehyde (504 mg, 2.7 mmol), N-iodosuccinimide (704 mg, 3.1 mmol) in TFA (10 mL) 
was heated to reflux and stirred for 8 h under nitrogen. The reaction mixture was diluted with 
EtOAc (20 mL), washed with saturated aqueous Na2S2O3 solution (20 mL), saturated aqueous 
NaHCO3 (20 mL x 2), and brine (20 mL). The organic layer was dried (MgSO4), filtered and 
silica was added to filtrate and the solvent was removed under reduced pressure. The adsorbed 
crude residue was purified by flash column chromatography (hexane/EtOAc 96:4) on silica gel 
OCH3
I
O H
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to give 3 (648 mg, 77%) as a tan solid. 1H NMR (400 MHz, CDCl3) δ 10.23 (s, 1H), 9.22 (d, J = 
8.48 Hz, 1H), 8.26 (s, 1H), 8.18 (d, J = 8.48 Hz, 1H), 7.71 (t, J = 7.63 Hz, 1H), 7.62 (t, J = 7.63 
Hz, 1H), 4.04 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 191.28, 162.11, 146.45, 131.97, 129.69, 
129.44, 128.64, 127.75, 125.41, 122.73, 85.22, 62.06; ESI MS: m/z 313.0 (M+H)+. 
 
N-((3-Iodo-4-methoxynaphthalen-1-yl)methyl)-2-phenylethanamine (4-I).4 To a stirring 
solution of 3 (106 mg, 0.34 mmol) dissolved in absolute EtOH was added phenylethylamine (44 μL, 0.35 mmol) at room temperature. The mixture was heated to reflux for 2 h. The reaction 
mixture was cooled down to room temperature and NaBH4 (32 mg, 0.84 mmol) was added. The 
mixture was again heated to reflux for 1 h. The solvent was removed under reduced pressure. 
The residue was diluted with EtOAc (10 mL) and washed with aqueous 1N NaOH (5 mL x 2) 
and brine (10 mL). Organic layer was dried (Na2SO4), filtered and concentrated under reduced 
pressure to give the title compound (125 mg, 88%) as a yellow oil. The crude was used in the 
next reaction without further purification. 1H NMR (500 MHz, CDCl3) δ 8.16 (dd, J = 6.4, 3.2 
Hz, 1H), 8.03 (dd, J = 6.3, 3.2 Hz, 1H), 7.79 (s, 1H), 7.54 (dd, J = 6.4, 3.2 Hz, 2H), 7.32 (t, J = 
7.4 Hz, 2H), 7.26-7.22 (m, 3H), 4.16 (s, 2H), 3.98 (s, 3H), 3.04 (t, J = 7.1 Hz, 2H), 2.89 (t, J = 
7.1 Hz, 2H). 13C taken on 400 varian: 13C NMR (100 MHz, CDCl3) δ 155.92, 139.92, 134.86, 
134.07, 132.95, 128.75, 128.54, 128.51, 126.82, 126.46, 126.23, 124.33, 122.94, 86.68, 61.66, 
51.07, 50.69, 36.36. 
 
N-Benzyl-1-(3-Iodo-4-methoxynaphthalen-1-yl)methanamine (4-II). Synthesized using the 
procedure for 4-I except benzylamine was used as the amine. The crude was subjected to flash 
column chromatography on silica gel to provide the title compound (197 mg, 76%) as a yellow 
H
N
OCH3
I
H
N
OCH3
I
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oil. 1H NMR (400 MHz, CDCl3) δ 8.16-8.10 (m, 1H), 8.08-8.01 (m, 1H), 7.80 (s, 1H), 7.57-7.50 
(m, 2H), 7.41-7.33 (m, 3H), 7.31-7.24 (m, 1H), 4.13 (s, 2H), 3.96 (s, 3H), 3.91 (s, 2H). 13C NMR 
(100 MHz, CDCl3) δ 155.96, 140.06, 135.05, 134.02, 133.01, 128.52, 128.46, 128.24, 127.10, 
126.79, 126.46, 124.44, 122.92, 86.55, 61.65, 53.76, 50.03. 
 
N-((3-Iodo-4-methoxynaphthalen-1-yl)methyl)-3-phenylpropan-1-amine (4-III). Synthesized 
using the procedure for 4-I except phenylpropylamine was used as the amine. The crude was 
subjected to flash column chromatography on silica gel to provide the title compound (216 mg, 
78%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 7.1 Hz, 1H), 8.08 (d, J = 7.7 Hz, 
1H), 7.77 (s, 1H), 7.55 (p, J = 5.9 Hz, 2H), 7.28 (q, J = 6.5, 5.1 Hz, 2H), 7.22-7.15 (m, 3H), 4.12 
(s, 2H), 3.97 (s, 3H), 2.77 (t, J = 7.1 Hz, 2H), 2.73-2.66 (m, 2H), 1.88 (p, J = 7.2 Hz, 2H). 13C 
NMR (100 MHz, CDCl3) δ 155.91, 142.07, 134.92, 134.27, 132.98, 128.53, 128.41, 128.35, 
126.82, 126.45, 125.80, 124.39, 122.95, 86.62, 61.65, 50.89, 49.45, 33.62, 31.69. 
 
2-(4-Chloro-3,5-dimethylphenoxy)-N-((3-iodo-4-methoxynaphthalen-1 
yl)methyl)ethanamine (4-IV). Synthesized using the procedure for 4-I except 7 was used as the 
amine. The crude was subjected to flash column chromatography on silica gel to provide the title 
compound (235 mg, 47%) as an orange oil. 1H NMR (500 MHz, CDCl3) δ 8.09-8.05 (m, 1H), 
8.05-8.00 (m, 1H), 7.76 (s, 1H), 7.50-7.43 (m, 2H), 6.57 (s, 2H), 4.10 (s, 2H), 3.96 (t, J = 5.1 Hz, 
2H), 3.89 (s, 3H), 2.99 (t, J = 5.0 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ 156.55, 155.94, 
136.91, 134.83, 133.91, 132.92, 128.47, 126.72, 126.39, 126.22, 124.36, 122.85, 114.49, 86.58, 
67.42, 61.49, 50.47, 48.53, 20.91. 
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Methyl 2-((1-methoxy-4-((phenethylamino)methyl)naphthalen-2-yl)thio)acetate (5-I). To a 
solution of 4-I (120 mg, 0.29 mmol) dissolved in dry 1,4-dioxane (2 mL) was added DIEA (101 
µL, 0.58 mmol) at room temperature. The mixture was evacuated and backfilled with nitrogen (3 
cycles) followed by addition of Pd2(dba)3 (15 mg, 0.016 mmol) and Xantphos (18 mg, 0.030 
mmol). The reaction mixture was stirred for 5 min at room temperature then methyl thioglycolate 
(27 µM, 0.29 mmol) was added. The mixture was heated to 95 oC for 2 h. The reaction mixture 
was cooled down to room temperature and solvent was removed under reduced pressure. The 
residue was adsorbed onto silica gel and subjected to flash column chromatography on silica gel 
to provide the title compound (80 mg, 69%) as a red oil. 1H NMR (500 MHz, CDCl3) δ 8.13 (d, J 
= 8.0 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.56-7.51 (m, 2H), 7.49 (s, 2H), 7.31 (t, J = 7.4 Hz, 2H), 
7.24 (q, J = 8.1, 7.3 Hz, 2H), 4.19 (s, 2H), 4.01 (s, 3H), 3.78 (s, 2H), 3.66 (s, 3H), 3.03 (t, J = 7.1 
Hz, 2H), 2.89 (t, J = 7.1 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ 170.23, 154.63, 140.01, 
132.74, 132.36, 128.75, 128.59, 128.47, 128.02, 126.50, 126.27, 126.17, 124.10, 122.59, 122.49, 
61.40, 52.48, 51.18, 51.04, 36.38, 35.45. 
 
Methyl 2-((4-((benzylamino)methyl)-1-methoxynaphthalen-2-yl)thio)acetate (5-II). 
Synthesized using the procedure for 5-I except 4-II was used as the starting material. The crude 
was subjected to flash column chromatography on silica gel to provide the title compound (109 
mg, 62%) as a red oil. 1H NMR (500 MHz, CDCl3) δ 8.12 (d, J = 8.0 Hz, 1H), 8.04 (d, J = 7.0 
Hz, 1H), 7.55-7.48 (m, 3H), 7.41-7.37 (m, 2H), 7.35 (t, J = 7.5 Hz, 2H), 7.30-7.25 (m, 1H), 4.18 
(s, 2H), 4.00 (s, 3H), 3.92 (s, 2H), 3.77 (s, 2H), 3.67 (s, 3H).13C NMR (125 MHz, CDCl3) δ 
170.21, 154.77, 140.16, 132.65, 132.45, 128.62, 128.42, 128.33, 128.22, 127.04, 126.49, 126.27, 
124.21, 122.58, 122.42, 61.40, 53.65, 52.48, 50.46, 35.51. 
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Methyl 2-((1-methoxy-4-(((3-phenylpropyl)amino)methyl)naphthalen-2-yl)thio)acetate (5-
III). Synthesized using the procedure for 5-I except 4-III was used as the starting material. The 
crude was subjected to flash column chromatography on silica gel to provide the title compound 
(153 mg, 82%) as a brown oil. 1H NMR (500 MHz, CDCl3) δ 8.17-8.12 (m, 1H), 8.12-8.06 (m, 
1H), 7.58-7.52 (m, 2H), 7.52-7.48 (m, 1H), 7.31-7.26 (m, 2H), 7.23-7.17 (m, 3H), 4.18 (s, 2H), 
4.02 (s, 3H), 3.79 (s, 2H), 3.69 (s, 3H), 2.83-2.75 (m, 2H), 2.74-2.67 (m, 2H), 1.94-1.86 (m, 2H). 
13C NMR (125 MHz, CDCl3) δ 170.24, 154.69, 142.09, 132.82, 132.40, 128.63, 128.41, 128.33, 
128.21, 126.55, 126.30, 125.78, 124.15, 122.63, 122.49, 61.41, 52.51, 51.28, 49.31, 35.50, 33.62, 
31.69. 
 
Methyl 2-((4-(((2-(4-chloro-3,5-dimethylphenoxy)ethyl)amino)methyl)-1-
methoxynaphthalen-2-yl)thio)acetate (5-IV). Synthesized using the procedure for 5-I except 4-
IV was used as the starting material. The crude was subjected to flash column chromatography 
on silica gel to provide the title compound (148 mg, 66%) as a yellow oil. 1H NMR (500 MHz, 
CDCl3) δ 8.15-8.11 (m, 1H), 8.11-8.07 (m, 1H), 7.56-7.49 (m, 3H), 6.64 (s, 2H), 4.24 (s, 2H), 
4.08 (t, J = 5.1 Hz, 2H), 4.00 (s, 3H), 3.78 (s, 2H), 3.68 (s, 3H), 3.10 (t, J = 5.1 Hz, 2H), 2.33 (s, 
6H). 13C NMR (125 MHz, CDCl3) δ 170.22, 156.57, 154.80, 137.07, 132.50, 132.39, 128.64, 
128.26, 126.55, 126.36, 126.30, 124.10, 122.63, 122.45, 114.52, 67.49, 61.41, 52.48, 51.01, 
48.52, 35.49, 20.93. 
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2-((1-Hydroxy-4-((phenethylamino)methyl)naphthalen-2-yl)thio)acetic acid (1-I). To a 
stirred solution of 5-I (79 mg, 0.20 mmol) dissolved in dry CH2Cl2 (1.5 mL) was added BBr3 (1 
M in CH2Cl2, 0.60 mL, 0.60 mmol) dropwise at 0oC under nitrogen. The mixture was allowed to 
warm up to room temperature. After 1hr stir, the mixture was cooled down to 0oC and quenched 
with H2O (2 mL). The reaction mixture was diluted with more H2O (10 mL) and extracted with 
EtOAc (10 mL x 2). The combined organic extracts were washed with brine (15 mL), dried 
(Na2SO4), filtered, and the solvent was removed under reduced pressure. The crude was purified 
using a C18 reverse phase semipreparative HPLC column with solvent A (0.1% of TFA in water) 
and solvent B (0.1% of TFA in CH3CN) as eluents to give the title compound  (36 mg, 49%) as a 
white solid. 99% pure by HPLC. 1H NMR (400 MHz, DMSO-d6) δ 8.28 (d, J = 8.3 Hz, 1H), 8.10 
(d, J = 8.4 Hz, 1H), 7.69 (s, 1H), 7.61 (t, J = 7.5 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 7.36-7.29 (m, 
2H), 7.28-7.20 (m, 3H), 4.52 (s, 2H), 3.55 (s, 2H), 3.31-3.23 (m, 2H), 3.00-2.89 (m, 2H). ESI 
MS: m/z 368.2 (M+H)+. 
 
2-((4-((Benzylamino)methyl)-1-hydroxynaphthalen-2-yl)thio)acetic acid (1-II). Synthesized 
using the procedure for 1-I except 5-II was used as the starting material. The title compound (8 
mg, 9%) as a white solid after HPLC purification. 90% pure by HPLC. 1H NMR (500 MHz, 
DMSO-d6) δ 8.27 (d, J = 8.3 Hz, 1H), 8.03 (d, J = 8.3 Hz, 1H), 7.71 (s, 1H), 7.65-7.60 (m, 1H), 
7.60-7.56 (m, 1H), 7.53 (d, J = 7.1 Hz, 2H), 7.44 (q, J = 6.2 Hz, 3H), 4.54 (s, 2H), 4.29 (s, 2H), 
3.71 (s, 2H). ESI MS: m/z 354.3 (M+H)+. 
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2-­‐((1-­‐Hydroxy-­‐4-­‐(((3-­‐phenylpropyl)amino)methyl)naphthalen-­‐2-­‐yl)thio)acetic	   acid	  
(1-­‐III).	  Synthesized using the procedure for 1-I except 5-III was used as the starting material. 
The title compound (6 mg, 8%) as a white solid after HPLC purification. 97% pure by HPLC. 1H 
NMR (500 MHz, DMSO-d6) δ 8.27 (d, J = 7.3 Hz, 1H), 8.11 (d, J = 7.7 Hz, 1H), 7.71 (s, 1H), 
7.64 (t, J = 8.1 Hz, 1H), 7.58 (t, J = 6.4 Hz, 1H), 7.30 (t, J = 6.1 Hz, 2H), 7.23-7.17 (m, 3H), 
4.51 (s, 2H), 3.68 (s, 2H), 3.03 (s, 2H), 2.64 (t, J = 7.9 Hz, 2H), 1.99-1.88 (m, 2H). ESI MS: m/z 
382.3 (M+H)+. 
 
2-((4-(((2-(4-Chloro-3,5-dimethylphenoxy)ethyl)amino)methyl)-1-hydroxynaphthalen-2-
yl)thio)acetic acid (1-IV). Synthesized using the procedure for 1-I except 5-IV was used as the 
starting material. The title compound (28 mg, 60%) as a white solid after HPLC purification. 1H 
NMR (500 MHz, DMSO-d6) δ 8.29 (d, J = 8.3 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.69 (s, 1H), 
7.58 (t, J = 7.5 Hz, 1H), 7.55-7.50 (m, 1H), 6.83 (s, 2H), 4.55 (s, 2H), 4.24 (t, J = 5.0 Hz, 2H), 
3.48 (s, 2H), 3.44-3.39 (m, 2H), 2.29 (s, 6H). ESI MS: m/z 446.1 (M+H)+. 
 
Methyl 2-((4-(((2-(4-chloro-3,5-dimethylphenoxy)ethyl)amino)methyl)-1-
hydroxynaphthalen-2-yl)thio)acetate (2-IV). To a stirred solution of 5-IV (50 mg, 0.10 mmol) 
dissolved in dry CH2Cl2 (1 mL) was added BBr3 (1 M in CH2Cl2, 0.32 mL, 0.0.32 mmol) 
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dropwise at 0oC under nitrogen. The mixture was allowed to warm up to room temperature. The 
starting material was entirely consumed as determined by TLC after 1 h. The mixture was again 
cooled down to 0oC and MeOH (2 mL) was added. After addition, the mixture was allowed to 
warm up to room temperature and stirred for 1 h till a new spot formed as monitored by TLC. 
The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (10 mL x 2). The 
combined organic extracts were washed with brine (15 mL), dried (Na2SO4), filtered, and the 
solvent was removed under reduced pressure. The crude was purified using a C18 reverse phase 
semipreparative HPLC column with solvent A (0.1% of TFA in water) and solvent B (0.1% of 
TFA in CH3CN) as eluents to give the title compound  (34 mg, 73%) as a white solid.  97% pure 
by HPLC. 1H NMR (500 MHz, DMSO-d6) δ 8.28 (d, J = 8.2 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 
7.72 (s, 1H), 7.65-7.61 (m, 1H), 7.61-7.57 (m, 1H), 6.83 (s, 2H), 4.61 (s, 2H), 4.25 (t, J = 4.9 Hz, 
2H), 3.76 (s, 2H), 3.58 (s, 3H), 3.47-3.41 (m, 2H), 2.29 (s, 6H). 13C NMR (125 MHz, DMSO-d6) 
δ 170.39, 156.19, 154.87, 137.13, 135.05, 132.72, 127.93, 126.33, 126.16, 125.46, 124.32, 
123.46, 119.85, 115.35, 112.86, 63.93, 52.68, 47.23, 46.20, 36.48, 20.92. ESI MS: m/z 460.0 
(M+H)+. 
 
5-(2-Bromoethoxy)-2-chloro-1,3-dimethylbenzene (6).6 To a stirring solution of 4-chloro-3,5-
dimethylphenol (1 g, 6.26 mmol) in dry THF (23 mL) was added 2-bromoethanol (0.7 mL, 9.40 
mmol) followed by PPh3 (2.53 g, 9.40 mmol) at room temperature. The reaction mixture was 
cooled down to 0oC and a solution of DIAD (1.95 mL, 9.40 mmol) in dry THF (2mL) was added 
dropwise over 3 min. The reaction mixture was warm up to room temperature and stirred 
overnight. The reaction mixture was diluted with H2O (50 mL) and extracted with CH2Cl2 (40 
mL x 2). Combined organic extracts were washed with brine, dried (Na2SO4), filtered and 
concentrated under reduced pressure. The crude residue was treated with a mixture of Et2O and 
hexanes to crash triphenyl phosphine oxide which was filtered off. The crude was next subjected 
to flash column chromatography on silica gel to provide the title compound (1.12 g, 68%) as an 
oil which solidified to a white solid upon standing. 1H NMR (500 MHz, CDCl3) δ 6.66 (s, 2H), 
Cl
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4.25 (t, J = 6.3 Hz, 2H), 3.62 (t, J = 6.3 Hz, 2H), 2.36 (s, 6H). 13C NMR (125 MHz, CDCl3) δ 
155.85, 137.30, 126.98, 114.76, 68.00, 29.08, 20.95. 
 
2-(4-Chloro-3,5-dimethylphenoxy)ethanamine (7).  
 
 
As previously reported7, to a solution of 6 (505 mg, 1.92 mmol) in DMF (8 ml) was added NaN3 
(374 mg, 5.75 mmmol) and the reaction mixture stirred at 60 ºC overnight at which time the 
reaction mixture was cooled down to room temperature. The reaction mixture was diluted with 
H2O (30 ml) and extracted with Et2O (30 ml x 2). The organic extracts were combined, washed 
with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to provide 5-(2-
azidoethoxy)-2-chloro-1,3-dimethylbenzene (421 mg, 97%) as a clear oil. The crude was used in 
the next reaction without further purification. 1H NMR (500 MHz, CDCl3) δ 6.66 (s, 2H), 4.07 (t, 
J = 4.9 Hz, 2H), 3.55 (t, J = 4.9 Hz, 2H), 2.36 (s, 7H). 13C NMR (125 MHz, CDCl3) δ 156.08, 
137.18, 126.80, 114.56, 67.08, 50.16, 20.87. 
 
As previously reported8, to a stirring solution of SnCl2 (700 mg, 3.69 mmol) in dry MeOH (3 
mL) was added 5-(2-azidoethoxy)-2-chloro-1,3-dimethylbenzene (102 mg, 0.45 mmol) dissolved 
in dry MeOH (1 mL) dropwise at room temperature. The mixture was stirred at room 
temperature for 1 h. The reaction mixture was concentrated under reduced pressure. To the 
residue was added cold H2O (10 mL) and the mixture was basified with 50% aqueous solution of 
NaOH. White solid (tin salts) precipitated and filtered. After filtration, the filtrate was diluted 
with more H2O (20 mL) and extracted with EtOAc (15 mL x 2). The organic extracts were 
washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to provide 
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the title compound (88 mg, 98%) as a yellow gel. Crude was used in the next step without further 
purification. 1H NMR (500 MHz, CDCl3) δ 6.60 (s, 2H), 3.87 (t, J = 5.1 Hz, 2H), 3.00 (t, J = 4.9 
Hz, 2H), 2.29 (s, 6H). 13C NMR (125 MHz, CDCl3) δ 156.66, 137.07, 126.31, 114.49, 70.17, 
41.48, 20.91. 
 
Protein purification 
 
His-tagged proteins containing Mcl-1 (residues 171–327) was expressed from the pHis-TEV 
vector (a modified pET vector) in E. coli BL21 (DE3) cells. Cells were grown at 37 ºC in 2×YT 
containing antibiotics to an OD600 density of 0.6. Protein expression was induced by 0.4 mM 
IPTG at 37 ºC for 4 hours. Cells were lysed in 50 mM Tris pH 8.0 buffer containing 500 mM 
NaCl, 0.1% bME and 40 µl of Leupectin/Aprotin. Mcl-1 was purified from the soluble fraction 
using Ni-NTA resin (QIAGEN), following the manufacturer’s instructions. Mcl-1 was further 
purified on a Source Q15 column (Amersham Biosciences) in 25 mM Tris pH 8.0 buffer, with 
NaCl gradient. Mcl-1 was stored in 25 mM Tris pH 8.0 buffers containing 150 mM NaCl and 2 
mM DTT and at -80 ºC in presence of 25% Glycerol.  
Determination of the Kd values of fluorescent probe to Mcl-1 
 
Fluorescein tagged BID peptide (Flu-BID), labeled with fluorescein on the N-terminus of the 
BH3 peptide (79-99) was used as a fluorescent probe in the FP-based binding assays. The Kd 
value of the tracer was determined Mcl-1 with a fixed concentration of the tracer (2 nM of Flu-
BID) and different concentrations of the tested proteins, in a final volume of 125 µl in the assay 
buffer (100 mM potassium phosphate, pH 7.5, 100 µg/ml bovine γ-globulin, 0.02% sodium 
azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at 
room temperature for 2 hours and the polarization values in millipolarization units (mP) were 
measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. 
Equilibrium dissociation constants (Kd) were calculated by fitting the sigmoidal dose-dependent 
FP increases as a function of protein concentrations using Graphpad Prism 6.0 software. The Kd 
value of Flu-BID to Mcl-1 was determined to be 34 ± 3.5 nM in our saturation experiments. 
Fluorescence polarization-based binding assays 
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Sensitive and quantitative FP-based binding assays were developed and optimized to determine 
the binding affinities of small-molecule inhibitors to the recombinant Mcl-1. Based on the Kd 
value, the concentrations of the proteins used in the competitive binding experiment was 90 nM 
for Mcl-1. The fluorescent probes, Flu-BID was fixed at 2 nM. 5 µL of the tested compound in 
DMSO and 120 µL of protein/probe complex in the assay buffer (100 mM potassium phosphate, 
pH 7.5; 100 µg/ml bovine gamma globulin; 0.02% sodium azide, purchased from Invitrogen, 
Life Technologies) were added to assay plates (Microfluor 2Black, Thermo Scientific), 
incubated at room temperature for 3 h and the polarization values (mP) were measured at an 
excitation wavelength at 485 nm and an emission wavelength at 530 nm using the plate reader 
Synergy H1 Hybrid, BioTek. IC50 values were determined by nonlinear regression fitting of the 
competition curves (GraphPad Prism 6.0 Software).  
Molecular modeling  
 
Molecular docking calculations were performed using GOLD molecular docking tool9. To begin 
with, in accordance with required guidelines, molecular docking software tool GOLD was 
validated10. For this purpose, initial conformation of the ligand bound in the Mcl-1 active site 
(PDB: 4HW2) was extracted from its active site and subsequently docked using GOLD 
molecular docking package. The ligand binding site was defined as a 10 Å cavity around the 
ligand present in the 4HW2 strcture. The remaining waters and part of the ligand present in the 
unit cell were deleted for docking purposes. Hydrogen atoms were added to the Mcl-1 protein 
molecule using GOLD with default settings of the amino acid protonation pattern. Side chains of 
amino acids were treated as rigid entities. In the validation procedure ligand present in the crystal 
structure was docked 10 times into the defined binding site by applying the following parameters 
of the GOLD genetic algorithm (GA) (population size = 100, selection pressure = 1.1, no. of 
operations = 100000, no. of islands = 5, niche size = 2, migrate = 10, mutate = 95, crossover = 
95) along with different scoring functions available in GOLD to provide initial measurement of 
binding affinity of the produced Mcl-1: ligand complex. The best agreement between the 
crystallized and docked pose was obtained using ChemPLP scoring function and it was used 
further for molecular docking calculations of the selected compounds from this study using the 
same docking settings. 
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Fardokht Abulwerdi designed, synthesized and characterized all the compounds and 
intermediates with supervision from Dr. Nikolovska-Coleska and Dr. Hollis Showalter. Ahmed 
Mady performed all the biochemical experiments. Dr. Andrej Perdih performed all the molecular 
docking studies. The protein used for biochemical assays was expressed and purified in Dr. 
Jeanne Stuckey lab at LSI.  
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